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Abstract	
During the past decade, 3ʹ untranslated regions (3ʹUTRs) of mRNAs continue to emerge as important sites
for gene regulation due to the binding of microRNAs (miRs), RNA-binding proteins (RBPs) and possibly other
trans-acting factors. Brain derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor
(GDNF) play important roles inside and outside the central nervous system (CNS). Whilst precise
spatiotemporal regulation of BDNF and GDNF levels are crucial in determining biological outcome,
mechanisms involved in controlling their levels are not fully understood. In this thesis, we investigated the
3ʹUTR mediated regulation of BDNF and GDNF. We demonstrate the presence of regulatory elements in the
3ʹUTR of BDNF and GDNF and, show that BDNF is regulated by 4 different miRs, namely miR-1, miR-10b,
miR-155 and miR-191, and by RBP tristetraprolin (TTP) in different cell lines. Further, we show that GDNF is
regulated by multiple miRs in cell lines and identify binding sites for miR-146 and miR-96 in the GDNF
3ʹUTR. We demonstrate that in vivo replacement of GDNF 3ʹUTR with a 3ʹUTR with reduced responsiveness
to negative regulators including miRs leads to elevated level of endogenous GDNF mRNA and protein in
various organs with profound effects on the brain dopaminergic system in mice. We conclude that 3ʹUTR
mediated regulation of BDNF and GDNF is biologically important and propose that 3ʹUTR replacement is a
highly informative way to study gene function in vivo.
	
11 Review	of	the	literature	
1.1 The	concept	of	neurotrophic	factors	
Development of vertebrate nervous system is a complex and highly coordinated process that requires
expression of various intracellular and extracellular factors in a controlled manner. Neurotrophic factors
(NTFs) are a group of secreted proteins which support the survival of neurons, promote neuritic growth and
branching, and regulate the number of neurons and density of innervation; in particular during the time of
target innervation in the development. Nerve growth factor (NGF) was the first growth factor and NTF
discovered more than half a century ago by Italian scientist Rita Levi-Montalcini (Levi-Montalcini and
Cohen, 1956, Levi-Montalcini, 1982). The classical target derived NTF hypothesis states that secreted NTFs
from target neurons/tissues act extracellularly as a chemoattractants and survival factors for innervating
neurons and facilitating synapse formation with the target cell. Without neurotrophic support from target
neurons/tissues during development, innervating neurons die via PCD (Figure 1.1). The underlying concept
here is that during embryonic development of the peripheral nervous system, neurons are produced in
excess and overproduced neurons are removed by PCD due to limited access to neurotrophic support. Only
neurons innervating the correct NTF producing targets in time will receive sufficient trophic support to
survive. Neurons innervating incorrect targets or displaying delayed development will die via PCD. This
process is believed to be crucial to ensure optimal neuronal connections in the nervous system
(Oppenheim, 1991).
Figure 1.1: Sketch presenting the classical neurotrophic factor hypothesis. If a neurotrophic factor is
secreted from a target tissue then innervating neuron expressing a cognate receptor makes connection and
survives otherwise the innervating neuron dies through PCD.
Originally proposed for peripheral neurons, this classical model  was extended to the CNS as well, where
target neurons synthesizes NTFs and provide trophic support to their afferent neurons  (Ernfors et al.,
1990). However, the role and mechanism of above the target field NTF theory is still matter of debate in the
context of the CNS.
21.2 Classification	of	NTFs	
NTFs are classified broadly into four major families: 1. Neurotrophins 2. GDNF family ligands (GFLs)
3. Neurokines 4. MANF/CDNF family.
NGF, BDNF, neurotrophin-3 (NT-3) and neurotrophin – 4 (NT-4) are the members of the mammalian
neurotrophin family. Neurotrophin mediated signaling is critically important for the development and
maintenance of the CNS  (Skaper, 2012).
GDNF, Neurturin (NRTN), Artemin (ARTN) and Persephin (PSPN) are the GDNF family members. GDNF and
GFLs are structurally related to the transforming growth factor beta (TGF-β) superfamily and play a crucial
role in the development, differentiation and maintenance of a variety of neurons  (Airaksinen and Saarma,
2002).
Neurokines or neuropoietic cytokines are neurally active cytokines and may signal via common cytokine
receptor components. Ciliary neurotrophic factor(CNTF), interleukin 6(IL-6), cardiotrophin 1 (CT-1),
cardiotrophin 2 (CT-2)  and leukemia inhibitory factor (LIF) are well known members of this family
(Nathanson, 2012).
MANF and CDNF are the only two members of this recently founded family (Petrova et al., 2003, Lindholm
et al., 2007). MANF and CDNF are also involved in inhibiting ER stress-induced cell death (Apostolou et al.,
2008, Cheng et al., 2013, Lindahl et al., 2014). Intracranial applications of ectopic MANF and CDNF are
shown to have beneficial effects in rodent models of Parkinson’s disease (Lindholm et al., 2007, Voutilainen
et al., 2009, Airavaara et al., 2012, Back et al., 2013).
1.3 BDNF	and	GDNF	biology		
1.3.1 BDNF	
		
In the year 1982, Yves Barde and his colleagues discovered  BDNF only the second  neurotrophic factor
found after the discovery of NGF (Barde et al., 1982). BDNF plays an important role in a wide spectrum of
brain functions which include the development of neuronal networks, the plasticity of synapses and the
survival of neurons (Kirschenbaum and Goldman, 1995, Bamji et al., 2006, Loeliger et al., 2008, Caputo et
al., 2011). Mice overexpressing BDNF exhibit enhanced learning and memory (Nakajo et al., 2008). BDNF
has acute effects on synaptic transmission and plays a role in long-term potentiation. It changes the
properties of ionotropic receptors (e.g. NMDA receptor, AMPA receptor, GABAA receptor) which rapidly
affect both excitatory and inhibitory synaptic transmission (Rose et al., 2004).
BDNF’s biological function is mediated via multiple intracellular signaling pathways triggered by its binding
to two classes of cell surface receptors namely Tropomyosin related kinase B (TrkB) and p75NTR (Numakawa
et al., 2010). By binding to TrkB, BDNF activates a broad range of signaling cascades such as MAP kinase,
PI3-kinase and PLC-gamma  that lead to variety of biological outcomes in different cell types  (Huang and
Reichardt, 2003). p75 is a receptor for all neurotrophins and it  can bind neurotrophin  precursors or their
mature forms (Figure 1.2). For example, the BDNF precursor (pro-BDNF) binds to p75 and leads to a
decrease in synaptic efficacy followed by a retraction of presynaptic terminals of neuromuscular synapses
(Roux and Barker, 2002, Yang et al., 2009). Pro-BDNF can also signal via p75 by binding to sortilin (Teng et
al., 2005).
3Figure 1.2: Both proBDNF and mature BDNF are biologically active but lead to opposite biological
outcomes. Mature BDNF can signal via TrkB in the presence or absence of p75, whereas proBDNF can signal
through sortilin and p75. Adapted from review by Deinhardt and Chao (2014).
BDNF is also involved in a wide range of functions outside the CNS. BDNF is expressed in skeletal muscle
precursors termed as satellite cells and inhibits myogenic differentiation. Mousavi and Jasmin (2006)
showed using rat myoblast cell line L6 that a reduction of BDNF levels is required for myoblasts to exit the
cell cycle and to initiate myogenic differentiation. In line with the functions of BDNF in muscle growth and
renewal, BDNF knockdown specifically from mouse skeletal muscle contributes to compromised
regeneration after injury (Clow and Jasmin, 2010). BDNF also promotes  angiogenesis both in vivo and in
vitro (Sun et al., 2006). Furthermore, activated microglia release BDNF which changes the anion gradient in
neurons; this may have a role in neuropathic pain (Siniscalco et al., 2011, Coull et al., 2005).
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5GDNF requires the GPI-anchored co-receptor protein GFRα 1 and transmembrane receptor tyrosine kinase
RET (Rearranged during Transfection) to form a receptor complex to exert its biological activity (Airaksinen
and Saarma, 2002, Sariola and Saarma, 2003). See Figure 1.4 for summary of GDNF family ligand
signaling.In addition, GDNF can signal independently from RET via neural adhesion molecule
(NCAM)(Paratcha et al., 2003) or directly without GFRα or RET through syndecan-3 (Bespalov et al., 2011) .
Figure 1.4:  Schematics showing receptors and signaling for GDNF and it’s family members. GFLs specificity
to GFRα receptors; GDNF binds to GFRα1, NRTN to GFRα2, ARTN to GFRα3 and PSPN to GFRα 4 . GDNF and
NRTN can cross-bind to GFRα2 and GFRα1 respectively (Cik et al., 2000). PSPN also appears to activate RET
also via GFRα1 (Sidorova et al., 2010). GFLs are homodimers and bring together two molecules of GFRα
receptors to form a signaling complex with two molecules of RET resulting in transphophorylation of their
tyrosine residues in the kinase domains leading to downstream signaling. Alternatively, GDNF can also bind
to the preformed GFRα1-RET complex (Bespalov and Saarma, 2007). Scheme adapted from Airaksinen and
Saarma (2002).
GDNF transcripts are detected outside the CNS in kidney, lung, bone, heart, liver, spleen, sciatic nerve and
blood (Suter-Crazzolara and Unsicker, 1994). It has been shown that Sertoli cells in mouse testis secrete
GDNF and regulate the fate and lineage determination of undifferentiated spermatogonia (Meng et al.,
2000). Skeletal muscles produce GDNF facilitating innervation of the neuromuscular junction in rats
(Wehrwein et al., 2002). Despite the detection of GDNF transcripts in various tissues and its known or
presumed role in many biological processes, the mechanisms regulating endogenous GDNF expression are
not well understood. BDNF and GDNF levels are linked to human diseases and have been widely studied in
the context of various pathological conditions in humans.
61.4 BDNF	and	GDNF	in	human	disease			
1.4.1 BDNF	in	human	disease		
BDNF mis-expression has been reported in several human disease conditions. AD is characterized by
progressive impairment of memory and learning due to loss of neurons in cerebral cortex and certain
subcortical areas of the brain (Berchtold and Cotman, 1998). BDNF mRNA levels are reduced by
approximately 2 fold in the hippocampal formation of postmortem brains of AD patients (Phillips et al.,
1991). A recent association study performed with 140 participants linked  reduced BDNF plasma levels to
AD and dementia (Aisen, 2014).
Specific loss of DA neurons in the SNpc is the cause of motor symptoms in PD patients and BDNF expression
is reported to be approximately 55% reduced compared to the control group in the melanized
dopaminergic neurons of the SNpc in PD patients (Parain et al., 1999). HD is another neurodegerative
disease which leads to loss of motor coordination and cognitive functions (Papoutsi et al., 2014). BDNF
protein expression is reported to be reduced by 50% to 80% in the caudate and putamen of HD patients
(Ferrer et al., 2000).
Reduced  levels of BDNF are linked to AD, PD and HD, but it is only HD in which multiple experimental
approach using in vitro cell systems, animal models and systematic analysis of postmortem tissues from
human have provided a strong link between the impaired production and transport of BDNF and the
manifestation of disease (Zuccato and Cattaneo, 2009). On the other hand, mechanisms attributing
reduced BDNF level to AD and PD are not well understood  (Zuccato and Cattaneo, 2009). In humans,
increasing  BDNF levels  has been proposed to be one of the potential therapeutic approaches to cure HD
(Zuccato and Cattaneo, 2014). BDNF is also linked to psychiatric disorders like schizophrenia and depression
(Muglia et al., 2003, D'Addario et al., 2013).
The congenital Val66Met polymorphism where methionine (Met) substituted for valine (Val) at codon 66 in
the pro-region of BDNF affects activity- dependent secretion of BDNF is associated with a poor episodic
memory and abnormal hippocampal activation in humans (Egan et al., 2003). However, there have been
conflicting reports on the role of the Val66Met polymorphism  as a risk factor for developing AD,PD ,HD and
schizophrenia (Zuccato and Cattaneo, 2009, Guan et al., 2014).
These studies highlight the role of aberrant BDNF levels in different human diseases. As the mechanisms of
regulation of BDNF levels are still poorly understood there is a need for basic research in this direction.
Studies on mechanisms controlling BDNF expression is one of the objectives of this thesis.
1.4.2 GDNF	in	human	disease	
ALS is a neurodegenerative disease attributed to preferential loss of motor neurons of the motor cortex,
brain stem and spinal cord, resulting in progressive muscle atrophy, paralysis and eventually death (Ajroud-
Driss and Siddique, 2014). Grundstrom et al. (2000) found elevated level of GDNF in the cerebrospinal fluid
of 13 patients with ALS suggesting that GDNF expression  may be enhanced to stall the loss of motor
neurons. There is an ongoing clinical trial for treatment of ALS using progenitor cells secreting GDNF.
HSCR, also known as congenital megacolon or intestinal aganglionosis, is a congenital abnormality
characterized by an absence of enteric  neurons from variable lengths of the hind gut (McKeown et al.,
2013). Mutation of the GDNF receptor component RET is found in in about 50% of familial and about 20%
of sporadic HSCR cases (Attie et al., 1995, Martucciello et al., 2000). Mutations in GDNF coding sequence
7are associated with about 4.6%  of all HSCR cases (Martucciello et al., 2000). Mutations in the GDNF
signaling component RET is involved in multiple endocrine neoplasia type 2 (MEN2), an autosomal-
dominant cancer syndrome (Lodish, 2013). Additionally, it is reported that activating mutations in GDNF
receptor RET cause familial medullary thyroid cell carcinoma (FMTC) syndromes (Airaksien and Saarma,
2002).
Intracranial GDNF protein delivery has been tested in two phase 2 clinical trials for therapy of PD with
inconclusive outcomes. In the first trial GDNF was injected to the ventricle and did not reach to the SNpc
and the second trial had some problems with connection between the delivery pump and catheter (Nutt et
al., 2003, Lang, 2006, Penn et al., 2006, Patel and Gill, 2007). Despite two failed clinical trials, GDNF
continues to be one of the best candidates among NTFs for neurorestorative therapy in PD due to its ability
to protect and restore dopaminergic function in vitro and in vivo in animal models of PD (Tarazi et al.,
2014).  Highlighting the clinical and economic importance of GDNF, currently four Phase II clinical trials with
GDNF in PD are ongoing.  Interestingly, Backman et al. (2006) found  significantly elevated  endogenous
GDNF but not  RET or GFRα1 mRNA expression in  patients diagnosed with idiopathic PD indicating a
compensatory mechanism involving GDNF attempting to rescue dying neurons at late stage of disease
progression.
Despite the use of GDNF in clinical trials for PD and its known or presumed role in human diseases, the
basic mechanisms regulating GDNF in vivo in particular in aging and diseased brain are largely unexplored
stressing a need for basic research in this direction. Studies on mechanisms of GDNF levels regulation is one
of the objectives of this thesis.
1.5 Mouse	models	to	study	the	functions	of	BDNF	and	GDNF		
1.5.1 Mouse	models	of	BDNF	
Mouse models are a central tool to study the functions of genes, including those involved in human
diseases. There are several mouse models to study BDNF functions in vivo. Since BDNF homozygous KO
mice die within 2-4 postnatal weeks, most studies on BDNF deficiency in mice are done with heterozygous
KO mice where one BDNF allele is intact (Korte et al., 1995). Such mice are viable and fertile with an
approximate 50% reduction in the BDNF mRNA and protein level. BDNF heterozygous KO mice show
phenotypes such as severe defects  in coordination and balance, impairment of long term potentiation in
the hippocampus and learning difficulties (Ernfors et al., 1994, Korte et al., 1995, Linnarsson et al., 1997,
Bartoletti et al., 2002).
Using cKO technology, BDNF was deleted specifically in hippocampal area CA3 and to some extent in
dentate gyrus, cerebellum and facial nerve nucleus. These mice exhibited increased aggressive behavior
with additional behavior changes like anxiety and deficient cognition (Ito et al., 2011). In another study with
conditional approach, Monteggia et al. (2004) used Cre- line with tetracycline inducible forebrain specific
promoter to delete BDNF in the forebrain of young and adult mice and, found hippocampal  dependent
memory impairment and hyperactivity during early stages of development in young mice in addition to the
antidepressant role of BDNF in adult mice. Later the same group also studied specific BDNF deletion in the
forebrain during pre and post natal development and found gender specificity in depression-related
phenotypes in these conditional BDNF KO mice (Monteggia et al., 2007). Clow and Jasmin (2010)
conditionally deleted BDNF in the muscles of mice using Cre-line specific to skeletal muscles and showed a
role of BDNF in the regulation of satellite cell differentiation and skeletal muscle regeneration.
Chen et al. (2006) created Val66Met polymorphic mice that have impaired BDNF secretion from neurons
despite normal expression of BDNF. These mice showed an increased anxiety related phenotype under
8stressful conditions that could not be rescued by administration of fluoxetine, an antidepressant drug
thought to act via BDNF signaling. There are at least two different BDNF overexpressing mice generated
under constitutive human β-actin and α Ca2+/calmodulin-dependent kinase II (αCaMKII) promoters
respectively. Mice overexpressing BDNF under human β-actin showed learning deficits, increased sensitivity
to seizures and elevated mental excitability (Croll et al., 1999). αCaMKII  promoter driven BDNF
overexpression was  mainly restricted to the forebrain  and these mice showed early development of visual
acuity and shortening of critical period for ocular dominance plasticity (Huang et al., 1999). Overall, these
studies stress the importance of animal models in understanding BDNF function and its regulation in
various biological processes.
1.5.2 Mouse	models	of	GDNF	
GDNF homozygous KOs die soon after birth due to complete kidney agenesis and lack of enteric nerves
distal to stomach limiting their usefulness to study the role of endogenous GDNF in adults (Sanchez et al.,
1996, Pichel et al., 1996, Moore et al., 1996). There have been multiple studies with GDNF heterozygous KO
mice that suggest a role of GDNF in  nigrostriatal  dopaminergic transmission (Gerlai et al., 2001, Airavaara
et al., 2004, Boger et al., 2006, Griffin et al., 2006, Airavaara et al., 2006, Boger et al., 2007, Littrell et al.,
2013).
There is a single study using a cKO approach where by tamoxifen inducible Esr1-cre is used to delete GDNF
by administering tamoxifen (TMX) in 2 month old mice resulting in the complete loss of noradrenergic
neurons in LC and massive loss of DA neurons in VTA and SN (Pascual et al., 2008). This study by Pascual et
al. (2008) concluded that GDNF is essential for survival of catecholaminergic neurons in the adult mice.
However,  the Saarma and Andressoo group has shown with three independent GDNF conditional ablation
approaches including step-wise repetition of experiments presented in Pascual et al.(2008) study  that
GDNF deletion has no consequence on midbrain dopaminergic system survival and function (Kopra et al., in
press). Additionally, Saarma and Andressoo group has found comparable up-regulation of several NTFs and
their receptors in the brain of GDNF KO heterozygous mice and in animals where GDNF is conditionally
deleted from the brain indicating that reduction or lack of GDNF in the brain is compensated for by the
elevation of alternative growth factors and their receptors (Varendi et al., unpublished).
Transgenic mice overexpressing GDNF have been widely used to study GDNF in various contexts using
different constitutive promoters such as human translation elongation factor–1α (EF-1α), myosin light
chain-1 (MLC1) and glial fibrillary acidic protein (GFAP). Testicular overexpression of GDNF under EF-1α
promoter demonstrated a role of GDNF in spermatogenesis and resulted in testicular tumors in 100% of
mice by 12 months of age (Meng et al., 2000). Overexpression of GDNF in muscles under the MLC1
promoter resulted in hyperinnervation of muscle fibers (Zwick et al., 2001).  Zhao et al. (2004)
overexpressed GDNF in CNS under the GFAP promoter demonstrating a potent effect of GDNF on motor
neuron survival. Skeletal muscle-specific overexpression of GDNF resulted in a slight but significant delay in
motor neuron loss in an ALS mouse model (Li et al., 2007). Kholodilov et al. (2004) used a double transgenic
approach with CaMKII promoter and tTA-response promoter to overexpress GDNF in the principal target
areas of the mesencephalic dopaminergic projections and concluded that the GDNF has a role in the
development of the mesencephalic dopaminergic system. However, it should be noted that the CaMKII
promoter drives expression in excitatory neurons (Klug et al., 2012), whereas native GDNF is expressed in a
specific subset of striatal inhibitory neurons which control striatal output (Hidalgo-Figueroa et al., 2012). It
remains unclear that to what extent transgenic overexpression reflects the function of endogenous GDNF.
9Apart from transgenic and KO approach, exogenous GDNF has been delivered to intact rodent brain. These
studies with exogenous GDNF demonstrated various effects on brain dopaminergic system function (See
table 1.2).
Procedure Increase Decrease References
Single intracranial dose of
GDNF protein
TH staining
TH+ neurite sprouting
DA release
DA turnover
DA and metabolite level
TH phosphorylation
ERK1/2 phosphorylation
Motor activity
Amphetamine turning
Food intake
Water Intake
Body weight
Hudson et al. (1995)
Hebert et al. (1996)
Hebert and Gerhardt
(1997)
Lapchak et al. (1997)
Xu and Dluzen (2000)
Salvatore et al. (2004)
Virally mediated
continuous expression
of GDNF in the midbrain
Early:
DA turnover
DA function
Late ( 6 weeks):
TH mRNA
Late (6 weeks):
TH protein
TH activity
DA
Rosenblad et al. (2003)
Georgievska et al.
(2004a)
Georgievska et al.
(2004b)
Sajadi et al. (2005)
Table 1.2: Summary of studies showing effects of ectopic GDNF delivery to intact rodent brain. Adapted
from doctoral thesis by Planken (2012).
Some phenotypic effects of exogenous GDNF varied based on method (Procedure section, table 1.2) of
GDNF delivery emphasizing that biological outcome of a trophic factor like GDNF is critically dependent
upon the injected dose as well as on the method of GDNF delivery. The main challenge with transgenic
overexpression and ectopic GDNF delivery is the inability to control the spread of GDNF and other NTF
molecules to the correct biological sites of action, which likely leads to undesired biological effects. Apart
from this, GDNF is a particularly poorly diffusing molecule, since it strongly interacts with heparin sulfates in
the extracellular matrix (Bespalov et al., 2011). An alternative measure enabling elevation of GDNF and
possibly BDNF at correct sites would be of interest to uncover but such a tool has been missing. In search
for such a tool, we turned to study the biology of 3ʹUTRs of GDNF and BDNF.
1.6 Gene	regulation	by	3ʹUTR	
Mature mRNAs in eukaryotes contain a protein coding sequence (CDS) with a 5ʹ and 3ʹ UTRs. The last
decade of research has revealed that 3ʹUTRs  are crucial regulators of gene expression through interaction
with various factors (Barrett et al., 2012) . 3ʹUTRs are used to control mRNA stability, translation,
polyadenylation and cellular localization (Siepel et al., 2005, Mercer et al., 2011). At least about 60% of
3ʹUTRs of protein coding genes are predicted to contain various cis- acting regulatory elements like miR
response elements, AU rich elements (AREs), iron responsive elements(IREs), alternate polyadenylation
signals or they fold  into various secondary structures with functional significance, all of which can affect
transcripts’ stability, translation or localization (Barrett et al., 2012).
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1.6.1 MicroRNAs		
miRs were discovered already in the early 1990s , but were recognized as a distinct class of biological
regulators almost a decade later (Lee et al., 1993, Ambros, 2001). miRs are a family of small ~22 nucleotide
long non coding RNAs  which regulate  gene expression by binding to complementary  nucleotide
sequences in their target mRNAs (Ambros, 2004). miR binding domains are mostly present in the 3ʹUTR
region of target mRNA  in mammals with few exceptions (Gu et al., 2009, Forman and Coller, 2010). miRs
are evolutionarily ancient regulatory molecules and conserved during the course of evolution (Wheeler et
al., 2009).The majority of miRs are derived from long pri-miR transcripts that are synthesized from specific
miR genes or from the introns of protein coding genes (host gene) by RNA polymerase II  (Lee et al., 2004,
Rodriguez et al., 2004). The processing of primary miR (pri-miR) transcripts to precursor miRs (pre-miRs) is
mediated by ribonuclease complex (Dorsha) and specialized double stranded RNA binding proteins (DGCR8)
in the nucleus, followed by transport to the cytoplasm for final cleavage by another ribonuclease called
Dicer resulting in double stranded  mature miRs (Figure 1.5 ) (Lee et al., 2002, Lee et al., 2003, Landthaler et
al., 2004). After sequential processing to mature miR duplexes, a ribonucleoprotein complex called RNA
induced silencing complex (RISC) is formed in the cytosol by interaction of argonaute (AGO) proteins with
mature duplex miRs (Yoda et al., 2010). One of two strands of miRs (guiding strand) guides the RISC
complex to complementary target mRNAs sequences while the other strand known as the passenger strand
is degraded (Matranga et al., 2005, Rand et al., 2005, Kawamata et al., 2009). Whether miRs repress the
expression of the target gene by inhibiting translation or by promoting  target mRNA decay is, at least in
part, determined by seed matching of the guiding strand to target mRNA sequences (Figure 1.6) (Yekta et
al., 2004). Interestingly, in animals just 6-8 complementary nucleotides matching at the 5’ end of the
guiding strand of miRs can be enough to inhibit the expression of target mRNAs (Lai, 2002, Lewis et al.,
2003). This is in stark contrast to plants where almost 100% complementarity is required to promote
repression of target mRNA expression (Rhoades et al., 2002)
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1.6.2 AREs	and	ARE-BPs	
AREs are  50-150  nucleotide long regions in the 3ʹUTRs which serve as binding sites for ARE binding
proteins (ARE-BPs) that can either stabilize or de-stabilize their target mRNAs (Barreau et al., 2005).
Roughly about 8% of mRNAs are estimated to contain functional AREs but their relevance in biological
functions is largely unexplored (Bakheet et al., 2003, Bakheet et al., 2001). They are classified into three
groups (Class I-III AREs), based on the presence of a core pentameric AUUUA sequence. Class I AREs have a
core AUUUA sequence  flanked by either A or U, Class II AREs have more than one overlapping AUUUA
sequences, whereas Class III AREs are not well defined and do not have a typical AUUUA sequence (Chen
and Shyu, 1995, Xu et al., 1997). Table 1.3 summarizes the known effects of ARE-BPs on the target mRNAs.
ARE-BPs Stabilizing effect on mRNA De-stabilizing effect on mRNA
Tristetraprolin(TTP) TNF-α,c-Fos, GM-CSF,Cox -2,IL-2,IL-3,
IL-6, IL-8, IL-10, IL-17, IL-1a, IL-23a,
Csf2, Ccl2, Ccl3, Vegfa, Cxcl1, Nos2,
Pitx2, Pim1, MYC, MMP1, TLR4,  Ptgs2,
HIV-1,
Approx. 250 transcripts upregulated in
TTP KO fibroblasts
Butyrate response factor 1
(BRF1)
TNF-α, GM-CSF, IL-3, Vegf, c-IAP2, STAR
Butyrate response factor 2
(BRF2)
TNF-α, , GM-CSF, IL-3
AU rich element binding
protein 1 (AUF1/HNRPD)
c-myc, c-fos, PTH, GM-CSF, TNF-α c-myc, c-fos, p21, Cyclin D1, GM-CSF,
IL-3
ELAV like RNA binding
protein 1 (ELAVL1/HuR)
c-fos, MyoD, p21, Cyclin A, Cyclin
B1, CyclinD1, NOS II/iNOS, GM-
CSF, TNF-α, COX-2, IL-3, Vegf,
Myogenin
ELAV like neuron-specific
RNA binding protein
(ELAVL4/HuD)
GAP-43, BDNF
KH-type splicing regulatory
protein (KSRP)
c-fos, TNF-α, NOS II/iNOS, IL-2, c-jun
Table 1.3: ARE-BPS and their effects on known target mRNAs. Broadly they can also be classified in two
major groups based on their stabilizing or destabilizing effects on target mRNAs. Notably, some ARE-BPs
like AUF1 can have stabilizing and de-stabilizing effect on same mRNA target in different biological
contexts. Based on information from publications by Barreau et al. (2005), Baou et al. (2009), Allen et al.
(2013) and Brooks and Blackshear (2013).
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1.6.2.1 Tristetraprolin	(TTP)		
Tristetraprolin/ Zinc finger protein 36 (TTP/Zfp36) is one of the most widely studied ARE-BPs and the
founding member of the TTP/family. A characteristic feature of the TTP ARE-BP family is the presence of a
CCCH zinc finger motif (Lai et al., 1990, DuBois et al., 1990). Butyrate response factor 1 (BRF1 /ZFP36L1) and
Butyrate response factor 2 (BRF2 /ZFP36L2) are the other two members of the TTP/TIS11 family. TTP, BRF1
and BRF2 are expressed in most mammals including humans, while rodents have an additional fourth
member called ZFP36L3 (Brooks and Blackshear, 2013).
TTP and its family members BRF1 and BRF2 have been shown to bind to ARE containing mRNAs resulting in
mRNA decay by mainly promoting deadenylation (Carballo et al., 1998, Stoecklin et al., 2002, Ciais et al.,
2004). Interestingly, some reports also suggest a role of TTP in regulation of gene expression at the
translational level (Qi et al., 2012, Pfeiffer and Brooks, 2012).
TTP KO mice are healthy at birth but develop progressive inflammatory disease with symptoms like patchy
alopecia, dermatitis, erosive arthritis, cachexia, conjunctivitis, myeloid hyperplasia, glomerular mesangial
thickening, and develop antinuclear antibodies 1-8 weeks postnatally. The phenotype of TTP KO mice is
largely rescued by injecting monoclonal antibodies against TNF-α (Taylor et al., 1996). Later, TTP was
demonstrated to  bind  directly to ARE present in the 3ʹUTR of TNF-α, validating it as the first physiological
target of TTP in vivo (Lai et al., 1999). Since then, TTP has been found to regulate a plethora of cytokines
and growth related transcripts (Table 1.3 ).  Notably, NTFs such as BDNF are also involved in regulating
inflammation in certain pathological conditions (Amoureux et al., 2008, Lin et al., 2011, Uchida et al., 2013,
Luhder et al., 2013). However, to date the potential of TTP to regulate NTF levels have remained
unexplored and is one of the objectives of this thesis.
1.6.3 	Other	mediators	of	3ʹUTR	regulation	
Apart from the above mentioned miR response elements and AREs, other regulatory elements exist in the
3ʹUTRs.  3ʹUTR contains signal sequences which lead to addition of  roughly 200 adenosine bases (polyA
tail) at the 3ʹ end of a mRNA that serve as a binding site for polyA binding proteins (PABPs) known to play a
role in processes like mRNA export, decay, stability and translation (Mangus et al., 2003). So far, five
different PABPs have been identified (Gorgoni et al., 2011). Furthermore, alternate polyadenylation signals
in the 3ʹUTRs facilitate generation of mRNAs containing 3ʹUTRs of various lengths. Roughly 50% of human
genes are estimated to contain alternate polyadenylation signals (Dickson and Wilusz, 2010). Iron response
elements (IREs) are another regulatory sequences present in 3ʹUTRs of various mRNAs encoding for
proteins involved in iron metabolism and serve as binding sites for IRE binding proteins (IRE-BPs) which
stabilize the target mRNAs (Guo et al., 1994). Finally, 3ʹUTR-s of several mRNAs may contain localization
signals which determine their active transport to different subcellular compartments particularly in such
highly polarized and differentiated cells as neurons. The disruption of these localization signal sequences
can cause a reduction in the corresponding mRNA and respective encoded protein levels in those sub-
cellular locations (Andreassi and Riccio, 2009). Last but not least are the secondary structure motifs of the
3ʹUTRs of mRNAs which can regulate RNA turnover (Sarnowska et al., 2007). For example, the 3ʹUTR of
BDNF has a secondary loop structure that stabilizes BDNF mRNA in neurons in the presence of Ca2+ signal
(Fukuchi and Tsuda, 2010). BDNF and GDNF transcripts contain long and conserved 3ʹUTRs (Results and
discussions, Figure 4.1). The current understanding of 3ʹUTR mediated regulation of BDNF and GDNF is
discussed in following section.
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1.7 3ʹ	UTR	mediated	regulation	of	BDNF	and	GDNF	
Apart from multiple promoter-mediated control, BDNF is additionally regulated by the 3ʹ UTR . A single
study suggested that the 3ʹUTR of BDNF mRNA plays a role in the subcellular localization of BDNF mRNA in
neurons leading to distinct cellular functions, although this conclusion needs further validation (An et al.,
2008). According to this study BDNF mRNAs containing long 3ʹUTRs are localized in dendrites whereas short
3ʹUTR containing transcripts generated due to presence of alternate polyA signal (See Figure 1.3A) are
restricted to the soma in vivo. An et al. (2008) made a mouse model generating  truncated long form of
BDNF 3ʹUTR (BDNF-L) and presented data suggesting impaired BDNF mRNA localization to dendrites leading
to defects in pruning and enlargement of dendritic spines resulting in selective impairment of long-term
potentiation in dendrites of hippocampal neurons . Despite the authors claim of no change in BDNF levels
in the 3ʹUTR truncated animal model the presented data suggests derepression of endogenous BDNF levels
which may alone or in addition to the localization defect explain the outcome. Future studies should
resolve this important issue.
In another study, Lau et al. (2010) has shown that the BDNF mRNA containing long 3ʹ UTR specifically
undergoes robust translational activation in the hippocampus upon seizure-induced neuronal activation.
Furthermore, regions of 3ʹUTR stabilize BDNF mRNA in response to Ca2+ signaling (Fukuchi and Tsuda,
2010). These studies highlight the importance of the 3ʹUTR   in the regulation of BDNF expression and
function, stressing the need for further in depth analysis of 3ʹUTR mediated regulators like miRs and RBPs.
Later studies indeed reported several miRs targeting the BDNF 3ʹUTR. miR-206 was shown to regulate BDNF
in the mouse model of Alzheimer disease and in vitro model of skeletal muscle differentiation (Lee et al.,
2012, Miura et al., 2012). Caputo et al. (2011) showed in another study that miR-26a and miR-26b down
regulates BDNF expression in a reporter assay  and that two single nucleotide polymorphisms (SNPs) in
BDNF 3ʹUTR specifically abolish their binding to 3ʹUTR in the same reporter assay. Table 1.4 shows an
overview of previous studies addressing regulation of BDNF by miRs.
Target miR Model Reference
miR-206 In vitro, In vivo Lee et al. (2012)
Miura et al. (2012)
Yang et al. (2014)
miR-26a, miR-26b In vitro Caputo et al. (2011)
miR-16 In vitro, In vivo Sun et al. (2013)
miR-22 In vitro Muinos-Gimeno et al. (2011)
miR-30a-5p, miR-195 In vitro Mellios et al. (2008)
Table 1.4: Overview of BDNF targeting miR studies.
 Importantly, the in vitro reporter based studies mentioned above used only a small fragment of the 3ʹUTR
of BDNF for validation of miR targets.  This leaves an open question about the validity and availability of
these target sequences in the context of full-length BDNF 3ʹUTR.
Apart from microRNAs, RBP HuD is shown to stabilize selectively BDNF mRNAs containing long 3ʹUTR in
vitro and in vivo but in this study as well, only a small fragment of BDNF 3ʹUTR, containing ARE was used for
in vitro assay (Allen et al., 2013). Interestingly, microarray studies on TTP KO cell line identified BDNF
among the 250 upregulated mRNAs, suggesting that TTP may, directly or indirectly, regulate BDNF levels
(Lai et al., 2006).
The structure of the mouse GDNF gene is far simpler in comparison to the BDNF gene (Figure 1.3B), it
contains three exons coding for transcripts including 1 kb long 5’- and 2.8 kb long 3ʹ-untranslated regions
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(UTRs) (Matsushita et al., 1997). Regions in the 3ʹUTR of GDNF are quite evolutionarily conserved (Results
and discussion section, Figure 4.1) indicating functional significance but surprisingly, there is just one single
study by Oh-hashi et al. (2012) which analyzed fragments from mouse GDNF 3ʹ UTR  with varying lengths
with luciferase reporter assay and concluded presence of  inhibitory elements in GDNF 3ʹUTR region.
However, analysis of GDNF 3ʹUTR for various regulators including miRs is still lacking and is one of the
primary objectives of the current thesis.
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2 Aims	of	the	study	
The aim of this study was to investigate 3ʹUTR mediated regulation of the neurotrophic factors BDNF and
GDNF by miRs and RBPs.  Along these lines, an alternative approach to study gene function was explored by
3ʹUTR replacement. The hypothesis is that when a 3ʹUTR is a subject of negative regulation, its replacement
with a 3ʹUTR devoid of negative regulation would lead to overexpression limited to natively expressing
cells, i.e. derepression of endogenous gene expression.
Specific aims:
- Characterize the 3ʹUTRs of BDNF for miR binding sites and identify BDNF regulating miRs in vitro.
- Analyze BDNF 3ʹUTRs for AREs and screen for BDNF regulating ARE-BPs in vitro.
-Characterize the 3ʹUTR of GDNF for miR binding sites and identify GDNF regulating miRs in vitro.
- Study mice where the GDNF 3ʹUTR is replaced with a 3ʹUTR less responsive to negative regulation by
miRs.
18
3 Materials	and	methods	
List of material and methods used in this thesis work. See original publications/manuscripts for detailed
information about material and methods.
METHODOLOGY PUBLICATION/MANUSCRIPT
RNA and DNA methods
Isolation of RNA and
DNA
I,II,III
Reverse
transcription(RT),
cDNA synthesis
I,II,III
Quantitative RT-PCR I,II,III
Northern Blot III
In situ hybridization III
Genotyping III
Dual-Glo® Luciferase
Assay System and
CellTiter-Glo®
Luminescent Cell
Viability Assay
I,II,III
Molecular cloning I,II,III
Electrophoretic
mobility shift assay
(EMSA)
II
RNA
immunoprecipitation
assay (RNA-IP)
II
Cell culture methods
In vitro cell culture I,II,III
Primary cell culture III
Immunological
methods
ELISA (GDNF/BDNF) I,II,III
Western blotting II,III
Immunohistochemistry III
Other methods III
Estimation of
monoamines and their
metabolites, HPLC
III
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Corridor test III
Amperometry III
Generation of knockin
animals and tissue
dissection
III
Web tools for in silico
analysis
Web page (Publication/manuscript)
Targetscan http://www.targetscan.org (I,III)
AREsite http://rna.tbi.univie.ac.at/cgi-bin/AREsite.cgi (II,III)
Genecards http://www.genecards.org/ (II)
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4 Results	and	discussion	
4.1 The	3ʹ	UTRs	of	BDNF	and	GDNF	contain	regulatory	sequences	(I,	II,	III)	
in silico analysis of BDNF and GDNF 3ʹ UTR  was performed using publically available web-tools (Material
and methods). Targetscan predicted multiple evolutionary conserved miR binding sequences in the  both
isoforms of 3ʹUTRs of BDNF (BDNF-S and BDNF-L) and GDNF 3ʹUTR (Figure 4.1). AREsite predicted multiple
evolutionally conserved class I AREs (AUUUA) in both isoforms of BDNF 3ʹUTRs and GDNF 3ʹUTR.  Notably,
regions closer to 5’ and 3ʹ end of both BDNF and GDNF 3ʹ UTR sequences were highly (81-90%) conserved
between M. musculus and H. sapiens (Figure 4.1) . Importantly, all miR binding sequences present were
shared between M. musculus and H. sapiens 3ʹUTRs except miR-190/190ab site for BDNF and miR-
216/216a site for GDNF (Targetscan). Additionally, Human BDNF 3ʹUTR had one extra ARE site (AUUUA) and
GDNF 3ʹ UTR had 3 extra ARE sites (AREsite). Furthermore, BDNF-S contained 7 miR sites out of total 13
predicted conserved miR sites and 2 AREs out of total 8 predicted conserved ARE sites in mouse BDNF
3ʹUTR (Figure 4.1).
Figure 4.1: Schematic diagram showing percentage of sequence identities between mouse (M. musculus)
and human (H. sapiens) 3ʹUTR of BDNF and GDNF. Vertical bars show predicted miR binding sequence
(Thicker bars indicates highly conserved miR binding sequences among vertebrates), black triangles show
predicted conserved AREs (AUUUA) and arrows show PolyA (polyadenylation) signals.
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4.2 BDNF	and	GDNF	level	is	regulated	by	miRs	in	vitro	(I,	III)	
4.2.1 BDNF	regulation	by	miRs	in	vitro	(I)	
The objective of this study was to analyze the regulation of both isoforms of BDNF 3ʹUTR : BDNF-L and
BDNF-S, by ten miRs (miR-1, miR-10b, miR-15a, miR-16, miR-30a,miR-30b, miR-155, miR-182, miR-191 and
miR-195) selected based on evolutionary conservation of their binding sequences within 3ʹUTRs of BDNF
and their co-expression with BDNF  in the tissues or cell lines with known BDNF functions using in vitro
tools.
miR-1, miR-10b, miR-155 and miR-191 as novel regulators of BDNF were identified  using luciferase
reporter assay, miR binding site mutational analysis, assessment of pre-miR overexpression effects on
endogenous BDNF levels and measurements of endogenous BDNF derepression upon application of  anti-
miRs against identified endogenously expressed miRs.  In addition, data suggest direct interaction between
BDNF long 3ʹUTR and endogenous miR-1/206 family miRs in C2C12 cell model of muscle differentiation,
where regulation of BDNF level is known to be critical. The findings were confirmed by showing that the
binding sites for miR-1 and mIR-10 in BDNF 3ʹUTR are used synergistically by endogenous miRs in several
cell lines.
This study is the first functional analysis of BDNF 3ʹUTR which addresses the effects of the ten most
conserved miRs on full-length BDNF 3ʹUTR isoforms. All the previous studies focused on one or two miRs at
a time and studied their effects on various fragments of BDNF 3ʹUTR making direct comparisons of different
studies difficult. Due to the co-expression of investigated miRs with BDNF in various tissues and
conservation of these miR sites among most vertebrates, it is speculated that BDNF/miR interaction plays
an important role in vivo.
4.2.2 GDNF	regulation	by	miRs	in	vitro	(III)	
The first objective of the study was to analyze the regulation GDNF 3ʹUTR by nine miRs (miR-9, miR-133a,
miR-133b, miR-125a-5p, miR-125b-5p, miR-30a, miR-30b, miR-96, miR-146a) selected based on
conservation of their binding sites within the GDNF 3ʹUTR and their co-expression with GDNF in various
tissues where GDNF has a known or presumed biological function. All the nine miRs negatively regulated
expression of a reporter construct containing the GDNF 3ʹUTR compared to controls. Furthermore,
mutating the evolutionary conserved miR-146a and miR-96 target sequence abolished the inhibitory effects
of respective miRs on the GDNF 3ʹUTR containing reporter, suggesting their direct interaction with the
3ʹUTR of GDNF. Mutational analysis of the presumed miR-9 binding site and miR-133 family binding sites in
the GDNF 3ʹUTR did not abolish inhibition, indicating that these two miRs bind to different sites or their
effect are indirect. Endogenous GDNF protein and mRNA levels were suppressed when precursors of miR-9,
miR-96, miR-146a and mir-133b (selected based on their most potent inhibitory effects in the luciferase
based reporter assay) were transfected to U-87 cells which express detectable amounts of endogenous
GDNF protein and mRNA(III, Figure 3B-E).
4.3 BDNF	but	not	GDNF	is	regulated	by	TTP	ARE-BP	via	the	3ʹUTR	in	vitro	(II,	III)	
4.3.1 BDNF	is	regulated	by	TTP	(II)	
 AREs in both isoforms of BDNF 3ʹUTRs are well conserved (AREsite, Figure 4.1). Selection of six ARE-BPs
(TTP, BRF1, BRF2, ELAVL1, ELAVL2 and AUF1) were based on their co-expression with BDNF in various
tissues (Genecard, Material and methods). ARE-BPs TTP, BRF1 and BRF2, but not ELAVL1 or ELAVL2,
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effect of miRs and TTP. Using the same reporter containing long 3ʹUTR (BDNF-L), we studied miR-1 and TTP
alone and together and found an additive effect in this system (Figure 4.3). This is an indication that TTP
and miR-1 can co-operate but this finding needs further validation in different systems including studies on
endogenous TTP and miR-1 co-inhibition on endogenous BDNF mRNA and protein levels.
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Figure 4.3: Additive effects of TTP and miR-1on the inhibition of luciferase reporter construct expression
containing BDNF-L. In the graph, Firefly/Renilla luciferase ratio for GFP+N1 control sample was set 1 and
fold changes compared to GFP is presented for other samples. Data were analyzed with 2-tail student’s t-
test assuming unequal variance. The level of significance was set at p= 0.01 . N1= Non-targeting miR
control,   *** P< 0.001, N=3
4.3.2 GDNF	is	not	regulated	by	tested	RBPs	in	vitro	reporter	assay	(III)		
Reporter construct containing GDNF3ʹUTR co-transfected with plasmid encoding for the selected ARE-BPs
(TTP, ELAVL1, AUF1, TIA1, ELAVL2, BRF1 and CELF1) revealed that the above RBP-s had no or mild effect (In
case of, BRF1) on reporter expression (Figure 4.4 and III, Supplementary Figure 3A). Mild binding effects  in
luciferase reporter assay with RBPs is subject to further validation by alternate direct methods such as
EMSA or RIP as indirect luciferase reporter based method is known to have nonspecific effect (Auld et al.,
2008). An independent study by Oh-hashi et al. (2012)  tested  several ARE-BPs in a luciferase reporter
assay ( ELAV family members: HuR, HuD, HuB and HuC) with similar conclusions.
       GFP        GFP+ N1       TTP      GFP+miR1   TTP+miR1
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Figure 4.4: No effect of RBPs on luciferase reporter expression containing GDNF 3ʹUTR. In the graph,
Firefly/Renilla luciferase ratio for GFP control sample was set 1 and fold changes compared to GFP is
presented for other samples. Data were analyzed with 2-tail student’s t-test assuming unequal variance.
The level of significance was set at p= 0.01.
Importantly, luciferase reporter containing full length GDNF 3ʹUTR was used in this thesis work whereas
Oh-hashi et al. (2012) used almost 13 different luciferase reporter constructs containing various lengths of
GDNF 3ʹUTR ( ranging from full length GDNF 3ʹUTR to shorter fragments (~80 nucleotides) with predicted 3
AREs, Figure 4.1). This indicates that these predicted AREs are not interacting with or unavailable to tested
RBPs and independent of the length of GDNF 3ʹUTR used with the luciferase reporter.
4.4 Generation	of	GDNF	3ʹUTR-crR	mice	(III)	
A mouse model with conditionally reversible replacement of GDNF 3ʹUTR (GDNF 3ʹUTR-crR mice) was
generated, as the GDNF 3ʹUTR possesses inhibitory properties (III, Figure 1). The effect of GDNF specific
miRs on the GDNF 3ʹUTR replacement cassette (designated as “GDNF 3ʹUTR-crR”) was assessed in luciferase
reporter assay and none of the tested miRs retained any inhibitory effect on the replacement sequence (III,
Figure 1). Compared to a reporter containing GDNF 3ʹUTR a reporter containing the GDNF 3ʹUTR-crR
yielded two-fold elevated expression in brain-derived U87 cells and eight-fold elevated expression in
kidney-derived HEK293 cells (III, Figure 1). The replacement cassette was flanked with FLP recombinase
recognition sites enabling conditional removal of the replacement cassette to restore transcription to the
GDNF native 3ʹUTR (GDNF 3ʹUTR-rest -/-, III).
4.5 In	vivo	replacement	of	3ʹUTR	elevates	GDNF	level	(III)	
GDNF 3ʹUTR replacement in mice resulted in elevation of GDNF mRNA and protein levels in the different
parts of the brain and in the developing kidneys (III, Figure 2 and Supplementary Figure 2) in both
homozygous and heterozygous animals in a gene dose-dependent manner. Analysis of GDNF mRNA
expression by in situ hybridization (ISH) in various organs revealed that GDNF mRNA expression in those
mice is limited to cells which natively express GDNF (III, Figure 2). This elevation in the GDNF levels in brain
and kidney was restored to wild type levels by conditional removal of the replacement cassette by crossing
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with Deleter-Flp mouse line (III, Figure 2C). This shows an advantage of the 3ʹUTR replacement method
over conventional transgene overexpression mouse models where variations in integration site and
recombinant construct most often lead to spatiotemporal misexpression confounding conclusions on
endogenous gene functions. Moreover, elevation in the GDNF levels in brain and kidney was restored to
wild type levels by conditional removal of the replacement cassette by crossing with Deleter-Flp mouse line
(III, 2C). This property of GDNF 3ʹUTR-crR mice allows future studies on the biology of GDNF levels in
various organ systems where GDNF is known to play important role.
4.6 Phenotypic	effect	of	3ʹUTR	replacement	of	GDNF	in	mice	(III)	
Homozygous GDNF 3ʹUTR-crR mice die before post-natal day (P) 18 because of defective kidneys and
urogenital tract (Andressoo group, unpublished) but heterozygous GDNF 3ʹUTR-crR mice are healthy with
normal life-span. Bodyweight measurements and studies with a physiological cage revealed no difference
between heterozygous and wild type littermates. Dopamine levels in the rostral brain of homo- (-/-)and
heterozygous (+/-) GDNF 3ʹUTR-crR mice at the age of P7.5 were elevated compared to wild type (III, Figure
4B). Similarly, dopamine levels in the striatum of adult (2.5-3 months age) GDNF 3ʹUTR-crR (+/-) mice were
elevated (III, Figure 4F). Restoration of wild type GDNF level by removing 3ʹUTR replacement cassette leads
to restoration of wild type dopamine level (III, 4B and 4F).
Furthermore, dopamine transporter (DAT) activity is increased up to 5-fold in a dopamine concentration
dependent manner and amphetamine-induced locomotor activity (but not basal) is significantly increased
in the GDNF3ʹUTR-crR (+/-) mice (III, Figure 5A-B). Additionally, GDNF 3ʹUTR-crR (+/-) mice were protected
in a unilateral supranigral lactacystin injection based rodent model of Parkinson’s disease (III, Figure 5C-G).
Thus, about 2-fold elevation in endogenous GDNF levels in the striatum (III, Figure 2C) results in significant
boost in brain dopamine system function and is sufficient to protect animals from chemically induced PD.
Since classical GDNF knockout mice die at birth due to a lack of kidneys with an intact midbrain dopamine
system little in vivo data on the postnatal function of endogenous GDNF exists. Since GDNF 3ʹUTR-crR mice
(+/-) are viable, we were able to analyze the postnatal role of endogenous GDNF in the development and
function of the postnatal dopamine system. GDNF 3ʹUTR-crR mice can also be useful for study of
endogenous GDNF in other organ systems with known GDNF functions such as the urogenital tracts and
enteric nervous system (Moore et al., 1996, Sainio et al., 1997).
We demonstrate a qualitative difference between ectopic and endogenous GDNF action on the dopamine
system (III, Table 1). Ectopic GDNF transiently increases dopamine turnover without lifting total dopamine
levels (Hudson et al., 1995, Georgievska et al., 2004b, Hebert et al., 1996), while elevation of endogenous
GDNF by 3ʹUTR replacement permanently elevates total dopamine levels but not its turnover. In addition,
results with GDNF3ʹUTR-crR mice show dopamine concentration-dependent increase in DAT activity which
has not been reported in studies with ectopic GDNF. We also show that, unlike ectopic GDNF which reduces
TH levels, endogenous GDNF has no effect on TH levels in SNpc and striatum.
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5 Conclusion	and	future	perspectives	
The physiological consequence of 3ʹUTR mediated levels regulation of important regulatory genes such as
neurotrophic factors in the brain has largely remained unexplored. In this thesis work we present analysis
of full length 3ʹUTRs of the neurotrophic factors BDNF and GDNF in vitro. We show role of miRs (miR-1,
miR-10b, miR-191 and miR-155) and ARE-BP TTP in the negative regulation of BDNF. We conclude that
GDNF is regulated by multiple miRs in cell lines and identify binding sites for miR-146 and miR-96 in the
GDNF 3ʹUTR. Finally,  the knowledge gained from in vitro experiments about 3ʹUTR mediated negative
regulation of GDNF  was applied to generate a new mouse model based on 3ʹUTR replacement of GDNF
which led to in vivo upregulation of GDNF levels. The latter mouse model enables studies on postnatal
GDNF function in midbrain and other organ systems that are largely inaccessible with previous genetic
tools.
The specific conclusions for each study:
I. miR-1, miR-10b, miR-155 and miR-191 are novel direct regulators of BDNF. Co-expression of BDNF and
miR-1/miR-10b/miR-155/miR-191 in various cell types and tissues suggests potential relevance of miR
mediated post-transcriptional regulations of BDNF in various physiological and pathological processes.
II. TTP is a direct post-transcriptional regulator of BDNF. BDNF and TTP are co-expressed in many cell types
and tissues.
Together, I and II report two different classes of negative regulators of BDNF expression via 3’UTR. These
findings open doors to future studies addressing the in vivo relevance of the identified miRs and TTP
mediated regulation of BDNF function in health and disease.
III. GDNF is regulated by multiple miRs in cell lines and at least miR-146 and miR-96 directly bind to the
GDNF 3ʹUTR. In vivo replacement of 3ʹUTR uncovers novel functions of GDNF and provides a potent tool for
future studies on GDNF.
The results presented in this thesis also indicate that the 3ʹUTR replacement approach could be of broad
interest to the scientific community. Currently, gene function in vivo is mostly studied by the gene knock-
out approach or by transgenic overexpression. However, the knock-out approach fails to reveal the extent
to which compensatory effects by functional homologues and, in the case of the brain, the use of
alternative neuronal networks, masks the effects of the lack of a gene.  On the other hand, the transgenic
overexpression of a gene has its own limitations because of frequent spatiotemporal mis-expression
resulting from recombinant construct and integration site variations. Our results suggest that in vivo studies
by targeting 3ʹUTRs with regulatory properties may provide information on gene function previously
inaccessible with current methods, and in a highly specific manner in natively expressing cells.
Of all organs, it is the brain where precision of spatial regulation of regulatory factors expression is
expected to play the most prominent role in building and maintaining the organ. We hypothesize that
systematic species and organ system-spanning genetic studies of 3ʹUTRs would provide important new
information on gene function and regulation. Based on our findings, we propose an improved approach
enabling studies on 3ʹUTR function and changes in endogenous gene product levels both spatially and
temporally. We compared sequences of important regulatory genes involved in development and plasticity
of nervous system.
Our analysis revealed long 3ʹUTRs with the majority of miR binding sequences conserved between mouse
and human for several important regulatory genes involved in brain development and function (Table 5.1).
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Gene Gdnf Bdnf EfnA3 EfnB2 Ntn1 En2 Robo1 Sema3A Ncam1
3ʹ UTR bp 2743 2891 954 3141 3632 1764 1730 2954 3275
No. of
conserved
miR sites
12 13 6 15 5 15 6 11 7
Identical
miR sites
Mm/Hs
11 12 6 14 5 13 6 11 7
Table 5.1: Representative genes with known regulatory function in brain ( III, Figure 5L)
As mentioned above, these results with the 3ʹUTR replacement model suggest that this method can provide
information beyond that accessible with previously available genetic manipulation tools. Along these lines,
Andressoo group has already generated a “Flex-cassette” (Schnutgen et al., 2005) based system allowing
conditionally replace GDNF 3ʹUTR in vivo. This model will provide additional opportunities to use Cre-based
mouse lines to conditionally derepress GDNF in a specific tissue and/or time.
Whether presented findings in this thesis can be transferred into clinically meaningful applications to treat
human diseases or age-related decline in brain function awaits the development and demonstration of
brain-deliverable and sufficiently gene specific 3ʹUTR regulators. Those may include virally encoded shRNAs
targeting specific miRs, miR sponges and miR target site protectors (Choi et al., 2007, Gentner et al., 2009,
Li et al., 2009). It is tempting to speculate that these as well as future results from 3ʹUTR replacement
studies will motivate development of new gene-specific means to manipulate 3ʹUTR regulation.
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Introduction
Brain-derived neurotrophic factor (BDNF) is a member 
of the neurotrophin family and has important functions in 
brain development, synaptogenesis, and memory and learn-
ing [19, 32, 37, 44, 50]. Disrupted BDNF function has been 
associated with several nervous system disorders, such as 
huntington’s disease [23, 69], depression [8, 11], and anxi-
ety [55], in both humans and rodent models. In addition, 
BDNF is involved in several physiological processes out-
side the brain, such as angiogenesis in the heart and skeletal 
muscles [16], myogenic differentiation [49], and skeletal 
muscle regeneration [13]. as evident from studies with mice 
heterozygous for the BDNF gene, 50 % reduction in BDNF 
protein levels is sufficient to cause notable phenotypic 
changes [1, 2, 15, 45]. thus, precise regulation of BDNF 
levels is important in several developmental and pathologi-
cal processes, highlighting the importance of understanding 
the mechanisms that control BDNF expression.
the 3′ untranslated regions (3′UtRs) of mammalian 
genes contain highly conserved sequences [60] important 
in the regulation of translational efficiency, polyadenyla-
tion, and stability of the mRNa. these functions are medi-
ated by binding to RNa-interacting factors, such as micro-
RNas (miRs) [6, 48]. miRs are short, non-coding RNa 
molecules predicted to interact with the transcripts of about 
60 % of all mammalian protein-coding genes [7]. miRs 
bind their target mRNas through a fully complementary 
seed sequence of 7–8 nucleotides in their 5′ end and less 
complementary area in the 3′ end, inducing translational 
repression and/or mRNa degradation [7, 24].
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cal outcome, the role of microRNas (miRs) in modulat-
ing BDNF expression has not been extensively analyzed. 
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One way to modulate miR-mediated regulation of 
gene expression is through the generation of alternative 
mRNa transcripts that differ in the length of the 3′UtR 
[58]. Brain-derived neurotrophic factor transcripts con-
tain either short (BDNF-Sh, 350 nt) or long 3′UtR 
(BDNF-L, 2891 nt [27]). In addition to length, second-
ary structure of the 3′UtR is also known to influence 
mRNa stability, at least in part by modifying accessi-
bility to miR target sites in the mRNa [29, 67, 68]. In 
general, miR sites near the ends of the 3′UtR are more 
effective than sites in the center of the 3′UtR, partly 
because regions in the middle of the 3′UtR are more 
likely to be incorporated into hairpin structures, hinder-
ing access to miRs [29]. BDNF-L contains a stem-loop 
structure necessary for the regulation of transcript stabil-
ity [26], raising the possibility that a secondary structure 
could determine access to factors like miRs that influ-
ence mRNa stability.
Despite the presence of more than ten in silico pre-
dicted highly conserved binding sites for different miRs 
in BDNF 3′UtR (www.targetscan.org, see below) and 
the physiological and pathological relevance of BDNF 
levels, to date only a few miRs have been studied in rela-
tion to BDNF. although BDNF regulation by miR-206 
has been well established in several studies [42, 47, 54], 
it has remained controversial which of the three miR-
206 sites is functional [42, 47]. the potential effect of 
another miR-1/206 family member, miR-1, which dif-
fers from miR-206 by four nucleotides outside the seed 
region and has a distinct expression pattern from miR-
206, has not been investigated to date. Other studies 
suggesting miR-BDNF 3′UtR interaction lack evidence 
that the effect of the putative BDNF-regulating miR on 
BDNF 3′UtR is direct [25, 46]. Most importantly, the 
effects of endogenous miRs on putative miR binding 
sites within BDNF 3′UtR have remained unaddressed 
altogether. Since 3′UtR length and secondary structure 
are likely to play an important role in miR-mediated tar-
get suppression [29, 58], the fact that all previous stud-
ies have exclusively analyzed BDNF 3′UtR fragments 
[25, 42, 46, 47] further stresses a need for analysis of 
BDNF 3′UtR-miR interaction in the context of native, 
full-length 3′UtR.
the objective of the current study was to analyze the 
regulation of both BDNF-L and BDNF-Sh full-length 
3′UtR isoforms by ten miRs selected based on evolution-
ary conservation of their seed sequences within BDNF and 
their expression within tissues or cell lines with known 
BDNF function [21, 40, 49, 51, 61, 63]. We assessed the 
effects of miR-1, miR-10b, miR-15a, miR-16, miR-30a, 
miR-30b, miR-155, miR-182, miR-191 and miR-195 on 
full-length BDNF-L and BDNF-Sh isoforms and identified 
miR-1, miR-10b, miR-155, and miR-191 as novel direct 
regulators of BDNF 3′UtR. In addition, we provide data 
suggesting direct interaction between BDNF long 3′UtR 
and endogenous miR-1/206 family miRs in a model system 
of muscle differentiation, where the regulation of BDNF 
levels is known to be critical. Finally, our results indicate 
that the binding sites for miR-1 and miR-10 in BDNF 
3′UtR are used synergistically by endogenous miRs in sev-
eral cell lines.
Materials and methods
Plasmids and constructs
Full-length and short BDNF 3′UtR sequences were 
obtained from BaC clone RP24-149F11 (RPCI-24: Mouse 
(C57BL/6 J Male) (Mus musculus) BaC library; BaCPaC 
Resources, Oakland, Ca, USa) using primers in Online 
resource 1 and inserted downstream of Renilla luciferase 
gene in pGL4.73[hRluc/SV40] vector (e6911, Promega, 
Madison, WI, USa) using restriction with XbaI. Lucif-
erase constructs containing BDNF 3′UtR with mutations 
in miR binding sites were generated with inverse PCR from 
the pGL4.73-BDNF3′UtR using primer pairs indicated in 
Online resource 1 (mutated nucleotides shown in bold). 
all constructs were verified by sequencing. Cotransfection 
with pGL4.13[luc2/SV40], encoding for firefly luciferase 
(e668a, Promega, Madison, WI, USa), was used for nor-
malization in the dual luciferase assay.
Cell culture
human embryonic kidney 293 (heK-293) cells were 
cultured at 37 °C with 5 % CO2 in Dulbecco’s modified 
eagle’s medium (DMeM) supplemented with 10 % fetal 
bovine serum (FBS; SV30160, thermo Fisher Scientific, 
Waltham, Ma, USa) and 1× Normocin (ant-nr-2, Invivo-
Gen, San Diego, Ca, USa).
human retinal pigment epithelium 19 (aRPe-19, [17]) 
cells were cultured at 37 °C with 5 % CO2 in DMeM/F-12 
(1:1) medium containing l-glutamine and 15 mM hePeS 
(31330, Invitrogen/thermo Fisher Scientific, Waltham, Ma, 
USa) supplemented with 10 % FBS and 1× Normocin.
human primary glioblastoma U-87 MG cells were cul-
tured at 37 °C with 5 % CO2 in DMeM supplemented with 
10 % FBS and 1× Normocin. In all experiments, heK-
293, aRPe-19 and U-87 MG cells were split 1:2 on two 
consecutive days prior to seeding.
C2C12 mouse skeletal myoblast cells [65] were main-
tained at subconfluent densities at 37 °C with 5 % CO2 in 
DMeM supplemented with 10 % FBS and 1× Normocin 
(growth medium, GM). Cells were kept at low density 
to prevent differentiation. Myogenic differentiation was 
miR-1, miR-10b, miR-155, and miR-191
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induced by replacing the growth medium with DMeM sup-
plemented with 2 % horse serum (hS; B15-021, Paa/Ge 
healthcare Life Sciences, helsinki, Finland) and 1× Nor-
mocin (differentiation medium, DM).
Luciferase assay
For the luciferase assay, cells were seeded to a 96-well 
plate at a density of 15,000–20,000 cells/well in a final vol-
ume of 100 μl. after 24 h of incubation, 80–90 % conflu-
ent cells were transfected with 50 μl Opti-MeM I Reduced 
Serum Medium, GlutaMaX (51985, Gibco/thermo 
Fisher Scientific, Waltham, Ma, USa) containing 0.3 μl 
Lipofectamine 2000 transfection Reagent (11668, 
Invitrogen/thermo Fisher Scientific, Waltham, Ma, USa), 
100 ng pGL4.73[hRluc/SV40] encoding for Renilla lucif-
erase with BDNF 3′UtR (BDNF-L), BDNF short 3′UtR 
(BDNF-Sh) or mutated BDNF 3′UtR cloned downstream 
of the luciferase coding sequence, 10 ng pGL4.13 encod-
ing for firefly luciferase and 10 nM pre-miRs (where 
indicated, applied Biosystems/thermo Fisher Scientific, 
Waltham, Ma, USa) per well. In experiments where miR 
binding site mutants were compared to each other, equi-
molar plasmid quantities were used. Cells were incubated 
for 3 h and transfection medium was replaced with 100 μl 
of fresh growth medium. Luciferase activity was measured 
after 24 h with Dual-Luciferase Reporter assay System 
(Promega, Madison, WI, USa) as recommended by the 
manufacturer. Briefly, cells were lysed with 35 μl of Pas-
sive Lysis Buffer per well. Culture plate was incubated 
for 15 min with shaking at 400 rpm at room temperature. 
to record luminescence, 100 μl of Luciferase assay Rea-
gent II was added to 30 μl of lysate for first measurement 
(firefly luciferase) and 100 μl of Stop & Glo Reagent was 
added for the second measurement (Renilla luciferase). 
Renilla/firefly luciferase ratio was used for statistical analy-
sis. three to four replicate wells were used in each experi-
ment and experiments were repeated 3–5 times.
to assess the utilization of miR binding sites in the 
BDNF 3′UtR during myogenic differentiation, C2C12 
cells were seeded to a 96-well plate at a density of 10,000–
15,000 cells/well in a final volume of 100 μl. after 24 h of 
incubation, 40–50 % confluent cells were transfected with 
50 μl OptiMeM containing 0.3 μl Lipofectamine, 100 ng 
pGL4.73[hRluc/SV40] encoding for Renilla luciferase with 
BDNF 3′UtR or mutated BDNF 3′UtR cloned after the 
luciferase coding sequence and 10 ng pGL4.13 encoding 
for firefly luciferase per well. Cells were incubated for 3 h 
and transfection medium was replaced with 100 μl of fresh 
medium, either GM (to keep cells growing as undifferentiated 
myoblasts) or DM (to induce differentiation to myotubes). 
Luciferase activity in myoblasts was measured after 8 h. DM 
was replaced every day and luciferase activity in myotubes 
was measured after 4 days, as described above. Renilla/firefly 
luciferase ratio was used for statistical analysis. three to four 
replicate wells were used in each experiment.
transfection with pre-miRs
to quantify endogenous BDNF protein levels after treat-
ment with pre-miRs, aRPe-19 cells and U-87 MG cells 
were seeded to 6- or 12-well plates and incubated for 24 h 
to reach 90–100 % confluency. the medium was changed 
to GM and cells were transfected using OptiMeM con-
taining 5 μl (2.5 μl for 12-well plate) Lipofectamine 
and 100 nM pre-miRs per well in a final volume of 1 ml 
(500 μl) for 4 h, then replaced with GM and cultured for 
48 h. all experiments were performed with at least two bio-
logical repeats.
Silencing endogenous miRs with anti-miRs
to assess endogenous BDNF expression after silencing 
endogenous miRs, aRPe-19 and U-87 MG cells were seeded 
to 12-well plates at 90–100 % confluency. Medium was 
changed to 250 µl OptiMeM containing 6 µM endoporter 
transfection agent, (Genetools, LLC, Philomath, OR, USa) 
and 10 nM anti-miRs (exicon, Vedbaek, Denmark) and cul-
tured for 24 h before substituting with 500 µl GM. Cells were 
cultured for 48 h before mRNa and protein isolation. all 
experiments were performed with two biological repeats.
BDNF enzyme-linked immunosorbent assay (eLISa)
Culture medium from cells treated with pre- or anti-miRs 
was centrifuged at 1,000 rpm to remove debris and used 
immediately for eLISa or stored at −80 °C. Cells were 
lysed with lysis buffer containing 137 mM NaCl, 20 mM 
tris–hCl (ph 8.0), 1 % NP40, 10 % glycerol, 1 mM PMSF, 
10 μg/ml aprotinin, 1 μg/ml leupeptin and 0.5 mM sodium 
vanadate. Lysate was centrifuged for 20 min at 13,000 rpm 
at 4 °C and supernatant was used immediately or stored at 
−80 °C.
to assess BDNF expression in C2C12 myoblasts and 
myotubes during differentiation, C2C12 cells were seeded 
to a six-well plate in a density of 500,000 cells/well in 
1 ml of GM. after 24 h, culture medium was isolated from 
undifferentiated myoblasts and replaced with DM to induce 
differentiation. DM was changed daily and culture medium 
from myotubes was isolated on day four. Culture medium 
was centrifuged at 1,000 rpm and used immediately for 
BDNF eLISa.
Brain-derived neurotrophic factor eLISa was performed 
using BDNF Emax Immunoassay System (Promega, Madi-
son, WI, USa) as recommended by the manufacturer. two 
replicates from each biological repeat were included in 
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eLISa. Brain-derived neurotrophic factor levels were nor-
malized to total protein concentration using DC Protein 
assay (500-0116, Bio-Rad, helsinki, Finland), as recom-
mended by the manufacturer.
RNa isolation
aRPe-19 and U-87 MG cells and hippocampi of C57BL/6 J 
mice were homogenized with tRI Reagent (tR 118, Molec-
ular Research Center, Inc., Cincinnati, Oh, USa) and RNa 
was isolated as recommended by the manufacturer. Briefly, 
after incubation of the homogenate at room temperature 
for 5 min, 1-bromo-3-chloropropane (BP151, Molecular 
Research Center, Inc., Cincinnati, Oh, USa) was added 
and the tubes were shaken vigorously for 15 s. the mix was 
incubated at room temperature for 5 min and centrifuged 
at 12,000 × g for 15 min at 4 °C. the aqueous phase was 
transferred to a fresh tube containing isopropanol (59300, 
Sigma-aldrich, St. Louis, MO, USa), mixed by vortexing 
and incubated at room temperature for 10 min. Samples 
were centrifuged at 12,000 × g for 8 min at 4 °C and RNa 
pellet was washed with 70 % ethanol (altia Oyi, helsinki, 
Finland), followed by centrifugation at 7,500 × g for 5 min. 
ethanol was then removed and the RNa pellet was allowed 
to briefly air dry and then dissolved in 30–50 μl h2O. 
the RNa samples were frozen immediately and stored at 
−80 °C until further processing. RNa quantity was meas-
ured with NanoDrop (thermo Scientific, Waltham, Ma, 
USa). the a260/a280 ratio was 1.78–2.01 and RNa yield 
was 3.5–9.5 μg (18–40 μg for hippocampus RNa).
Reverse transcription
RNa samples were treated with turbo DNa-free DNase 
treatment and removal reagents, as recommended by 
the manufacturer (aM1907, Invitrogen/thermo Fisher 
Scientific, Waltham, Ma, USa), to prevent contamina-
tion with genomic DNa. cDNa was synthesized from 
150–500 ng of RNa (equal amount of RNa was used 
within a single experiment) with random hexamer primers 
in a final volume of 20 μl using transcriptor First Strand 
cDNa synthesis kit as recommended by the manufacturer 
(04896866001, Roche, Basel, Switzerland). Briefly, 2 μl of 
random hexamer primers was mixed with 11 μl of RNa 
sample diluted with nuclease-free water, and incubated at 
65 °C for 10 min. then 7 μl of mix containing 4 μl of 5× 
Rt buffer, 2 μl of 100 mM dNtP, 0.5 μl of RNase inhibitor 
and 0.5 μl of transcriptor reverse transcriptase was added, 
mixed gently, and incubated at 25 °C for 10 min, 55 °C for 
30 min, and 85 °C for 5 min. No reverse transcriptase con-
trol was included in each experiment. cDNa was cooled on 
ice, diluted 1:10, and stored at −20 °C or used immediately 
for qPCR.
Quantitative real-time PCR
Quantitative PCR reaction was performed with the Light-
Cycler 480 real-time PCR system (Roche Diagnostics, 
Basel, Switzerland) using LightCycler 480 SYBR Green 
I Master, complemented with 2.5 pmol of primers in the 
final volume of 10 μl on white 384-well plates sealed with 
adhesive plate sealer (04729749001, Roche, Basel, Swit-
zerland). an amount of 2.5 μl of the diluted cDNa product 
was used in each reaction. Oligonucleotide primers (Oli-
gomer Oy, helsinki, Finland) used for the qPCR reactions 
are indicated in Online resource 1. No-reverse transcrip-
tion control and no-template control were included for each 
experiment. two or three replicates of each reaction were 
included in the qPCR runs. the following qPCR program 
was used: [1] pre-incubation 10 min at 95 °C, [2] amplifica-
tion 10 s at 95 °C, 15 s at 60 °C, 15 s at 72 °C for 45 cycles, 
[3] melting curve 5 s at 95 °C, 30 s at 55 °C, continuous 
acquisition mode at 95 °C with two acquisitions per degree 
Celsius, and [4] cooling 10 s at 40 °C. the results were 
analyzed with LightCycler 480 Software Release 1.5.0 SP1 
using the absolute Quantification/2nd Derivative Max cal-
culation. the quantification cycle (Cq) for the no-template 
control was 40 (or 0) in all experiments. Beta-actin was 
used as a reference gene. Results for a biological repeat 
were discarded when the Cq value for one or more of the 
replicates was 40 (or 0) or when the Cq difference between 
replicates was >1. For each primer pair, primer efficiencies 
(the ratio of amplified products if average Cq difference is 
one; the ideal efficiency would be two) were determined 
(Online resource 1). Fold difference to the reference gene 
was calculated according to the following formulation: 
FD = (E(GOI)−Cq1(GOI) + E(GOI)−Cq2(GOI))/(E−Cq1(ref)(ref) + E−Cq2(ref)(ref)), 
where EGOI and Eref are the primer efficiencies of the gene 
of interest (GOI) and reference gene (ref), respectively, and 
Cq1 and Cq2 are the Cq values of individual replicates.
microRNa expression
MicroRNa expression was assessed using taqMan 
MicroRNa assay reactions (applied Biosystems/thermo 
Fisher Scientific, Waltham, Ma, USa) according to the 
manufacturer’s recommendations with minor modifica-
tions. Briefly, RNa was isolated as described above. 
cDNa from 0.3–1 μg RNa was synthesized with 
taqMan MicroRNa Reverse transcription Kit (applied 
Biosystems/thermo Fisher Scientific, Waltham, Ma, 
USa) using Megaplex Rt Primers, Rodent Pool a or B 
(applied Biosystems/thermo Fisher Scientific, Waltham, 
Ma, USa) without preamplification in a final volume of 
7.5 μl. With the exception of miR-155 and miR-182, all 
the primers in the MegaPlex Rodent Pool were suitable 
for the amplification of human microRNas. For miR-155 
miR-1, miR-10b, miR-155, and miR-191
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and miR-182, 5x Rt primers provided by the taqMan 
MicroRNa assay were used for reverse transcription 
reaction. the cDNa product was diluted 1:30 and 2.5 μl 
of the diluted cDNa was used for each real-time PCR 
reaction in a final volume of 10 μl in 384-well plates. 
each sample was run in duplicate. microRNa expression 
from mouse-derived cells was normalized to sno202 and 
microRNa expression from human-derived cells was nor-
malized to miR-191 [52].
Statistical analysis
all values are presented as mean ± SeM. Statistical sig-
nificance level was set at p < 0.05. Quantitative PCR data 
was calculated based on primer efficiencies and analyzed 
using fold difference compared to reference gene. Statisti-
cal analysis was performed using paired or unpaired Stu-
dent’s t test, Mann–Whitney U test, or one-way aNOVa 
followed by tukey’s hSD (honestly significant difference) 
or Games–howell post hoc analysis.
Results
Both BDNF 3′UtR isoforms are predicted to contain 
conserved binding sites for multiple miRs
We performed in silico analysis of BDNF 3′UtR-miR 
interactions using publicly available bioinformatics tool 
targetScan (www.targetscan.org) and found that the 3′UtR 
of BDNF contains evolutionarily conserved seed sequences 
for multiple miRs (Fig. 1). In addition to miR sites, the 
overall nucleotide sequence of BDNF 3′UtR is highly 
conserved across species, especially near both ends of 
the 3′UtR (Fig. 1), suggesting important biological func-
tion of these regions. Most of the predicted miR binding 
sites fall into the 5′ end of the 3′UtR and the nucleotide 
sequences near miR sites are highly conserved across ver-
tebrates (Online resource 2). Brain-derived neurotrophic 
factor transcripts have either a long (BDNF-L, 2891 nt) or 
short (BDNF-Sh, 350 nt) 3′UtR ([27], Fig. 1). although in 
silico analysis with different target prediction tools, includ-
ing targetScan ([43], http://www.targetscan.org), PIta 
([34], http://genie.weizmann.ac.il/pubs/mir07/index.html), 
miRanda ([33], http://www.microrna.org), Pictar ([38], 
http://pictar.mdc-berlin.de/) implies that BDNF 3′UtR can 
be regulated by a multitude of miRs (Online resource 3), to 
date only a few BDNF 3′UtR-miR interactions have been 
investigated, and in these, relatively short BDNF 3′UtR 
fragments have been used [25, 42, 46, 47]. Since there is 
potential for several miRs to bind BDNF 3′UtR, we set 
out to systematically investigate the role of ten miRs with 
conserved putative binding sites in BDNF 3′UtR isoforms 
in the regulation of BDNF expression. miRs of interest 
were selected based on the conservation of their binding 
site within BDNF 3′UtR, co-expression with BDNF in 
cells and tissues where BDNF is known to have important 
roles, and/or their overall expression level (Online resource 
2, microRNa.org, [20, 22, 31, 40]). We used full-length 
BDNF-L and BDNF-Sh sequences to better preserve the 
potential effects that secondary structure and nucleotide 
context may have on miR binding.
Mus musculus BDNF 3'UTR
1 kb 2 kb
miR-10abc/10a-5p
miR-190/190ab
miR-210 miR-1ab/206/613
miR-182
miR-103a/107/107ab
miR-1ab/206/613
miR-1ab/206/613
miR-33a-3p/365/365-3p
miR-15abc/16/16abc/195/322/424/497/1907
miR-191
miR-30abcdef/30abe-5p/384-5p miR-155
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R. norvegicus BDNF-L
Conserved sites for miRNA families broadly conserved among vertebrates
low identity90% identity
95% identity
94% identity
98% identity
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M. musculus BDNF-L
M. musculus BDNF-SH
590 bp 850 bp1030 bp
Fig. 1  Scheme of long (BDNF-L) and short (BDNF-Sh) BDNF 
3′UtR isoforms with evolutionarily conserved miR sites predicted 
by targetScan. Sites within BDNF-Sh are shown in light blue. Con-
servation between mouse, rat, and human BDNF 3′UtR is shown in 
purple bars. Arrows denote polyadenylation sites
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analysis of BDNF 3′UtR isoforms for miR regulation
We asked whether the in silico predicted miRs (Fig. 1) 
regulate protein synthesis from a transcript containing full-
length BDNF-L. For that, we transfected human embryonic 
kidney 293 (heK-293) cells with precursors for ten miRs 
predicted by four different target prediction tools (Online 
resource 3) to bind BDNF-L (miR-1, miR-10b, miR-15a, 
miR-16, miR-30a, miR-30b, miR-155, miR-182, miR-191, 
and miR-195, Fig. 2a). Scrambled pre-miR (scr. miR) and 
precursor for miR-9 that do not have a strongly conserved 
predicted binding site in BDNF-L were used as negative 
controls. We found that miR-1, which has three binding 
sites in BDNF-L (Fig. 2a), reduces luciferase signal most 
efficiently (Fig. 2b). Of the other miRs, miR-10b, miR-
155, and miR-191 significantly inhibited luciferase signal 
compared to the scrambled miR control. Unlike in previous 
studies, which utilized fragments of BDNF 3′UtR in the 
same reporter assay, we found no significant effect for 
miR-30a or miR-195 (Fig. 2b).
In parallel, we tested the ability of the same miRs to 
inhibit protein synthesis from transcript containing BDNF-
Sh, which contains binding sites for six miRs out of the 
ten assessed in BDNF-L (Fig. 2a, c). We found that miR-1 
and miR-10b significantly reduced luciferase activity. Of 
the three miR-1 sites present in BDNF-L, only the first is 
located within BDNF-Sh (Fig. 2a, c). If miR-1 sites act 
additively to regulate BDNF levels, miR-1 is expected 
to have a milder effect on a reporter construct carrying 
BDNF-Sh compared to BDNF-L. Matching the prediction, 
we found a statistically significant difference in the extent 
of luciferase signal reduction by miR-1 on BDNF-Sh com-
pared to BDNF-L (Fig. 2b). Similarly, unlike BDNF-L, 
BDNF-Sh lacks binding sites for miR-155 and miR-191. 
c
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nylation sites. b Luciferase activity of reporter constructs contain-
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as expected, miR-155 and miR-191 had no effect on 
BDNF-Sh, while they had a significant effect on BDNF-
L (Fig. 2b). thus, we found a statistically significant dif-
ference in the extent of luciferase signal reduction between 
BDNF-L and BDNF-Sh by miR-1, miR-155 and miR-191 
that have a different number of predicted binding sites in 
the long and short BDNF 3′UtR isoforms. In contrast, 
there was no difference in luciferase activity after treatment 
with miR-10b that has a single binding site predicted to 
regulate both BDNF-L and BDNF-Sh (Fig. 2a–c). these 
data suggest that miR-1, miR-10b, miR-155, and miR-191 
are novel regulators of BDNF 3′UtR and that a subset of 
them are able to differentially regulate expression from 
transcripts containing either short or long 3′UtR isoform.
Regulation of endogenous BDNF levels by miRs
Next, we asked if the miRs that regulate BDNF 3′UtR 
in a reporter assay can also regulate endogenous BDNF. 
towards that end, we made use of human retinal pigment 
epithelial (aRPe-19) cells and human glioblastoma cell-
line U-87 MG that secrete a detectable amount of endog-
enous BDNF. Relative expression of BDNF and BDNF-
regulated miRs in different cell lines used in this study is 
shown in Online resource 4a and 5. We found that approxi-
mately 80 % of BDNF mRNa transcripts in aRPe-19 
cells and 95 % of BDNF transcripts in U-87 MG cells are 
expressed as short 3′UtR isoforms (Fig. 3a), suggesting 
that miR-155 and miR-191, which only have a binding site 
within BDNF-L, should be unable to regulate the majority 
of BDNF transcripts in these cells (Fig. 2a). We transfected 
aRPe-19 cells with precursors for miR-1, miR-10b, miR-
155, and miR-191, and measured BDNF mRNa levels with 
primers recognizing total BDNF and BDNF transcript car-
rying the long 3′UtR (BDNF-L). miR-10b significantly 
decreased both total BDNF and BDNF-L levels, while 
miR-155 and miR-191 only reduced BDNF-L expression, 
as expected (Fig. 3b–c). We then determined BDNF pro-
tein levels in the cell lysate and culture medium by eLISa. 
We found that miR-1 and miR-10b effectively suppressed 
endogenous BDNF synthesis, while miR-155 and miR-
191 did not significantly reduce BDNF levels (Fig. 3d–e). 
Brain-derived neurotrophic factor levels in the culture 
medium were decreased more compared to the whole cell 
lysate, indicating that in addition to BDNF, miR-1 and 
miR-10b could regulate the expression of proteins involved 
in BDNF secretion. Surprisingly, although BDNF mRNa 
levels were increased by transfection with miR-1, pro-
tein levels were decreased (Fig. 3b–e), suggesting that the 
mechanism by which miR-1 suppresses BDNF may be dif-
ferent from that of other miRs and may involve other fac-
tors that regulate BDNF expression. taken together, these 
data suggest that miR-1 and miR-10b inhibit endogenous 
BDNF levels but do not exclude the ability of miR-155 and 
miR-191 to do the same in cells expressing BDNF tran-
script with the long 3′UtR isoform.
Since BDNF has multiple functions in the central nerv-
ous system, we also tested pre-miRs in U-87 MG glioblas-
toma cells that originate from the CNS. however, only 5 % 
of BDNF transcripts in these cells carry the long 3′UtR 
isoform (Fig. 3a). We found that while total BDNF lev-
els were not reduced after treatment with any of the pre-
miRs, the expression of BDNF transcripts carrying the 
long 3′UtR was significantly decreased by about 20 % by 
all the pre-miRs tested (Fig. 3f–g). Interestingly, although 
miR-1 and miR-10b have a binding site within BDNF-Sh 
and should therefore be able to regulate the expression of 
all BDNF transcripts, they seem to be effective only in sup-
pressing BDNF-L in U-87 MG cells (Fig. 3f–g). Consistent 
with our finding that miRs only regulate a marginal sub-
population of BDNF transcripts, resulting in about 20 % 
decrease in BDNF-L levels, BDNF protein levels in U-87 
MG cells were not suppressed by transfection with pre-
miRs (Fig. 3h–i).
Finally, we transfected aRPe-19 cells with anti-miR-10 
and found that silencing endogenous miR-10b significantly 
increased BDNF mRNa and protein levels (Fig. 3j–m). 
We were unable to address the effect of miR-1 in aRPe-
19 cells, since it is not expressed in this cell line (Online 
resource 5). In summary, our results suggest that miR-
1, miR-10b, miR-155, and miR-191 are able to regulate 
BDNF expression, although the effect may vary depending 
on the cell line.
miR-1, miR-10b, miR-155, and miR-191 regulate BDNF 
3′UtR directly through their predicted sites
Quantifying endogenous BDNF expression after treatment 
with pre- or anti-miRs does not allow to distinguish whether 
miRs regulate BDNF levels directly or indirectly. to inves-
tigate the interaction between the miRs identified to sup-
press BDNF-L (Fig. 2b) and their concomitant binding sites 
within the BDNF 3′UtR, we created constructs harboring 
mutations in one or several miR binding sites in BDNF-L 
(Fig. 4a–b). Since miR-1 has three predicted sites, we gen-
erated mutant constructs for each of the sites individually 
(miR1-1m, miR1-2/191m, miR1-3m) and a triple mutant 
with all three binding sites mutated (miR1m). It should be 
noted that the second binding site of miR-1 (miR-1-2) partly 
overlaps with miR-191 binding site and therefore both 
sites were mutated in miR-1-2 mutant (Fig. 4a–b). We co-
transfected mutant constructs with the corresponding pre-
miRs into heK-293 cells as above and assessed the relative 
extent of inhibition. In accordance with analysis of BDNF-
L vs. BDNF-Sh (Fig. 2b), mutating the first site (miR1-
1m), which is also present within BDNF-Sh, reduced 
K. Varendi et al.
1 3
suppression by miR-1 most effectively compared to mutat-
ing the other miR-1 sites (Fig. 4c), suggesting that miR-
1-1 site is more important in regulating BDNF 3′UtR than 
miR-1-2 and miR-1-3 sites. Furthermore, mutating the third 
miR-1 site (miR1-3m) did not change 3′UtR inhibition by 
exogenous miR-1 (Fig. 4c), suggesting that this site may not 
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be used by miR-1 for suppression of BDNF 3′UtR. Mutat-
ing miR-10b (miR10m), miR-155 (miR155m), and miR-
191 (miR1-2/191m) sites effectively abolished the inhibi-
tory effect of the corresponding exogenous miRs (Fig. 4d), 
suggesting that these miRs also directly inhibit protein syn-
thesis by binding to the predicted site in the BDNF 3′UtR.
miR-1/206 sites in BDNF 3′UtR are used by endogenous 
miRs in differentiated but not in undifferentiated muscle 
cells
Regulation of BDNF expression has been shown to be 
required for postnatal growth and repair of skeletal muscle 
in vivo [13]. to gain further insight into the physiological 
relevance of miR sites identified to regulate BDNF 3′UtR, 
we extended our analysis to a model of muscle differentia-
tion, the mouse myoblast C2C12 cells, where reduction in 
BDNF levels is believed to be required to allow myotube 
generation from undifferentiated myoblasts [47]. miR-206, 
a miR-1/206 microRNa family member that has identi-
cal seed sequence to miR-1 but differs from miR-1 by four 
nucleotides (Online resource 4b), is believed to be involved 
in BDNF downregulation in C2C12 cells [47]. however, it 
is unknown whether the predicted miR-1/206 sites are the 
sites used by endogenous miR-1 and/or miR-206 during 
muscle differentiation. Furthermore, it has remained unclear 
if BDNF suppression by miR-1/206 is used in myoblasts to 
induce differentiation, in myotubes to maintain differentia-
tion, or both. to gain further insight into these questions, we 
first confirmed earlier findings that BDNF is downregulated 
with concurrent upregulation of miR-1 and miR-206 upon 
myogenic differentiation of muscle cells (Online resource 
4c–e; [12, 35, 47, 49]). then we analyzed the effect of 
miR-1/206 site mutations on reporter construct expression 
in myoblasts and myotubes. We found that BDNF-L was 
repressed in differentiated myotubes by about 50 %, while 
miR1m mutant construct was not (Fig. 5a). Furthermore, 
although both miR-1 and miR-206 are expressed in myo-
blasts (Online resource 4e, 5), there was no difference in the 
expression of BDNF-L and miR1m containing reporters in 
those cells (Fig. 5a). this suggests that interaction between 
BDNF 3′UtR and miR-1/206 family miRs is utilized in 
C2C12 myotubes to maintain differentiation by BDNF 
repression but not to induce myogenic differentiation.
endogenous miRs regulate BDNF 3′UtR in different cell 
lines through the predicted sites
Next we turned to cell lines where interaction between 
BDNF 3′UtR and endogenous miRs has not been addressed 
before. We determined the endogenous miR expression 
levels in human embryonic kidney cell line heK-293 and 
human retinal pigment epithelial cell line aRPe-19. We 
found that miR-1 was not expressed in aRPe-19 cells and 
miR-155 was not expressed in heK-293 cells, while the 
other miRs were expressed but their relative levels were 
different between heK-293 and aRPe-19 cells (Online 
resource 5). to assess the interaction between BDNF 3′UtR 
and endogenous miRs, we transfected heK-293 and aRPe-
19 cells with luciferase assay reporter containing native 
BDNF-L or constructs harboring various miR site mutants: 
mutations for each individual miR-1 site (miR1-1m, miR1-
2/191m, miR1-3m), all three miR-1 binding sites (miR1m), 
miR-10b site (miR10m), miR-155 site (miR155m) and a 
quadruple mutant for three miR-1 sites and miR-10b site 
(miR1,10m). as indicated above, miR-191 site was mutated 
in miR1-2/191m mutant construct (Fig. 4b). We found that 
mutating miR-10b site significantly derepressed luciferase 
construct in both cell lines (Fig. 5b–c). Consistent with our 
findings with miR-1 transfection (Fig. 4c), we found that 
mutating the miR-1-1 site, but not the other miR-1 sites 
increased luciferase signal in heK-293 cells (Fig. 5c). In 
aRPe-19 cells, luciferase signal obtained with the quadru-
ple mutant miR1,10m was increased by approximately two-
fold compared to wild-type BDNF-L. however, in heK-
293 cells, mutating all three sites for miR-1 and the single 
miR-10b site (miR1,10m) derepressed luciferase activity to 
the level comparable to the empty luciferase vector carrying 
SV40 late 3′UtR (Fig. 5c), which is in essence devoid of 
binding sites for strongly conserved miRs (Online resource 
6). these results indicate that miR-1 and miR-10 sites within 
BDNF 3′UtR are used synergistically by endogenous miR-
1/206 and miR-10 family miRs to repress BDNF 3′UtR, and 
at least in heK-293 cells miR-1/206 and miR-10 sites are 
responsible for the majority of BDNF 3′UtR repression.
Discussion
here we present the first systematic functional analysis 
of nine evolutionarily conserved miR recognition sites in 
BDNF 3′UtR. Unlike previous studies, we have analyzed 
full-length sequences of both BDNF 3′UtR isoforms, 
BDNF-L (2891 nt) and BDNF-Sh (350 nt). We identify 
Fig. 3  Regulation of endogenous BDNF levels by pre- and anti-
miRs. a expression of BDNF-L and BDNF-Sh mRNa isoforms in 
aRPe-19 and U-87 MG cells. endogenous BDNF levels in aRPe-
19 (b–e) and U-87 MG (f–i) cells transfected with pre-miRs, relative 
to scrambled control. j–m endogenous BDNF levels in aRPe-19 
cells transfected with anti-miRs, relative to scrambled control. b, f, j 
total BDNF mRNa levels, normalized to β-actin. c, g, k mRNa lev-
els of BDNF transcripts containing the long 3′UtR (BDNF-L), nor-
malized to β-actin. d, h, l BDNF protein levels in whole cell lysate, 
normalized to total protein content. e, i, m BDNF protein levels in 
culture medium, normalized to total protein content. n = 3. Aster-
isks show difference from negative control, *p < 0.05, **p < 0.01, 
***p < 0.001. Error bars denote mean ± SeM
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polyadenylation sites. b miR binding site mutations in BDNF-L. 
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miR-1, miR-10b, miR-155, and miR-191 as novel regulators 
of BDNF 3′UtR and show that BDNF-L and BDNF-Sh 
can be differentially regulated by a subset of miRs. Using 
mutated constructs we show that the interaction between the 
identified miRs and BDNF 3′UtR is direct. Our results sug-
gest that miR-1/206 sites within BDNF 3′UtR are used in 
C2C12 myotubes to maintain differentiation rather than in 
myoblasts to induce differentiation. Finally, we show that 
the predicted binding sites for miR-1/206 and miR-10 fam-
ily miRs are used in a synergistic manner to repress BDNF 
3′UtR in aRPe-19 and heK-293 cells.
the potential physiological importance of BDNF regu-
lation by miRs has been suggested by a study where Dicer, 
an enzyme required for miR maturation, was conditionally 
deleted from the forebrain. Prior to the onset of neurode-
generation, BDNF levels in such animals were increased 
with concomitant functional changes in the CNS [36]. 
Recently, the conclusion was confirmed by Lee et al., who 
demonstrated BDNF regulation by miR-206 in the brain 
[42]. In addition, other studies have addressed the poten-
tial interaction between BDNF 3′UtR and specific miRs. 
Interestingly, miR-30a and miR-195 did not have an effect 
in our study (Fig. 2b) while previous results have suggested 
that these miRs regulate BDNF 3′UtR in a reporter assay 
[46]. these different results can at least partly be explained 
by the use of 3′UtR fragments in the reporter assay of the 
previous study, which may affect the accessibility of miRs 
to their binding site in the target mRNa. It has been shown 
that miR sites residing near the two ends of long 3′UtRs 
are generally more effective than those near the center 
[29]. thus, a site normally unavailable in the native 3′UtR 
may become more accessible if only a small region of the 
3′UtR is analyzed in reporter assay and in some cases, 
the situation may be the other way around. miR-191 has 
been shown not to inhibit BDNF 3′UtR [46], whereas 
our results clearly show that miR-191 does in fact directly 
inhibit BDNF 3′UtR via the predicted site (Fig. 2b, 4d).
Further illustrating the potential problems stemming 
from analysis of fragments rather than full-length 3′UtRs 
are the conflicting results of studies by Miura et al. and Lee 
et al. [42, 47], where the first study showed that of three 
miR-206 sites within BDNF 3′UtR, the first two and not 
the third are functional, while the other study reached the 
opposite conclusion. although both studies analyzed frag-
ments of BDNF 3′UtR, the size of fragments used in [47] 
was longer than those studied in [42] and thus resembled 
the full-length BDNF 3′UtR better. Our analysis of full-
length BDNF 3′UtR interaction with miR-1, another fam-
ily member of miR-1/206 family, supports the conclusion of 
(Fig. 2b, 4c, [47]). Our data on miR-1 also confirms the in 
silico prediction that miR-1 and miR-206 share the binding 
sites on BDNF 3′UtR (Fig. 1). however, it is important to 
keep in mind that miR-1 and miR-206 differ by four nucleo-
tides outside the seed sequence (Online resource 4b). there-
fore, it would be interesting to analyze miR-206 and BDNF 
3′UtR interaction in the context of full-length 3′UtR.
We also found that endogenous miR-1/206 and miR-10 
family miRs act cooperatively to repress BDNF expres-
sion through its 3′UtR in two cell lines of different origin 
(Fig. 5b–c). this is consistent with the notion from previ-
ous reports that multiple miR sites within a 3′UtR can act 
in a synergistic manner, especially if the sites are located 
a  
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Fig. 5  Mutating miR-1 and miR-10 sites abolishes suppression of 
BDNF-L by endogenous miRs in a reporter assay. a Reporter activ-
ity in C2C12 cells before and after differentiation with constructs 
containing either wild-type BDNF-L or BDNF-L miR site mutants. 
n = 7. b, c Luciferase activity of reporter constructs containing wild-
type BDNF-L or BDNF-L miR site mutants. Asterisks show differ-
ence from BDNF-L. n = 3–4. b Luciferase activity in aRPe-19 cells. 
c Luciferase activity in heK-293 cells. n = 3–5. Error bars denote 
mean ± SeM. *p < 0.05, **p < 0.01, ***p < 0.001
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close together [29, 56, 57]. In line with this, recent experi-
mental evidence shows that noncoding pseudogenes can 
bind to and compete for the same combination of miRs as 
their ancestral gene [53], suggesting that there has been 
evolutionary pressure on pseudogenes to preserve the same 
miR binding site pattern or “miR code” that is used to reg-
ulate protein synthesis from the ancestral transcript. even 
though the expression levels of pseudogenes are low, they 
seem to be sufficient to derepress endogenous parent gene 
expression in case their 3′UtR contains binding sites for 
multiple miRs that act in synergy. Our data imply that regu-
lation of BDNF by its 3′UtR is important in tissues where 
miR-1/206 and miR-10 family miRs are co-expressed. In 
addition, although mutating miR-155 and miR-191 sites 
had no effect on reporter activity in heK-293 and aRPe-
19 cells, it cannot be excluded that BDNF 3′UtR interacts 
with miR-155 or miR-191 in other tissues or cell types.
although some studies have suggested that inhibition 
by miRs depends mostly on miR expression levels [18, 
28], others suggest that additional factors such as specific 
nucleotide composition [53, 57], or the number of target 
genes [4] may be more important in defining the repressive 
activity of miRs. Our results indicate that endogenous miR 
expression levels do not solely determine the inhibition 
efficiency. In assays utilizing reporter constructs and pre-
miR transient transfection, miR-1 through its sites 1 and 2, 
miR-10b and miR-191 all suppress BDNF 3′UtR (Fig. 2b, 
4c–d). however, despite the presence of relatively high 
levels of endogenous miR-191 compared to endogenous 
miR-1 and miR-10b in both heK-293 and aRPe-19 cells 
(Online resource 5), mutating miR-191 site did not lead to 
an increase in luciferase signal, whereas mutating miR-10b 
site or miR-1 sites together with miR-10b site had a clear 
effect (Fig. 5b–c). thus, results suggesting direct interac-
tion between miR and 3′UtR in transient transfection 
assays do not allow conclusions on the interaction between 
endogenous miR and the corresponding site within the 
3′UtR, even if the endogenous miR expression levels are 
high, underlining the need to test each case separately.
While the role of miR-1/206 family member miR-206 in 
the regulation of BDNF levels is well established [42, 47, 
54], the interaction between BDNF 3′UtR and miR-1 has 
not been investigated. although miR-1 and miR-206 have 
identical seed sequences, the mature miR-1 differs from 
miR-206 by four nucleotides (Online resource 4b). miR-1 
is encoded by two distinct genomic locations in both mouse 
and human genomes and displays partially different expres-
sion pattern from miR-206. For example, both miR-1 and 
miR-206 are expressed in high levels in the skeletal mus-
cle [12, 35, 39, 59, 68], but unlike miR-206, miR-1 lev-
els are high in the heart [40]. Since BDNF is known to be 
required for heart angiogenesis [16], it would be interest-
ing to assess the role of miR-1 and BDNF interaction in 
heart development. Moreover, appropriate BDNF levels are 
important for adjusting the number of dopaminergic neu-
rons in the substantia nigra midbrain [5] and regulation 
of BDNF expression in the hippocampus is important in 
learning and memory (see [64]). miR-1 is expressed within 
the midbrain [40], hippocampus (Online resource 5), and 
in several other neuron populations within the central nerv-
ous system [30]. taken together, there is potential for miR-
1-mediated regulation of BDNF levels during development, 
warranting further investigation.
While miR-191 is widely expressed in different tis-
sues and cell types, miR-10b and miR-155 have a more 
restricted expression pattern [40]. For example, one of the 
few expression sites of miR-10b is the skin [40], whereas 
expression of BDNF in the skin is required for its proper 
sensory innervation [21]. miR-155, on the other hand, is 
robustly upregulated after the activation of immune cells, 
including microglia [9], whereas BDNF expression by 
microglia has been implicated in the induction of neuro-
pathic pain [14, 66].
Our results also suggest that selected miRs are able to 
differentially regulate BDNF transcripts with either long or 
short 3′UtR isoform. Indeed, the considerably shorter half-
life of BDNF mRNas containing the long 3′UtR compared 
to the short 3′UtR [10] may at least partly be a consequence 
of miR regulation. Furthermore, the relative abundance of 
BDNF 3′UtR isoforms varies during developmental pro-
cesses, for example, in muscle differentiation [47], and 
in different brain areas, such as the cortex, hippocampus 
and cerebellum [3, 62], suggesting that the long and short 
3′UtR isoforms have different biological functions. In line 
with this, it was recently shown that in response to neuronal 
activation, BDNF protein synthesis in hippocampal neu-
rons is rapidly initiated from transcripts containing the long 
3′UtR, while expression from transcripts containing the 
short 3′UtR maintains basal BDNF levels [41].
Overall, co-expression of BDNF and miR-1/miR-10b/
miR-155/miR-191 in various cell types and tissues suggests 
potential relevance of the interaction between miRs and 
BDNF 3′UtR isoforms in different physiological and path-
ological processes, which remain a target of future studies 
addressing post-transcriptional BDNF regulation.
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ristetraprolin is a novel regulator of BDNF
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Abstract
Brain-derived neurotrophic factor (BDNF) regulates multiple biological processes ranging from central nervous system
development and function to neuroinflammation and myogenic differentiation and repair. While coordination of BDNF
levels is central in determining the biological outcome, mechanisms involved in controlling BDNF levels are not fully
understood. Here we find that both short (BDNF-S) and long (BDNF-L) BDNF 3’UTR isoforms contain conserved
adenylate- and uridylate rich elements (AREs) that may serve as binding sites for RNA-binding proteins (ARE-BPs). We
demonstrate that ARE-BPs tristetraprolin (TTP) and its family members butyrate response factor 1 (BRF1) and 2 (BRF2)
negatively regulate expression from both BDNF-S and BDNF-L containing transcripts in several cell-lines and that
interaction between TTP and AU-rich region in proximal 5’ end of BDNF 3’UTR is direct. In line with the above,
endogenous BDNF mRNA co-immunoprecipitates with endogenous TTP in differentiated mouse myoblast C2C12
cells and TTP overexpression destabilizes BDNF-S containing transcript. Finally, RNAi-mediated knock-down of TTPnd
l c
rist
b
iat
the
ism
od
re
ts
DN
o
v
n d
ur
iff
g
ts
o
,
yl
bp
tr
theincreases the levels of endogenous BDNF protein in C2C12 cells. Our fi
BDNF assisting future studies in different physiological and pathologica
Keywords: Brain-derived neurotrophic factor; 3’ untranslated region; T
troduction
DNF is involved in a wide range of developmental,
nctional and pathological processes in the central
rvous system (CNS) (Nagahara and Tuszynski 2011;
irschenbaum and Goldman 1995; Cohen-Cory et al. 2010;
amji et al. 2006; Nieto et al. 2013; Mu et al. 1999).
utside the CNS, processes regulated by BDNF include
flammation (Uchida et al. 2013; Lin et al. 2011;
omes et al. 2013; Amoureux et al. 2008; Luhder et al.
13), development of neuromuscular junctions (Je et al.
12), muscle regeneration after injury (Clow and
smin 2010) and myogenic differentiation (Mousavi and
smin 2006).
Precise regulation of BDNF levels is critical in determining
e biological outcome. Reduction of BDNF levels by 50% in
NF knock-out heterozygous mice is associated with a
nge of phenotypes in the CNS (Lyons et al. 1999;
luzen et al. 2002; Abidin et al. 2006; Abidin et al. 2008).
n the other hand, a 2-fold elevation in endogenous
DNF by the suppression of miR-206, a direct negative
gulator of BDNF levels, alleviates disease phenotype
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in any medium, provided the original work is properly credited.ings uncover TTP as a novel regulator of
ontexts.
etraprolin; C2C12 cells
elieved to be required to allow myogenic
ion (Mousavi and Jasmin 2006). However,
biological and potential clinical relevance,
s controlling BDNF levels are not fully
.
sult of alternative polyadenylation, BDNF
have either a long (BDNF-L, 2891 nt) or
F-S, 350 nt) 3’UTR (Timmusk et al. 1993).
between transcripts containing BDNF-L and
aries with BDNF-L levels ranging between
ifferent tissues and cells-lines (Timmusk et al.
a et al. 2012). Alternative 3’UTR isoforms allow
erentially regulate expression from transcripts
long or short 3’UTR.
within the 3’UTR that control mRNA stability
adjust the expression of important regulatory
including neurotrophic factors. Adenylate-
ate (AU)-rich elements (AREs) are typically
areas in the 3’UTR that serve as binding
ans-acting ARE binding proteins (ARE-BPs)
r stabilize or destabilize transcripts (Xu et al.
au et al. 2005). Although the exact consensus
f AREs is not in depth understood, AREs are
ighted by high AU content and concomitant
f AUUUA pentamers (Chen and Shyu 1995;
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htarreau et al. 2005). According to current estimations, ap-
oximately 8% of the human transcriptome contains
REs. However, relatively few AREs are experimentally
rified as functional targets of ARE-BPs (Barreau et al.
05; Bakheet et al. 2006; Barrett et al. 2012; Apponi et al.
11; Gruber et al. 2011; Pascale and Govoni 2012).
RE-BPs tristetraprolin (TTP), butyrate response factor 1
RF1) and 2 (BRF2) form the TIS11/TTP family of
RE-BPs that target mRNAs for rapid degradation by
nding to AREs (Hudson et al. 2004; Brooks and
lackshear 2013; Sanduja et al. 2011). TIS11/TTP
mily proteins are central regulators of the expres-
on of inflammatory cytokines and several oncogenes
udson et al. 2004; Brooks and Blackshear 2013;
nduja et al. 2011). Whether TIS11/TTP family could
ntrol the expression levels of neurotrophic factors, such
BDNF, has remained unknown.
In the current study, we used publicly available in
lico tools to search for conserved AREs in BDNF-L and
DNF-S, and look for ARE-BPs co-expressed with BDNF
sites with known BDNF function. We find that ARE-BPs
TP, BRF1 and BRF2, but not ELAVL1 or ELAVL2, inhibit
pression from luciferase reporters containing BDNF-L
d BDNF-S, and that AUF1 has a mild inhibitory effect in
e same assay. Using electrophoretic mobility shift
say (EMSA), we demonstrate a direct interaction
tween the 5’ region of BDNF-S and recombinant
TP protein and find that endogenous BDNF mRNA
-immunoprecipitates with TTP. In line with the
ove, over-expression of TTP destabilizes transcript
ntaining BDNF-S. Finally, we show that siRNA-mediated
wn-regulation of TTP during myogenic differentiation
mouse myoblast C2C12 cells leads to increased BDNF
otein expression. Altogether, our findings suggest
at TTP is a new post-transcriptional regulator of BDNF
pression.
aterials and methods
ll culture
uman Embryonic Kidney 293 (HEK-293), Chinese Hamster
vary (CHO), HeLa and C2C12 cells were cultured at 5%
O2 and 37°C in growth medium (GM) containing
ulbecco’s Modified Eagle Medium (DMEM, Invitrogen/
ibco) supplemented with 10% fetal bovine serum
BS; SV30160, Thermo Fisher Scientific) and 100 μg/ml
ormocin (InvivoGen). Cells were kept at sub-confluent
nsity and split one day before plating for an experiment.
2C12 wells were seeded to 6-well plates pre-coated
ith 0.1% gelatin. Myogenic differentiation of C2C12
ouse skeletal myoblast cells was induced by replacing
owth medium with differentiation medium (DM)
ntaining DMEM supplemented with 2% horse serum
S; B15-021, PAA) (Miura et al. 2012) and 100 μg/ml
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pcDNA™-DEST40 vectors encoding for
ng proteins for expression in mammalian
btained from Genome Biology Unit (Institute
ology, University of Helsinki, Finland). Long
BDNF 3’UTR-s (BDNF-L and BDNF-S) were
from BAC clone RP24-149 F11 (RPCI-24:
ulus (C57BL/6 J male) BAC library; BACPAC
using primers with XbaI sites (Additional file 1:
and cloned into XbaI site in pGL4.13 vector
Firefly luciferase gene (E6681,Promega) and in
pGL4.73 vector downstream Renilla luciferase
1,Promega). Similarly, U1 and U2 fragments
lified with primers containing XbaI sites
file 1: Table S1) from BDNF long 3’ UTR se-
cloned into pGL4.73 vector (E6911,Promega)
ript KS + (Stratagene). All constructs were
sequencing. In addition, ARE-BP protein
from various ARE-BP encoding Gateway®
EST40 vectors in HEK-293 cells was verified
ern blotting (Additional file 1: Figure S1a). We
ed whether the C-terminal tag (V5 or His)
pcDNA™-DEST40 vectors has an impact on
y in luciferase assay and found no difference
e tested tagged and non-tagged ARE-BP activity
file 1: Figure S1b and see below).
eporter assay
se reporter assay, cells were seeded to 96-well
-coated with 0.1% gelatin for HEK-293 cells),
sity per well was 15,000 (HEK-293 and CHO
0,000 (HeLa cells) in a volume of 100 μl one
transfection. Reporter plasmids in 10:1 ratio
c-BDNF-L, Luc-BDNF-S, Luc-U1 and Luc-U2,
cated otherwise) and 10 ng either pGL4.73
0] or pGL4.13 [luc2/SV40]) as internal controls
nsfected per well on 96 well plate to normalize
se signal in dual luciferase assay. BDNF-L/
anscript ratio in HEK-293 cells transfected
-L is 60/40, as assessed by QPCR analysis.
ns were done according to standard protocol
ded for Lipofectamine 2000 (11668–019,
. Growth medium was replaced with fresh
medium after 3–4 hours after transfection.
assay was performed with Dual-Luciferase®
ssay System (E1960, Promega) as recommended
ufacturer. Briefly, cells were lysed 24 hours after
tion with Passive Lysis Buffer (E1960, Promega).
either stored at −80°C or analyzed immediately
uciferase Reporter Assay reagents. Results from
iment were normalized to controls from the
iment. Data for each figure panel was collected
t of several experiments where constructs
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hte find that TTP suppressive effect on BDNF 3’UTR
ntaining reporter gene expression is observed in all
periments, but the strength of inhibition on reporter
ne expression varies up to about 1.7 fold between
fferent sets of experiments. The reason for variance
tween different experimental sets is not known, but
ely reflects normal variance in cell-culture experiments.
ch experiment contained 3–4 replicates per construct/
eatment and was repeated 2–8 times as specified in the
ure legends.
combinant TTP protein production
uman TTP open reading frame was cloned into a
7lac based vector containing a His-tag (Peranen et al.
96). The vector was transformed into BL21 (DE3) cells
ovagen), and the protein was expressed in the presence of
TG (isopropyl β-D-thiogalactoside) for 4 h at 24°C. The
lls were lysed in buffer A (20 mM Tris HCl, pH 8.0, 0.5%
riton X-100, 10 mM b-mercaptoethanol, 0.4 mM PMSF)
sonication. Then, NaCl and imidazole were added to a
al concentration of 0.5 and 0.02 M, respectively. After
ntrifugation (15,000 × g for 15 min at 4°C) the supernatant
as passed through a 0.45 μm filter. The His-TTP protein
as purified by the HisTrap kit according to the manufac-
rer (GE Healthcare). Buffer B (50 mM Tris–HCl (pH 8.0),
0 mM NaCl, 0.5 mM EDTA, 1 mM DTT) exchange was
ne by using a PD-10 column (GE Healthcare). His-tag
as cleaved from His-TTP by AcTEV (Invitrogen). The
is-tag and AcTEV were removed by application to a
iTrap Chelating column and TTP was collected from the
w-through. TTP was concentrated using an Amicon
ltra-4 filter device (Millipore). Aliquots of TTP were snap
ozen in liquid nitrogen and stored at −80°C.
ectrophoretic Mobility Shift Assay (EMSA)
epending on the orientation of U1 and U2 fragments,
7 or T3 RNA polymerase was used to synthesize RNA
obes in vitro. RNA 3' End Biotinylation Kit (20160,
hermo Scientific Pierce) was used to label RNA probe at
e 3’ end according to manufacturer’s protocol. Biotin
beling efficiency was assessed by dot plot as recom-
ended by the manufacturer. Biotin-labeled RNA probes
ere diluted (5-10x) based on labeling efficiency obtained
dot plot assay. Diluted RNA probes were incubated
ith different concentrations of purified TTP protein at
om temperature for 30 minutes in 20 μl reaction
ixture containing 10 mM HEPES (pH 7.3), 40 mM
Cl, 3 mM MgCl2, 2 mM DTT, 5% glycerol and
mg/ml tRNA. The reaction was mixed with 1X REMSA
ading buffer (Thermo Scientific Pierce) and run for
hours in 6% native polyacrylamide gel at 130 V. The
nds were transferred to positively charged nylon mem-
ane (Roche) and UV cross-linked at 120 mJ/cm2 for
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ons and quantitative real-time PCR
C2C12 cells was isolated using either TRI
R 118, Molecular Research Center Inc.) or
596–018, Ambion) according to protocol
the manufacturers. RNA samples were treated
DNA-free DNase (AM1907, Invitrogen) to
A. cDNA synthesis using random hexamer
a final volume of 20 μl was performed using
r First Stand cDNA synthesis kit (04896866001,
recommended by manufacturer. Quantitative
PCR (RT-PCR) was done with Lightcycler
me PCR system (Roche Diagnostics) using
480 SYBR Green I Master Mix. Three
ells were run for each sample. Primers used for
e indicated in Additional file 1: Table S1.
rence
ool siGENOME mouse Zfp36 (TTP) siRNA
-01-0005,Thermo Scientific) and siGENOME
ting siRNA Pools (D-001206-13, Thermo
were transfected to C2C12 cells 50–75
using Lipofectamine® RNAiMAX Transfection
3778030, Invitrogen) as recommended by the
er.
t
ion of RBP expression in cell-lines, samples
n 12% acrylamide gel for 1 hour and blotted
-ECL membrane (G1492720, GE Healthcare).
brane was incubated in blocking solution
at milk, TBS, 0.1% Tween) for 30 minutes
ted in anti-V5 Mouse Monoclonal Antibody
nvitrogen) at 1:6000 dilution in the blocking
50 minutes. The membrane was washed and
n polyclonal goat-anti-mouse HRP-conjugated
antibody (P0447, Dako) at 1:2000 dilution in
g solution for 50 minutes. Pierce ECL Western
bstrate (32106, Thermo Scientific Pierce) was
ignal detection according to manufacturer’s
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ked immunosorbent assay (ELISA)
tion medium (DM) from C2C12 cells was
t day 5 as described in the experimental
re 1a and centrifuged at 2000 rpm at +4°C for
to remove cell debris. BDNF protein levels in
re measured using BDNF Emax® ImmunoAssay
7611, Promega) according to manufacturer’s
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Figure 1 AUUUA- motifs in mouse BDNF 3’ UTR and their conservation among vertebrates. a. Schematic diagram of BDNF mRNA products
with long (BDNF-L) and short (BDNF-S) 3’UTRs. AUUUA sequences, often serving as ARE-BP binding motifs within AU-rich elements (AREs) are
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ABSTRACT 
Genetic studies on the effect of 3'UTR on gene expression levels in mammalian nervous 
system are currently missing. GDNF has been tested in clinical trials to treat Parkinson’s disease 
with variable outcome, but mechanisms of GDNF regulation and its post-natal function have 
remained obscure. Here we show that GDNF expression is negatively regulated via its 3’UTR in vitro 
and in vivo. Our data suggest suppression of GDNF expression via direct interaction between Gdnf 
3’UTR and miR-96 and miR-146a, and identify other candidate miR-s for GDNF regulation. Further, 
we show that elevation of endogenous GDNF by 3’UTR replacement in mice augments striatal 
extracellular dopamine (DA) clearance rate in DA concentration-dependent manner, increases 
striatal DA levels and elevates the number of DA neurons in adult substantia nigra. Adverse effects 
associated with ectopic GDNF applications are not observed, while striatal DA levels and function in 
proteasome inhibitor lactacystin induced Parkinson’s disease model are preserved. Our results 
reveal novel post-natal functions of endogenous GDNF and highlight 3’UTR replacement as a potent 
genetic tool to study mammalian genes in vivo. 
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SIGNIFICANCE 
Currently, gene function in vivo is mostly concluded based on effects associated with its 
deletion. To what extent compensation occurs remains unknown. Transgenic 
overexpression on the other hand, is limited due to spatiotemporal misexpression. Recently, 
3’UTR-s have emerged as important site of gene levels regulation but genetic studies have 
remained scarce. We find that the 3’UTR of GDNF, a dopaminergic growth factor currently in 
phase 2 clinical trials for Parkinson’s disease, contains strong inhibitory property and we 
identify candidate microRNA-s involved in this process. Replacement of GDNF’s 3’UTR in 
mice derepressed endogenous GDNF levels and allowed studies inaccessible with alternative 
methods. Our data pinpoint that 3’UTR-s are an important target for genetic studies. 
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INTRODUCTION 
Currently, gene function in vivo is mostly studied by transgenic overexpression or deletion 
within endogenous locus (gene knock-out) methods. However, transgenic overexpression of 
a gene is limited due to spatiotemporal misexpression resulting from recombinant construct 
and integration site variations. The gene knock-out approach, on the other hand, fails to 
reveal the extent to which compensatory effects by functional homologues and, in the case 
of the brain, the use of alternative neuronal networks, masks the effects of the lack of a 
gene.  
3’UTR replacement strategy to modulate endogenous gene product levels to complement 
the limitations of existing methods has been proposed almost ten years ago(1) but follow up 
studies have remained scarce(2, 3). Genetic studies on the role of 3'UTR in the regulation of 
gene expression levels in mammalian nervous system are currently lacking.  
Neurotropic factors (NTFs) such as Glial cell line-derived neurotrophic factor (GDNF) carry 
great therapeutic potential.  However, whether in vivo upregulation (derepression) of 
endogenous NTFs by 3’UTR replacement provides scientifically and therapeutically valuable 
information has remained unexplored.  
GDNF has been identified as a potent NTF particularly for the midbrain dopamine (DA) 
neurons in substantia nigra (SN) both in vitro and in vivo(4, 5). DA neurons in SN innervate 
mainly the dorsal striatum(6) and primarily regulate initiation of voluntary movements and 
basal motor activity(7). Degeneration and loss of these neurons is specifically accelerated in 
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Parkinson’s disease (PD), which is characterized by reduction in striatal dopamine levels and 
concomitant slowness of movement, resting tremor and rigidity (8).  
Because of its strong dopaminotrophic effects, GDNF is extensively studied in pre-clinical 
and clinical trials of PD by intracranial delivery(8). However, intracranial ectopic GDNF 
application has undesired side-effects and benefits have remained inconclusive, 
underpinning a need for basic studies on GDNF biology (9-16). To what extent results on 
ectopic GDNF applications reflect endogenous GDNF function has remained unclear. This is 
at least in part because knock-out mice of Gdnf and its receptors,  and Ret die at birth 
due to the lack of kidneys, while the DA system, which largely matures postnatally, is  intact 
at that age (17).  
Here, we show that GDNF levels are negatively regulated via its 3’UTR and generate mice in 
which Gdnf 3’UTR is conditionally reversibly replaced resulting in enhanced, but spatially 
unchanged expression of endogenous GDNF. While homozygous Gdnf 3’UTR-crR mice die by 
P18 due to defects in kidney development, heterozygous animals are healthy. Analysis of 
the new mouse model revealed that moderate, 30-50% elevation in endogenous GDNF 
levels augments the number of adult DA neurons in SNpc and striatal DA levels, boosts 
extracellular striatal DA clearance rate in a DA concentration dependent manner and 
increases amphetamine-induced but not spontaneous motor activity in mice. Further, we 
find that endogenous GDNF protects DA neuron function in proteasome inhibitor lactacystin 
induced mouse PD model. Side effects associated with ectopic GDNF applications such as 
spontaneous hyperactivity, reduction in key enzyme in DA synthesis tyrosine hydroxylase 
(TH) levels and loss of appetite were not observed.  
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Our findings suggest that next to the classical gene deletion or transgenic over-expression 
methods, 3’UTR replacement is a potent tool to study gene function and regulation in vivo. 
 
RESULTS 
The 3’UTR of Gdnf contains an inhibitory property  
We found that Gdnf 3’UTR contains an inhibitory property that suppresses Firefly luciferase 
expression in human embryonic kidney (HEK293) cells. We also found that suppression by 
Gdnf 3’UTR is similar when different reporter gene is used, suggesting that it is independent 
of the preceding coding sequence (Fig. 1A), extending the findings of an earlier study(18). 
Human brain-derived U87 glioblastoma cells are one of the few cell-lines known to produce 
and secrete detectable amounts of endogenous GDNF protein(19). We found that inhibition 
by Gdnf 3’UTR occurs, although less prominently than in HEK293 cells, also in U87 cells (Fig. 
1A).  
 
Conditionally reversible replacement of Gdnf 3’UTR  
Our goal was to study the in vivo relevance of the inhibitory property in Gdnf 3’UTR with the 
focus on midbrain DA system development and function. We set to generate mice with 
conditionally reversible replacement of Gdnf 3’UTR (Gdnf 3’UTR-crR) as shown on Fig 1B. To 
test the principle, we preceded 2.8kb Gdnf 3’UTR in the reporter construct with FLP 
recombinase recognition site flanked 2.5 kb marker gene PR/TK (20), where transcription 
termination is induced by bovine Growth Hormone polyadenylation signal (bGHpA), (Fig 
S1A). bGHpA is a strong initiator of transcription termination broadly used for gene-trap 
experiments in mice(21, 22). We confirmed that bGHpA prevents transcription to Gdnf 
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3’UTR in our construct (Fig. S1B-C). Inhibition of transcription using actinomycin D revealed 
that Gdnf 3’UTR-crR renders the preceding gene product more stable than Gdnf 3’UTR, 
suggesting that negative regulation occurs at post-transcriptional level (Fig. S1D). 
Comparison of Gdnf 3’UTR and Gdnf 3’UTR-crR on reporter gene expression revealed 8-fold 
derepression relative to Gdnf 3’UTR in HEK293 cells and about 2-fold derepression in U87 
cells (Fig. 1C). Next, Gdnf 3’UTR-crR cassette was flanked with homologous arms to generate 
Gdnf 3’UTR-crR mice carrying an allele depicted on (Fig. 1D). Because we also aimed to 
compare phenotypes of heterozygous Gdnf 3’UTR-crR mice to heterozygous Gdnf coding 
sequence knock-out (KO) mice, Gdnf exon 3 encoding for GDNF protein was “floxed” (Fig. 
1D).  
 
Gdnf levels and site of expression in the Gdnf 3’UTR-crR mice  
We found that homozygous Gdnf 3’UTR-crR animals died before post-natal day (P) 18 due to 
kidney defects while heterozygous (+/-) Gdnf 3’UTR-crR mice were healthy (see below). 
Similar to HEK293 and U87 cells, GDNF mRNA and protein in Gdnf 3’UTR-crR homozygous 
mice were about 6-fold derepressed in the kidney (Fig. S2A) and up to about 2-2.5 fold both 
in the rostral brain at P7.5 (Fig. 2A-B) and in various brain regions in adult mice (Fig 2C-D) as 
measured using qPCR and ELISA methods, respectively. We noted that Gdnf mRNA was 
more efficiently derepressed in the brain areas where Gdnf mRNA levels were relatively 
higher (Fig. 2C). Removal of the 3’UTR replacement cassette with crosses to Deleter-Flp line 
resulting in a Gdnf 3’UTR-restored allele, normalized GDNF levels in brain (Fig. 2C) and 
kidney (Fig S2A). 
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Next, we studied the site of Gdnf expression. Unfortunately, antibodies reliably recognizing 
endogenous GDNF protein in histological sections are currently not available. To further 
address this, we tested over ten commercially available anti-GDNF antibodies and all 
recognized a 37kD band of a “wrong “size in western blotting analysis of brain lysates 
derived from GDNF gene knock-out mice (MW of GDNF monomer is ca 15kD). We therefore 
used in situ hybridization (ISH) method to detect Gdnf mRNA. Gdnf mRNA levels in mouse 
brain are the highest at around P12.5 facilitating the analysis (23, 24). In the striatum (Fig. 
2E) and in other brain areas (Fig. S2B) Gdnf expression site in Gdnf 3’UTR-crR+/- mice 
matched the wt Gdnf expression pattern and the previously published results (24, 25). In 
line with enhanced Gdnf expression, ISH signal was stronger in Gdnf 3’UTR-crR+/- mice 
striatum (Fig. 2E). Because there are always cells with borderline ISH signal (Fig. 2E) it is 
impossible to directly assess whether the seemingly increased number of Gdnf+ cells in the 
striata of Gdnf 3’UTR-crR+/- mice reflects an increase in Gdnf-positive cell number or ca 2-
fold increase in Gdnf mRNA expression (Fig 2C,E). However, Gdnf and parvalbumin (PV) are 
almost exclusively co-expressed in the same striatal neurons (24). Quantification of striatal 
PV+ cells did not reveal difference between the genotypes (Fig. 2F). ISH analysis of Gdnf 
mRNA in other organs with well-defined Gdnf mRNA expression sites, including developing 
kidney, testis and hind-limb revealed stronger signal in Gdnf 3’UTR-crR+/- mice but no 
difference in the site of expression between wt and Gdnf 3’UTR-crR mice (Fig S2C-F). 
Northern blot analyses of Gdnf mRNA (Fig. S2G) and Gdnf transcript sequencing (Fig. S2H-I) 
further confirmed that Gdnf 3’UTR replacement was successful in vivo.  
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Identification of Gdnf 3’UTR regulating micro-RNAs  
Gdnf 3’UTR contains inhibitory property but the inhibitors involved remained unknown (18) 
(Fig 1A). miRs and RNA-binding proteins (RBPs) are the most important mRNA stability and 
translation regulating factors that can bind to 3’UTR-s (2, 26). Oh-Hashi et al. tested several 
RBP-s but found no impact on Gdnf 3’UTR containing reporter gene expression (18), a 
finding which we independently confirmed (Fig S3A).  
Next we turned our attention to micro-RNAs (miRs). Analysis of Gdnf and its family ligands 
(GFL-s: neurturin, artemin, persephin) and their receptors (-4, Ret)(17) revealed 
multiple conserved miR sites in the 3’UTR’s of Gdnf (Fig. 3A, Table S1A) and GDNF family 
ligands (GFL) signaling receptor Ret mRNAs, a single conserved miR site in the 3’UTR of 
neurturin and Gfr but none in other GFL-s and their receptors (Fig. S3B). 
We studied whether the 3’UTR of Gdnf can be specifically regulated by the predicted miRs 
using the Dual-Glo reporter system. Currently there are no reports on miR regulation of 
GDNF. We selected miR-133a, miR-133b, miR-125a-5p, miR-125b-5p, miR-30a, miR-30b, 
miR-96, miR-9 and miR-146a for further analysis based on their co-expression with Gdnf in 
various brain areas (24, 25, 28) and (30), www.microrna.org. We also confirmed that miR-9, 
miR-133a, miR-125a-5p, miR-125b-5p, miR-30a, miR-30b and miR-146a are expressed in 
adult dorsal striatum (Fig. S3C). HEK-293 cells were transfected with RNA-s encoding for 
different control pre-miRs (Negative control-N) and with putative GDNF-regulating pre-
miRs: miR-133a, miR-133b, miR-125a-5p, miR-125b-5p, miR-30a, miR-30b, miR-9, miR-96 
and miR-146a. All of the above miRs, relative to the controls, negatively regulated the 
expression of a reporter construct containing the Gdnf 3’UTR (Fig. 3B). Mutating the 
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predicted miR binding sites (seed sequence, Table S1) in the Gdnf 3’UTR abolished the 
inhibitory capability of the tested miR-146a and miR-96 (Fig. 3C). We also found that miR-s 
lack effect on the Gdnf 3’UTR-crR cassette (Fig. 3F) in the same assay. This is in line with in 
silico prediction that Gdnf 3’UTR-crR cassette contains about 2-fold less total potential miR 
sites and 9-fold less conserved sites present in Gdnf 3’UTR (Fig. S3E-F). Transient expression 
of a combination of multiple miRs (miR-9, miR-96, miR-146a and miR-133b), which were 
selected based on their ability to interact with Gdnf 3’UTR and suppress the Gdnf 3’UTR-
containing reporter construct (Fig. 3B), additively suppressed both endogenous GDNF 
protein and mRNA levels (Fig. 3D-E), without affecting U87 cell survival (Fig. S3D).  
 
Kidney development disturbed but enteric nervous system function maintained  
Heterozygous Gdnf knock-out (KO) animals with about 50% reduced GDNF levels frequently 
have one kidney (17). Both homo- and heterozygous Gdnf 3’UTR-crR animals always had 
two kidneys, but excess GDNF negatively regulated kidney size in a GDNF concentration-
dependent manner (Table S2A, Fig. S4A-B). However, while homozygous Gdnf 3’UTR-crR-/- 
mice died most likely due to miniature and poorly functioning kidneys by P18, kidney defect 
in heterozygous mice was mild or absent and animals were found at the Mendelian 
frequency and healthy at all ages (Table S2B, Fig. S4C-F, and see below). Analysis of the GI 
tract revealed that the number of enteric neurons in Gdnf 3’UTR-crR animals was increased, 
while the GI tract in both homo- and heterozygous mice appeared anatomically normal. 
Bodyweight measurements and studies with physiological cage revealed no difference 
between heterozygous 3’UTR-crR and wt littermates (see below), supporting the idea of 
normally functioning GI tract. Detailed role of the increased GDNF levels in the kidney and 
ENS will be described elsewhere. 
11 
 
 
Effect of GDNF derepression on postnatal nigrostriatal DA system development 
Since homozygous Gdnf KO mice die at birth due to lack of kidneys, the post-natal role of 
GDNF in  DA system function has remained poorly understood (17, 31). We found that in 
Gdnf 3’UTR-crR mice striatal phosphorylated extracellular signal-regulated kinase 2 (Erk2) 
levels, a known target of GDNF signaling(17), are increased at P7.5 (Fig. 4A). DA levels in the 
rostral brain at P7.5 were elevated to a comparable level in both homo- and heterozygous 
Gdnf 3’UTR-crR animals and normalization of GDNF levels restored wt DA levels (Fig. 4B). 
Unbiased stereological cell counts of TH immunoreactive DA neurons in the SNpc revealed 
analogous increase in both homo- and heterozygous Gdnf 3’UTR-crR animals at P7.5 (Fig. 
4C). Similarly, quantification of the number of all monoaminergic neurons using 
immunostaining against vesicular monoamine transporter 2 (VMAT2), revealed a tendency 
towards increase in both hetero- and homozygous mutants, which did not reach statistical 
significance (Fig. 4D). DA metabolite levels in the rostral brain at P7.5 remained unaltered in 
Gdnf 3’UTR+/- and -/- mice (Fig. S4G-H). DA system and kidney development are not linked, 
since kidney function was severely compromised only in Gdnf 3’UTR-crR homozygous 
animals, which was further confirmed by correlation analysis of kidney and DA system 
parameters in individual heterozygous animals (Table S3).  
 
Nigrostriatal DA system in adult Gdnf 3’UTR-crR+/- mice 
Next we addressed the effects of GDNF derepression in adult mice. At 2.5-3 months of age 
tissue DA levels in Gdnf 3’UTR-crR+/- mice striatum were elevated (Fig 4E). To control for 
the effects of one mutant allele, we measured DA levels in Gdnf KO heterozygous mice. In 
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line with previous studies (32, 33), DA levels in Gdnf KO heterozygous mice were at the wt 
level (Fig. 4E). Restoration of wt Gdnf levels restored wt DA levels (Fig. 4F). Similar to P7.5, 
we found no change in striatal DA metabolite levels and turn-over in striata of adult Gdnf 
3’UTR-crR+/- mice (Fig. S4I-K). Unbiased stereological cell counts of TH immunoreactive DA 
neurons in the SNpc revealed a tendency towards increase (13%) in Gdnf 3’UTR-crR+/- 
animals which did not reach statistical significance (Fig. 4G). However, unbiased 
stereological cell counts of VMAT2 immunoreactive neurons revealed a significant increase 
in the SNpc Gdnf 3’UTR-crR+/- animals (Fig. 4H). Microscopy analysis of TH immunostaining 
of striatum and midbrain revealed no gross anatomical or other changes (Fig. S4L-M). 
 
Dopamine transporter activity in adult Gdnf 3’UTR-crR+/- mice 
To assess dopamine transporter activity in adult Gdnf 3’UTR-crR+/- mice, we measured 
extracellular DA clearance rate in the striatum using in vivo amperometry and found that 
DAT activity is increased up to five fold in a DA concentration-dependent manner in Gdnf 
3’UTR-crR +/- mice (Fig. 5A). While striatal DA uptake rate in wt littermate controls reached 
a plateau, DAT activity in the striata of Gdnf 3’UTR-crR +/- animals increased at all DA 
concentrations tested (Fig. 5A). Measurements of total DAT protein levels in the nigrostriatal 
system revealed no difference between genotypes (Fig. S5A). Changes in DAT activity in 
amperometry measurements occur within seconds suggesting that DAT activity in Gdnf 3’UTR-crR 
+/- mice is regulated by fast post-translational modifications and/or protein-protein interactions. 
Amphetamine releases DA from synaptic vesicles into the cytoplasm and reverses its flow 
across the synaptic DAT, increasing extracellular DA and concomitantly inducing an increase 
in locomotor activity (34). To gain insight whether the observed augmentation in DAT 
function can be related to changes in locomotor function, mice were injected i.p. with 
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1mg/kg amphetamine. Compared to wt littermate controls, amphetamine-induced 
locomotor activity was significantly enhanced in Gdnf 3’UTR-crR +/- mice (Fig. 5B), 
suggesting that DAT activity is enhanced also in awake Gdnf 3’UTR-crR +/- animals. 
 
Effects of GDNF derepression on DA system in lactacystin model of Parkinson’s 
disease 
Mouse models phenocopying the slow progression of human PD are not available(35). 
Currently, the most widely used animal models for PD are based on toxins MPTP and 6-
OHDA, which are delivered specifically into the DA neurons via DAT (35). Since DAT activity 
in Gdnf 3’UTR-crR+/- mice is five-fold increased (Fig. 5A) the use of DAT-based toxins would 
confound the outcome. Therefore, we looked for alternative PD models. Abnormal protein 
aggregation is generally accepted as a pathological process common in most 
neurodegenerative disorders including PD. In line with this, intracranial application of 
proteasome inhibitors such as lactacystin (LC) has recently been shown to induce PD in 
rodent and fish models (36-38). We found that unilateral supranigral LC injection induced 
significant side bias in corridor test in wt, but not in Gdnf 3’UTR-crR heterozygous mice (Fig. 
5C). DA and its metabolite levels were better preserved in the Gdnf 3’UTR-crR +/- mice (Fig. 
5D-F). DA cell number in the SNpc was comparable between the genotypes (Fig. 5G) 
suggesting that the rescue in Gdnf 3’UTR-crR +/- mice occurs at the level of neuronal 
function.  
Although ectopic GDNF application into the nigrostriatal DA system has beneficial 
dopaminotrophic effects in PD models and clinical trials, it also induces undesired effects 
such as hyperactivity (9, 10, 12, 13, 16), down-regulation of TH levels(13, 14), and reduction 
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in food-intake and bodyweight (9, 39). In Gdnf 3’UTR-crR +/- mice these features were not 
observed (Fig. 5H-K, Fig. S5B-E). 
 
DISCUSSION 
During the recent decade, 3’UTR-s have emerged as important sites of gene levels 
regulation by binding of micro-RNA-s, RNA binding proteins, etc but genetic studies have 
remained scarce (2). We found that Gdnf levels are negatively regulated via its 3’UTR. Our 
mutational analysis strongly suggests that miR-96 and miR-146a directly interact with Gdnf 
3’UTR via the predicted binding sites. Online datasets from two genome wide screens for 
identifying miR target mRNA-s: i) Argonaute cross-linked immunopercipitation followed by 
RNA sequencing analysis i.e. miR CLIP-seq dataset; and ii) microarray analyses following miR 
transfection dataset, both suggested that miR-9 and miR-96 may directly interact with Gdnf 
3’UTR in mouse brain and regulate Gdnf expression in cell-lines 
(40), http://servers.binf.ku.dk/antar/. Our data validates data from genome-wide screens 
suggesting functional interaction between miR-9 and miR-96 with Gdnf. In addition to miR-
9, miR-96 and miR-146a, our data propose miR-133a, miR-133b, miR-125a-5p, miR-125b-5p, 
miR-30a and miR-30b as potential regulators of GDNF levels. Our results with miR-s also 
suggest that GDNF levels may be fine-tuned by a single miR, or more likely, by concerted 
action of several miR-s. Unlike in plants and insects, mammalian 3’UTR-s most often contain 
multiple conserved miR sites suggesting that the effect of miR-s on gene expression in 
mammals is additive and/or coordinated by several miR-s (26, 41). Which miR or 
combination of miR-s regulates Gdnf levels in PV+ striatal neurons remains to be identified. 
We also observed that Gdnf mRNA in Gdnf 3’UTR-crR +/- mice is significantly derepressed 
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only in the brain areas of higher Gdnf mRNA expression. The reason for this is unknown but 
may relate to relative concentration ratio of mRNA and inhibiting miR’s and/or to the fact 
that miRs have different effects on their target mRNA-s depending on the tissue and 
developmental stage (42). A common notion that cellular environment is important in 3’UTR 
regulation is also illustrated by our finding that in human cells and mouse tissues, GDNF 
derepression is more pronounced in kidney than in brain cells. Future research will reveal 
the molecular mechanisms involved. 
Classical GDNF KO mice die at birth due to the lack of kidneys with intact midbrain 
dopamine system which largely matures postnatally. Thus there is very little in vivo data on 
the postnatal function of endogenous GDNF in midbrain neurons. Despite clinical relevance, 
to date only a single study with conditional GDNF deletion in adult mice has been published 
(43). Because Gdnf 3’UTR-crR+/- mice are viable, we were able to analyze the role of GDNF 
in the function of postnatal DA system. We found that GDNF regulates DA cell number 
during development and adult SN, striatal tissue DA levels, DAT activity in a DA 
concentration-dependent manner, and prevents the decline in striatal DA levels in supra-
nigrally injected lactacystin model of PD. Data on uncovered GDNF functions, and 
comparison to results from ectopic GDNF is summarized in Table 1. 
Adverse effects associated with ectopic GDNF application such as downregulation of TH 
levels, loss of appetite and bodyweight, and hyperactivity were not observed in Gdnf 3’UTR-
crR mice (Table 1). Interestingly, while application of low doses of ectopic GDNF into the DA 
system has no effect on DA system function, ectopic GDNF amounts exceeding hundreds of 
times the endogenous GDNF levels transiently increase DA turnover without affecting total 
striatal DA levels (9, 13, 16). We find that elevation of endogenous GDNF does the opposite - 
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augments tissue DA levels, not the turn-over (Table 1), suggesting a qualitative difference 
between the two sources of GDNF. Future studies using mice with conditional GDNF 3’UTR 
replacement (see below) will reveal the effects of GDNF derepression in adult animals.     
We also compared Gdnf 3’UTR-crR+/- mice with constitutively active GDNF receptor Ret 
(Met919Thr, MEN2B) animals (44). While striatal DA levels, TH+ cell number and striatal DAT 
activity are increased in both mutants, elevation in DAT and TH protein levels, increased DA 
turn-over and reduced spontaneous locomotion was specific to MEN2B mice(45-47). Thus, 
derepression of endogenous GDNF is not equal to constitutively active Ret, a finding which 
may have broader implications for drug design and studies on receptor/ligand biology. 
Finally, in line with findings in MPTP model of PD in Ret conditional KO mice (48), we find 
that GDNF signalling is important in preserving striatal DA levels and function rather than 
TH+ cell bodies in proteasome inhibitor lactacystin induced PD model.  
Sequence comparison of arbitrarily selected genes with known regulatory functions in brain 
development and plasticity revealed long 3’UTRs with the majority of miR sites conserved 
between mouse and man for many genes (Fig. 5L). Our results suggest that 3’UTR 
replacement can provide information inaccessible with, and complementary to the 
previously available tools. We propose a “Flex-cassette”(21) based approach enabling 
conditional 3’UTR replacement (Fig. 5M). Such animals would constitute an “opposite” 
system to classical conditional gene knock-out, which may enable to expand knowledge on 
gene function and regulation in vivo. Our results also indicate that the 3’UTR of GDNF and its 
regulators may be interesting drug targets for the development of treatment for PD. 
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Materials and Methods 
Experiments were performed using routine methods applied in such studies. Details 
with appropriate references are provided in Online Materials and Methods. 
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FIGURE LEGENDS 
Figure 1. Characterization of inhibitory property of Gdnf 3’UTR and design of the 
conditionally reversible Replacement (Gdnf 3’UTR-crR) allele.  
(A) Mouse Gdnf 3’UTR was cloned to proceed Renilla (Ren) and Firefly (FF) luciferase coding 
sequence in the Dual-Luciferase Reporter Assay System (Fig. S1A). Comparison with SV40 
late pA revealed a strong inhibitory property for Gdnf 3’UTR proceeding both reporter genes 
in human embryonic kidney HEK-298 cells and about twofold weaker inhibitory property in 
brain derived U87 glioblastoma cell line. (B) Schematic representation of a principle of the 
proposed conditionally reversible Replacement of a 3’UTR. (C) Expression from equimolar 
amounts of FF-Gdnf 3’UTR, FF-Gdnf 3’UTR-crR and FF-SV40 late pA constructs reveals eight 
fold derepression of FF-Gdnf 3’UTR-crR in human embryonic kidney cells (HEK293) and two 
fold derepression in brain derived glioblastoma U87 cells.  experiments with 3-4 repeats 
per construct/cell line per experiment; pooled data from all experiments is shown, Error 
bars indicate SEM; ** and *** P< 0.01 and 0.001 respectively, data was analyzed with 
Student’s t-test. (D) Schematic representation of conditionally reversible Replacement allele 
for Gdnf 3’UTR (Gdnf 3’UTR-crR), A and B designate primers used in QPCR analysis. bGHpA-
bovine Growth Hormone polyadenylation signal, PR/TK- bifunctional marker gene(20), black 
triangle-loxP site, F-FRT site.  
 
Figure 2. Site and levels of GDNF expression in Gdnf 3’UTR-crR mice. 
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(A) QPCR analysis of Gdnf mRNA levels at post-natal day 7.5 (P7.5) in rostral brain; 
heterozygous Gdnf KO mice are known to harbor ~2-fold less Gdnf mRNA, serves as a 
control for QPCR sensitivity. (B) ELISA analysis of GDNF protein levels at post-natal day 7.5 
(P7.5) in rostral brain. (C) QPCR analysis of Gdnf mRNA levels in adult brain, removal of the 
3’UTR- crR cassette by crosses to Deleter-FLP line (Fig. 1D) resulted in restoration of wt Gdnf 
mRNA levels, Gdnf 3’UTR-rest, 4-10 animals per genotype always including controls from the 
same litter were analyzed in 2-8 experiments each containing 3-4 replicates. (D) ELISA 
analysis of GDNF protein levels in dorsal striatum of adult mice, N=5 per genotype. (E) In situ 
hybridization analysis of Gdnf mRNA expression in the striatum at P12.5; white triangles 
point cells with clearly detectable Gdnf expression in both genotypes, black triangles denote 
cells with “borderline” detection in the wt but clear signal in +/- animals; scale bar upper, 
500μm and lower 50μm. (F) the number of parvalbumin (PV), marker of Gdnf expressing 
cells in the striatum is comparable between genotypes; N=4 +/+ and N=7 Gdnf 3’UTR+/- 
mice; two tissue slices and 45-55 microscopic fields per animal were analyzed. dSTR-dorsal 
striatum, OB-olfactory bulb, Hyp-hypothalamus, PFC-prefrontal cortex, NAc-Nucleus 
Accumbens, Hip-hippocampus, SN-substantia nigra, VTA-ventral tegmental area, RN- dorsal 
Raphe nucleus, CB-cerebellum. Error bars indicate SEM, data was analyzed with Student’s t-
test; +/+ indicates wt animals, *, ** and *** are P<0.05; 0.01 and 0.001 respectively.  
 
Figure 3. Evolutionary conservation and regulation of Gdnf 3’UTR by miR-s.  
(A) The 3’UTR of Gdnf mRNA is evolutionarily conserved. Exons and 3’UTR are drawn in 
scale. Percent of identities between human (Hs) and mouse (Mm) sequences is indicated, 
the conserved miR binding sites cluster within the areas conserved between Mm and Hs. 
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Shown are conserved sites for miRs broadly conserved among vertebrates; miRs underlined 
with a red bar were identified as “hits” in two existing genome wide screens i) Argonaute 
cross-linked immunopercipitation followed by RNA sequencing analysis (miR CLIP-seq 
dataset), and ii) microarray analyses following miR transfection dataset(40). Source: Blast, 
TragetScan. (B) The Gdnf 3’UTR analyzed using Dual-Luciferase Reporter Assay System in 
HEK-293 cells either with negative control pre-miRs (N1, N2) or putative Gdnf 3’UTR-
regulating pre-miRs. (C) Two nucleotide mutation within miR-96 and miR-146a seed 
sequences in the Gdnf 3’UTR specifically abolishes their inhibitory properties. (D-E) 
Endogenous GDNF protein and mRNA in human U87 glioblastoma cells is suppressed by 
miRs in an additive manner. (F) Lack of miR mediated suppression from FF-Gdnf-3’UTR-crR 
construct (Fig. S1A) in HEK-293 cells. Experiments were repeated at least 3 times with 3-5 
replicates within the experiment, error bars indicate SEM, data was analyzed with Student’s 
t-test; *, ** and *** are P<0.05; 0.01 and 0.001.  
 
Figure 4. Characterization of the nigrostriatal dopamine system at P7.5 and in adult mice 
(A) Levels of phosphorylated ERK2 at P7.5 in the striatum of Gdnf 3’UTR-crR-/- mice is 
increased, N=4 animals per genotype, data averaged from two western blotting 
experiments, GAPDH and ERK were used for normalization, N=5 animals per genotype. (B) 
HPLC analysis of rostral brain DA levels at P7.5. Left: N=8 wt , N=5 Gdnf 3’UTR-crR +/- and 
N=8 Gdnf 3’UTR-crR -/-, and right: removal of the Gdnf 3’UTR replacement cassette from 
Gdnf 3’UTR-crR animals by crosses to Deleter-FLP generate Gdnf 3’UTR-restored mice (Fig. 
1D) with wt DA levels at P7.5; N=5 wt and N= 5 Gdnf 3’UTR-rest -/- (F=7.44, P=0.016). (C) 
Unbiased stereological cell counts of TH immunoreactive neurons (F= 7.44, P=0.0048) and 
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(D) VMAT2+ neurons in substantia nigra pars compacta (SNpc) at P7.5 reveal increase in 
Gdnf 3’UTR-crR +/- and Gdnf 3’UTR-crR -/- animals, N=7 animals per genotype, except N=6 
wt animals in TH staining and N=6 Gdnf 3’UTR-crR -/- animals in VMAT2 staining; p<0.01 
only for TH+ cells. (E) DA levels in the dSTR of adult 3’UTR-crR +/- mice are elevated; DA 
levels are not elevated in the dSTR of Gdnf KO +/- mice; N=5-8 animals analyzed per group. 
(F) DA levels are not elevated in the dSTR of adult Gdnf 3’UTR-rest -/- mice, compared to wt 
littermate controls, N=6 animals per genotype. (G-H) Number of DA cells in the SNpc of 
adult Gdnf 3’UTR-crR +/- mice is increased as revealed by stereological countings of TH+ and 
VMAT2+ cells, N=8 animals per genotype, * p<0.02 only for VMAT2 positive neurons.  
Figure 5. Effects of elevated endogenous GDNF on adult dopamine system function 
(A) In vivo amperometry; dopamine concentration-dependent increase in dopamine 
transporter (DAT) activity in Gdnf 3’UTR-crR +/- mice is revealed by intrastriatal DA injection. 
      
     
 
/s; calculated using Michaelis-Menten first-order rate constant, k1; N=4 animals per 
genotype (F=47,931; * P<0.05; ** P<0.01; *** P<0.001 between wt and Gdnf 3’UTR-crR +/- 
mice). (B) Compared to wt gender matched littermate controls (N=10), amphetamine 
(1mg/kg, i.p.) increases locomotor activity in Gdnf 3’UTR-crR +/- mice (N=9); F= 4.386, P= 
0.040). Experiment was repeated 3 times with similar results, representative experiment is 
shown. (C) Corridor test in a proteasome inhibitor lactacystin (LC) based Parkinson’s disease 
(PD) model in 3 month old mice (N=7 Gdnf 3’UTR-crR +/- mice; N=5 wt mice) indicated a 
lesion in the wt but not in Gdnf 3’UTR-crR +/- mice right hemisphere at 5 weeks post LC 
injection (F=6.087, P=0.033). (D-F) At the endpoint at 5 weeks post LC injection, dorsal 
striatum (dSTR) DA and its metabolite 3,4-dihydroxyphenylacetic acid (DOPAC) and 
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homovanillic acid (HVA) levels are better preserved in Gdnf 3’UTR-crR +/- mice, as revealed 
by HPLC analysis, expressed as a percent of the levels in the unlesioned side. (G) 5 weeks 
after LC injection, mean number of TH+ neurons in SNpc does not differ between the 
genotypes. (H-K) Evaluation of side effects associated with intracranial ectopic GDNF 
expression; (H) Spontaneous motor activity of Gdnf 3’UTR-crR +/- mice is not increased, 
N=31 +/- and N=34 wt mice. (I) Optical density of striatal TH immuno-staining is not changed 
Gdnf 3’UTR-crR +/- mice, N=10 wt, N=11 Gdnf 3’UTR-crR +/- animals. (J) Food intake in Gdnf 
3’UTR-crR +/- mice is not changed N=10 wt, N=10 Gdnf 3’UTR-crR +/- animals (K) 
Bodyweight of Gdnf 3’UTR-crR +/- mice is not changed N=31 +/- and N=34 wt male mice; 
N=9 +/- and N=11 wt female mice. (L) Representative genes with known regulatory function 
in brain development and plasticity harboring long 3’UTRs with miR binding sites conserved 
between mouse (Mm) and man (Hs), bp-base pair, con-conserved. (M) a “Flex-cassette” 
(black and white triangles)(21) enables conditional 3’UTR replacement at the time and place 
of interest.  
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Table 1. GDNF function revealed by 3’UTR replacement method 
 
 
 
 
 
 
Elevation of 
endogenous GDNF 
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Supplementary Figure 1, related to Figure 1 
In vitro analysis of Gdnf 3’UTR. 
(A) Schematic representation of the reporter constructs and the derived mRNA used in this study. Bovine growth 
hormone polyadenylation signal (bGHpA) at the 3’ end of the Puro-TK cassette is well established to efficiently induce 
termination of transcription in genome-wide gene-trap experiments in mice (Consortium; Schnutgen et al., 2005). (B) 
Northern analysis of expression from construct harbouring Firefly (FF) coding sequence upstream of the conditionally 
reversible Replacement cassette for Gdnf 3’UTR (Fig. 1D and Fig. S1A) using a probe complementary to Gdnf 3’UTR 
revealing a lack of transcription to Gdnf 3’UTR while the derived FF luciferase mRNA (Fig. S1C) and protein (Fig. 1C) 
are clearly detectable. 28S ribosomal RNA serves as loading control, experiment was repeated twice. (C) Northern 
analysis of total RNA from HEK293 cells transfected with constructs depicted on (A) using a probe complementary to 
Firefly luciferase coding sequence, experiment was repeated 2 times. (D) Compared to FF-Gdnf 3’UTR, a product 
derived from FF-Gdnf 3’UTR-crR or FF-SV40 late pA is more resistant to transcriptional inhibition (10 μm of 
actinomycin D), indicating negative regulation of Gdnf-3’UTR bearing transcripts at the post-transcriptional level. 
HEK-293 cells were transfected with Renilla-SV40 late pA together with either FF-Gdnf 3’UTR, FF-Gdnf 3’UTR-cr or FF-
Sv40 late pA, data is derived from 9 biological replicates assayed in three experiments. * p<0.05; ** p<0.01, error 
bars represent SEM, FF-firefly luciferase, Renilla- Renilla luciferase.  
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Supplementary Fig. 2, related to Figure 2 
Analysis of Gdnf mRNA expression in Gdnf 3’UTR-crR mice. 
 
(A) QPCR and ELISA analysis of Gdnf mRNA and protein levels at embryonic day 18.5 (E18.5) in kidney. (B) In situ 
hybridization analysis of Gdnf mRNA expression in coronal cryo-sections from brain at P12.5 using a probe 
recognizing GDNF exons revealed no differences in the site of expression between genotypes, white triangle points 
striatum, triangle with black edge - ventromedial thalamus; triangle with white edge - thalamic nuclei; black triangle-
hippocampus, scale bar 1 mm. (C) Scheme represents known location of Gdnf mRNA expression (blue) in developing 
kidney at E11.5. Gdnf mRNA is expressed at high levels in a structure called the cap (CAP) condensate of the 
metanephric mesenchyme (MM) sharply bordered by ureteric bud (UB), where Gdnf is not expressed. (D) In situ 
analysis of Gdnf mRNA expression (blue) on vibratome sections from the urogenital tract at E11.5. Site of Gdnf mRNA 
expression was indistinguishable between genotypes. Consistent with elevated GDNF levels in embryonic kidney (Fig. 
S2A), signal with a probe complementary to Gdnf exons as indicated with a red line in Fig. 1D is stronger in hetero- 
and homozygous Gdnf 3’UTR-crR mice. In accordance with in vitro results (Fig. S1B-C), and the established property of 
bGHpA to initiate termination of transcription in vivo (Consortium; Schnutgen et al., 2005) a probe recognizing the 
Gdnf 3’UTR gave a weaker signal in heterozygous and no signal in homozygous mice in the CAP (lower panel). The 
experiment was repeated 4 times, at least 4 animals were analyzed per genotype. Representative images are shown. 
Scale bar 10μm. (E) In situ hybridization analysis of Gdnf mRNA in Gdnf 3’UTR-crR -/- mice at the anatomical level in 
whole-mount preparations of E11.5 hind limb. Establishment of limb innervation is known to depend upon controlled 
temporospatial expression of GDNF(Kramer et al., 2006). Gdnf expression island (stained blue, indicated with white 
arrow heads) is comparable between genotypes, experiment was repeated 4 times with N=animals per genotype, 
scale bar 1.5 mm. (F) In situ hybridization analysis of Gdnf mRNA in Gdnf 3’UTR-crR -/- mice in a 5 μm paraffin slice 
3 
 
from P7.5 seminiferous tubule of the testis. Gdnf mRNA is mostly expressed by large cells believed to be Sertoli 
cells(Meng et al., 2000; Sariola and Saarma, 2003) aligned mostly in the periphery of the tubule (white arrow heads), 
Gdnf mRNA signal appears stronger in Gdnf 3’UTR-crR mice, scale bar 5μm, Gdnf CDS probe, experiment was 
repeated 2 times. (G) Northern blot analysis of Gdnf mRNA in E18.5 testis, a timepoint when Gdnf mRNA is known to 
be particularly abundant in this organ facilitating the analysis. As expected (Fig. S1A-C) Gdnf CDS probe hybridizes to 
about ~500 bp shorter transcript in Gdnf 3’UTR-crR -/- mice, experiment was repeated 2 times with RNA derived from 
different animals. (H) Schematic representation of conditionally reversible Replacment allele for Gdnf. bGHpA-bovine 
Growth Hormone polyadenylation signal, PR/TK- bifunctional fusion protein between puromycin N-acetyltransferase  
and a truncated version of herpes simplex virus type 1 thymidine kinase (TK)(Chen and Bradley, 2000), black triangle-
loxP site, F-FRT site. A and B designate primers used in QPCR analysis of Gdnf mRNA levels in Gdnf 3’UTR-crR mice, 
primers A and C depict primers used in (I), for Gdnf transcript sequence analysis. (I) cDNA from E18.5 testis was used 
as a template for PCR reaction with primers A and C. The observed PCR product in Gdnf 3’UTR-crR -/- mice using 
primers A and C was of the expected length (977bp) and was sequenced for validation, experiment was repeated 
three times. Cp values indicating cDNA quality from testis for beta-actin were 18.04 ±0.2, 18.5 ±0.08 and 18.8 ±0.08 
for cDNA derived from wt, Gdnf 3’UTR-rest-/- and Gdnf 3’UTR crR-/- mice respectively. * p<0.05, ** p<0.01, *** 
p<0.001; error bars indicate SEM at all graphs. 
 
Supplementary Fig. 3, related to Figure 3.  
Analysis of 3’UTR-s of GDNF family members, RNA binding proteins, miR effect and expression. 
(A) Analyses of the Gdnf 3’UTR revealed three conserved AU-rich elements (black triangles on Fig. 3A), the putative 
binding sites for RNA binding proteins (RBPs), which may regulate mRNA levels. We tested overexpression of the 
most common RBPs, tristetraprolin (TTP/ZFP36), embryonic lethal abnormal vision like protein 1 (ELAVL1/HuR) and 
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heterogeneous nuclear ribonucleoprotein D0 (HNRNPD/AUF1) in our reporter assays. Consistent with an 
independent, parallel study(Oh-Hashi et al., 2012), RBPs were found to have no or little effect. HEK293 cells were co-
transfected with either negative control, green fluorescent protein (GFP), or putative Gdnf 3’UTR-regulating RBPs. 
TTP/ZFP36 reduced reporter construct levels by about 10%  (P<0.05), data is derived from 9 biological replicates 
assayed in three experiments. (B) Depicted are the 3’UTR-s of neurturin (Nrtn), artemin (Artn), primary binding 
receptors -4 and the common signaling receptor tyrosine kinase Ret. The most stringent default search modes 
in TargetScan for miR seed sequence identification, and Blast for homology search were used. Identical search criteria 
were used for the Gdnf 3’UTR (Fig. 3A). Note that besides Gdnf (Fig. 3A) only the 3’UTR of Ret contains multiple 
conserved miR target sites for miRs broadly conserved in vertebrates. Nrtn and its primary receptor  harbor a 
single conserved miR site each and other family members harbor no conserved miR sites. Conserved sequence areas 
are depicted as colored bars, percentage indicates number of identities between Mus musculus and Homo sapiens. 
Relative lengths of 3’UTRs are drawn to scale. No data from the www was found for Pspn 3’UTR. (C) Levels of mature 
miRs expressed as fold difference relative to sno202 levels in adult (10weeks) mouse (Mm) dorsal striatum. Mature 
miR levels were assessed with TaqMan QPCR; 2 experiments were performed with 4 repeats per miR per QPCR run. 
(D) Co-transfection of a combination of pre-miRs is non-toxic to cells, as assayed with CellTiter-Glo Luminescent Cell 
Viability Assay (Promega), N-negative control, experiment was repeated 3 times. (E-F) Number of bioinformatics 
(PITA(Kertesz et al., 2007)) predicted miR sites in Gdnf 3’UTR, Puro/TK cassette (3’UTR-crR cassette) and bGHpA; and 
SV40 late pA, error bars represent SEM. 
 
Supplementary Fig. 4, related to Figure 4 
Analysis of kidneys and dopamine system in Gdnf 3’UTR-crR mice. 
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(A) Representative images of kidneys of Gdnf 3’UTR-crR -/- (N=10, left panel) and +/- (N=20, right panel) animals at 
P7.5. In about half of the Gdnf 3’UTR-crR +/- animals the size of the kidneys was reduced up to ~25%, whereas 
kidneys in all -/- animals were miniscule. (B) Kidneys in the Gdnf 3’UTR-rest -/- animals are normal, N=20 animals 
analyzed per genotype. Scale bars on A and B are 1 mm.  (C-D) Kidneys of Gdnf 3’UTR-crR -/- function poorly, as 
revealed by measurements of serum urea (N= 7 Gdnf 3’UTR-crR -/-, N= 26 Gdnf 3’UTR-crR +/-, N= 16 wt) and 
creatinine (N= 3 Gdnf 3’UTR-crR -/-, N= 12 Gdnf 3’UTR-crR +/-, N= 7 wt) levels. (E) Serum urea levels in adult 4 month 
old animals were mildly increased in Gdnf 3’UTR-crR +/- animals. However, at least in humans, up to two-fold 
variation in serum urea levels between individuals is considered normal suggesting that kidney function in +/- animals 
is in a normal range (N= 16 wt, N= 19 Gdnf 3’UTR-crR +/-). (F) Consistent with (E), measurement of serum creatinine 
levels revealed no difference between genotypes at 4 months. 
(G-K) Analysis of the dopamine system.  We found that dopamine (DA) levels and dopaminergic neuron numbers 
were increased to an equal extent in the brain of both -/- and +/- Gdnf 3’UTR-crR mice (Fig. 4B-C) suggesting a lack of 
correlation between kidney and brain DA system development. To further address this, we performed correlation 
analyses of brain DA and serum urea levels in individual +/- animals at P7.5 and found that those parameters 
reflecting DA system and kidney function were indeed non-correlated (Supplementary Table 3). 
(G-H) High performance liquid chromatography (HPLC) analysis of P7.5 rostral brain dopamine metabolites 3,4-
dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), N = 2 experiments, in the depicted experiment N=8 
wt, N=5 Gdnf 3’UTR-crR +/-, N=8 Gdnf 3’UTR-crR -/-, no statistically significant difference was found (I-J) HPLC 
analysis of dopamine metabolites DOPAC and HVA in dSTR at 2.5-3 months of age reveals no difference between the 
genotypes. 5-8 animals were analysed per genotype. (K) HVA/DA ratio at 2.5-3 months of age reflecting DA turnover 
did not differ between the genotypes, 5-8 animals were analysed per genotype.  
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(L-M) TH+ immunostaining revealed no gross morphological changes in the STR (L) and midbrain of Gdnf 3’UTR-crR 
+/- mice, scale bar(L) 75μm, in inset 1mm, scale bar (M) 0.5 mm, in inset 30μm. Note that the arbitrary difference 
between genotypes on (L-M) reflects normal variation, N=8 animals per genotype. 
 
Supplementary Fig. 5, related to Figure 5 
Analysis of DAT and TH protein levels in Gdnf 3’UTR-crR mice. 
 (A) DAT protein levels in dSTR and SNpc as measured by western blotting revealed no difference at 10 weeks of age, 
N= 5 animals per genotype, data averaged from two western blots, alpha-tubulin and gapdh were used to normalize 
loading. (B) Optical density (OD) measurements of striatal TH immunolabelling reflecting striatal TH levels and density 
of striatal dopaminergic innervation at the macroscopic level revealed no difference between genotypes at P7.5 (N=7 
animals per genotype), OD of TH was analysed blind to genotype. (C) TH protein levels in dSTR as measured by 
western blotting revealed no difference at P7.5, N= 4 animals per genotype, data averaged from two western blots, 
gapdh was used to normalize loading. (D) OD measurements (as in B) of striatal TH immunolabelling in adult mice at 
2.5-3 months of age did not differ between genotypes, N=10 wt, N=11 Gdnf 3’UTR-crR +/- animals. (E) TH protein 
levels in dSTR at 2.5-3months of age as measured by western blotting revealed no difference between wt and Gdnf 
3’UTR-crR  heterozygous mice, N= 5 animals per genotype, data averaged from three western blots, gapdh was used 
to normalize loading.  
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Supplementary Table 1, related to Figure 3 
Alignment of conserved miR target sites within the 3’UTR of GDNF gene spanning 20bp 5’ and 5bp 3’ of the miR 
seed sequence. 
 
Code: white-miR seed sequence, miR seed conservation, conservation outside miR seed 
 
miR-204/204b/211 
M. musculus (mouse) AUUCCUGCUACAGUGCGAAGAAA-----------------GGGACCAAG
H. sapiens (human) AUUCCUGCUACAGUGCAAAGAAA-----------------GGGACCAAG
P. troglodytes (chimpanzee) AUUCCUGCUACAGUGCAAAGAAA-----------------GGGACCAAG
M. mulatta (rhesus macaque) AUUCCUGCUACAGUGCAAAGAAA-----------------GGGACCAAG
O. garnettii (bushbaby) AUUCCUGCUACAGUGCAAAGAAA-----------------GGGACCAAG
T. belangeri (treeshrew) AUUCCUGCUACAGUGCAAAGAAA-----------------GGGACCAAG
R. norvegicus (rat) AUUCCUGCUACAGUGCGAAGAAA-----------------GGGACCAAG
C. porcellus (guinea pig) AUUCCUGCUACAGUGCAAAGAAA-----------------GGGACCAAG
O. cuniculus (rabbit) AUUCCUGCUACAGUGCAAAGAAA-----------------GGGACCAAG
S. araneus (shrew) AUUCCGGCUACAGUGCAAAGAAA-----------------GGGACCAAG
E. europaeus (hedgehog) AUUCCUGCCACGGGACAGGGACG-----------------GGGACCGAG
C. l. familiaris (dog) AUUCCUGCUACAGUGCAAAGAAA-----------------GGGACCAAG
F. catus (cat) AUUCCUGCUACAGUGCAAAGAAA-----------------GGGACCAAG
E. f. caballus (horse) AUUCCUGCUACAGUGCAAAGAAA-----------------GGGACCAAG
B. taurus (cow) AUUCCUGCUGCAGUGCAAAGAAA-----------------GGGACCAAG
D. rerio (zebrafish) -------------------------------------------------
L. africana (elephant) AUUCCUGCUACAGUACAAAGUAA-----------------GGGACCAAG
E. telfairi (tenrec) AUUCCGGCUACAGUACAAAGUCA-----------------GGGACCAAG
M. domestica (opossum) AUUCCUGCUACAGUGCAAAGAAA-----------------GGGACCAAG
O. anatinus (platypus) AUUCCUACGACAGCGCAGAGGAA-----------------GGGACCACG
A. carolinensis (lizard) AUUCCUGCUAAAAUGGCAAAGAA-----------------GGGACCAAG
G. gallus (chicken) AUUCCUGCGAUAAUGAAAAGAGA-----------------GGGACCAAG
X. tropicalis (frog) AUUCCCAAUAUAAUGCAAAAAAAAUAAAUAAAUAACGAGUGGGAUCAAG
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miR-133abc 
M. musculus (mouse) CUGCUACAGUGCGAAGAAA-----------------GGGACCAAGGUUC
H. sapiens (human) CUGCUACAGUGCAAAGAAA-----------------GGGACCAAGGUUC
P. troglodytes (chimpanzee) CUGCUACAGUGCAAAGAAA-----------------GGGACCAAGGUUC
M. mulatta (rhesus macaque) CUGCUACAGUGCAAAGAAA-----------------GGGACCAAGGUUC
O. garnettii (bushbaby) CUGCUACAGUGCAAAGAAA-----------------GGGACCAAGGUUC
T. belangeri (treeshrew) CUGCUACAGUGCAAAGAAA-----------------GGGACCAAGGUUC
R. norvegicus (rat) CUGCUACAGUGCGAAGAAA-----------------GGGACCAAGGUUC
C. porcellus (guinea pig) CUGCUACAGUGCAAAGAAA-----------------GGGACCAAGGUUC
O. cuniculus (rabbit) CUGCUACAGUGCAAAGAAA-----------------GGGACCAAGGUUC
S. araneus (shrew) CGGCUACAGUGCAAAGAAA-----------------GGGACCAAGGUUC
E. europaeus (hedgehog) CUGCCACGGGACAGGGACG-----------------GGGACCGAGGUUU
C. l. familiaris (dog) CUGCUACAGUGCAAAGAAA-----------------GGGACCAAGGUUC
F. catus (cat) CUGCUACAGUGCAAAGAAA-----------------GGGACCAAGGUUC
E. f. caballus (horse) CUGCUACAGUGCAAAGAAA-----------------GGGACCAAGGUUC
B. taurus (cow) CUGCUGCAGUGCAAAGAAA-----------------GGGACCAAGGUUC
D. rerio (zebrafish) -------------------------------------------------
L. africana (elephant) CUGCUACAGUACAAAGUAA-----------------GGGACCAAGGUUC
E. telfairi (tenrec) CGGCUACAGUACAAAGUCA-----------------GGGACCAAGGUUC
M. domestica (opossum) CUGCUACAGUGCAAAGAAA-----------------GGGACCAAGGUUC
O. anatinus (platypus) CUACGACAGCGCAGAGGAA-----------------GGGACCACGGUUC
A. carolinensis (lizard) CUGCUAAAAUGGCAAAGAA-----------------GGGACCAAGGCUC
G. gallus (chicken) CUGCGAUAAUGAAAAGAGA-----------------GGGACCAAGGUUC
X. tropicalis (frog) CCAAUAUAAUGCAAAAAAAAUAAAUAAAUAACGAGUGGGAUCAAGCUCC
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miR-133abc 
M. musculus (mouse) UUGCCCAGAGUGGAAG-------AUAA--GGACCAAGAU---GG
H. sapiens (human) UUGCCCAGAAUGGAAG-------AUGA--GGACCAAGGA---GG
P. troglodytes (chimpanzee) UUGCCCAGAAUGGAAG-------AUGA--GGACCAAGGA---GG
M. mulatta (rhesus macaque) UUGCCCAGAAUGGAAG-------AUGA--GGACCAAGGA---AG
O. garnettii (bushbaby) UUGCCCAGAAUGGAAG-------AUGA--GGACCAAGGA---GG
T. belangeri (treeshrew) UUGCUCAGAAUGGAAG-------AUGA--GGACCAAGGA---GG
R. norvegicus (rat) UUGCCCAGAAAGGAAG-------AUAA--GGACCAAGAA---GG
C. porcellus (guinea pig) UUGCCCGGAAGGGAAG-------AUGA--GGACCAAGGA---GG
O. cuniculus (rabbit) UUGCCCAGAAUGGAAG-------AUGA--GGACCAAGAA---GG
S. araneus (shrew) UUGCCCAGAAUGGAAG-------AUGA--GGACCAAGGA---GA
E. europaeus (hedgehog) CUGCCCCGAA-GGAAG-------ACGA--GGACCAAGGA---GG
C. l. familiaris (dog) UUGCCCCGAAUGAAAG-------AUGA--GGACCAAGGA---GG
F. catus (cat) UUGCCCAGAACGGAAG-------AUGA--GGACCACGGA---GG
E. f. caballus (horse) UUGCCCAGAAUGGAAG-------AUGA--GGACCAAGGA---GG
B. taurus (cow) UUGCCCAGAGUGGAAG-------AUGA--GGACCAAGGA---GG
D. rerio (zebrafish) --------------------------------------------
L. africana (elephant) UUGCCCAGAAUGGAAG-------AUGA--GGACCAAGGA---GG
E. telfairi (tenrec) UUGCCCAGAAUGGAAG-------AUGA--GGACCAAGGA---GG
M. domestica (opossum) UUGCCCAGAAUGGAGA-------AUGA--GGACCAAGGA---UG
O. anatinus (platypus) UUGCUGAGGAUGGAGA-------AUGA--GGACCAAGGACAG--
A. carolinensis (lizard) UGGCUUUGAAUGAAGG-------AAGA--GGACCAAGCG---UA
G. gallus (chicken) CUGCUCAGAACAGAAA-------AAAAAAGGACCAAGAA---UG
X. tropicalis (frog) UC-CCAAGGAUGGAGACGAGACAAAGA--GGACCAAGAAU--CA
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miR-145 
M. musculus (mouse) AAG------AA--GGCC-------CAG-------------CUACAGAAAACUGGAUAGGA
H. sapiens (human) AGG------GA--GAUC-------CAG-------------CUACAGACAACUGGACAGGA
P. troglodytes (chimpanzee) AGG------GA--GAUC-------CAG-------------CUACAGACAACUGGACAGGA
M. mulatta (rhesus macaque) AGG------GA--GAUC-------GAG-------------CUACAGACAACUGGACAGGA
O. garnettii (bushbaby) AAG------GA--GAUC-------CAG-------------CUACAGACAACUGGACAGGA
T. belangeri (treeshrew) AGG------AA--GAUC-------CAG-------------CUACAGAAAACUGGACAGGA
R. norvegicus (rat) AAG------GA--GGCC-------CAG-------------CUACAGGAAACUGGAUAGGA
C. porcellus (guinea pig) GGG------GA--GGUC-------CAG-------------CUAUGGAAAACUGGAUGGGA
O. cuniculus (rabbit) AGG------GA--GAUC-------CAG-------------CUACAGAAGACUGGACAGGA
S. araneus (shrew) AGG------GG--GAUC-------CAG-------------CUGCAGAAAACUGGACAGGA
E. europaeus (hedgehog) AGG------GG----UC-------CGG-------------CCACAGACACCCGGACAGGA
C. l. familiaris (dog) AGG------GA--GAUC-------CAG-------------CUACGGAGAAGCGGACGGGA
F. catus (cat) ------------------------------------------------------------
E. f. caballus (horse) AGG------GA--GAUC-------CAG-------------CUACAGAAAACUGGACAGGA
B. taurus (cow) AGG------GA--GAUC-------CAG-------------CUACAGAAAACUGGACAGGA
D. rerio (zebrafish) ------------------------------------------------AACUGCACAG--
L. africana (elephant) AAG------GA--GAUC-------CAG-------------CUACAGAAAACUGGACACAU
E. telfairi (tenrec) AAG------GC--GAUC-------CAG-------------GGGCAGAAGGCUGAACAGGC
M. domestica (opossum) AGG------GA--GAUC-------CAG-------------CUACAGAUGGCUGGAUAGGA
O. anatinus (platypus) AGA------GGAUGCUC-------CGG-------------CCACCGGGAAUGGGAUGGGG
A. carolinensis (lizard) AUGAUUGGAGA--AGAUACAACCACUGGAGGUCUUUGUUUCUACAGGA------------
G. gallus (chicken) AUG------GA--GGUU-------UUUGAAGUC-------CUACAGGA------------
X. tropicalis (frog) AGG------CAUUUGUC-------CGG-------------C--------AGUGGGCCGUA
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miR-125a-5p/125b-5p/351/670/4319 
M. musculus (mouse) GCAGC-UGA--UGUCAC------CAGAA---GCUCAGG-GCUGGU
H. sapiens (human) GCAGC-CGA--UGUCAC------UAGAA---GCUCAGG-GCUGAU
P. troglodytes (chimpanzee) GCAGC-CGA--UGUCAC------UAGAA---GCUCAGG-GCUGAU
M. mulatta (rhesus macaque) GCAGC-CGA--UGUCAC------UAGAA---GCUCAGG-GCUGAU
O. garnettii (bushbaby) GCA-C-CAA--UGUCAC------CAGAA---GCUCAGG-GCUGAU
T. belangeri (treeshrew) GCAGC-CGA--UGUCAU------CAGCA---ACUCAGG-GCCGGU
R. norvegicus (rat) GCAGC-UGA--UGUCAC------CAGAA---GCUCAGG-GCUGGU
C. porcellus (guinea pig) GCAGC-CAA--UGUCAC------CAGAA---GCUCAGG-GCUGGU
O. cuniculus (rabbit) GCCGC-CGA--UGCCAG------CAGAA---GCUCGGG-GCUGGG
S. araneus (shrew) GCAGC-CGA--UGUCAC------CAGCA---GCUCGGG-GCUGGG
E. europaeus (hedgehog) CCUGC-CGCCCUGUCAC------C----------------CUGUC
C. l. familiaris (dog) GCAGC-CCA--UGUCAC------CAGAA---GCUCAGG-GCUGGU
F. catus (cat) ---------------------------------------------
E. f. caballus (horse) GCAGC-CGA--UGUCAC------CCAAA---GCUCAGG-GCUGGU
B. taurus (cow) GCAGC-UGA--CGUCAC------CGGAA---GCUCAGG-GCCGGU
D. rerio (zebrafish) GCAGC-CGA--UGGCAU------CAGAA---GCUCAGG-GCUGGU
L. africana (elephant) GCAGC-CAA--UGCCAU------CAGAA---GCUCAGG-GCUGGU
E. telfairi (tenrec) GCAGC-CAA--CGGCAU------CCGGA---GCCCAGG-GCUGGU
M. domestica (opossum) GCAACUUAA--AGGCAU------CACAA---GCACAGG-GCUGGU
O. anatinus (platypus) GCAACUCGC--AGACAG------CCAAA---GUUCAGG-GCCGGG
A. carolinensis (lizard) --------A--CGCAAACGGACAUCAAU---GCUCAGG-GCAGAC
G. gallus (chicken) --------A--AGUAAA------UAAAA---GCUUAGGUGAGGAU
X. tropicalis (frog) GGAAU-CGA----GCAG------CUGAAUGUGUUCUGA-GAUGAA
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miR-214/716/3619-5p 
M. musculus (mouse) CCUC--UUGUCACUACAUUUU-ACUGCUGAAAAUA
H. sapiens (human) UUCC--UUGUUAUUACGUUUU-ACUGCUGAAAGUA
P. troglodytes (chimpanzee) UUCC--UUGUUAUUACGUUUU-ACUGCUGAAAGUA
M. mulatta (rhesus macaque) UUCC--UUGUCAUUAUGUUUU-ACUGCUGAAAGUA
O. garnettii (bushbaby) CUCC--UUGUUAUUACAUUUU-ACUGCUGAAAGGA
T. belangeri (treeshrew) CUCC--UUGUCAUUACGUUUU-ACUGCUGAAAGUA
R. norvegicus (rat) CCUC--UUGUCACUACAUUUU-ACUGCUGAAAAUA
C. porcellus (guinea pig) CUCC--UUGUGAUUACAUUCU-ACUGCUGAAAGUC
O. cuniculus (rabbit) CUCC--UUGUCAUUAUGUUUU-ACUGCUGGAAGUC
S. araneus (shrew) UUCC--UUGUCAUUAUGUUUUUACUGCUGAAAGCA
E. europaeus (hedgehog) --CC--UGGUCACUGUGUCGC--CUGCUGACAGCC
C. l. familiaris (dog) UUCC--UUGU---GACGUUUC-ACUGCUGAAAGCA
F. catus (cat) UUCC--UUGUCGUGACGUUUU-ACUGCUGAAAGCA
E. f. caballus (horse) UUCC--UUGCUGUUACAUUUU-ACCGCUGAAAGCA
B. taurus (cow) UUCC--UUGUCAUU--GUUUU-ACUGCUGAAAGCA
D. rerio (zebrafish) GCCCACUUGUCCUUACGUUCU-ACUGCUGAAAGCA
L. africana (elephant) GCCCACUUGUCAUGAUGUGUU-ACUGCUGAAAGCC
E. telfairi (tenrec) GCCCACU-GCUGUGCCGCGUU-ACUGCGGCAAGUC
M. domestica (opossum) ACUCGCGUGGCAUUAAGAGUC-AUUACUGAAAGUC
O. anatinus (platypus) GCCCCUUUGUCAAGAAGCUUG-AUUAC-GGAAGUA
A. carolinensis (lizard) -----------------------------------
G. gallus (chicken) GCCU--GUGCCCUCA-GCUCU-ACC----------
X. tropicalis (frog) -----------------------------------
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miR-30abcdef/30abe-5p/384-5p 
M. musculus (mouse) G-GAGACC--------------CCGGG-GCCU----GUUGGUUUACAAAGA--C
H. sapiens (human) G-GAGAGC-CC-----------CUCAG-GCCU----GUUGGUUUACAGAGAGAC
P. troglodytes (chimpanzee) G-GAGAGC-CC-----------CUCAG-GCCU----GUUGGUUUACAGAGAGAC
M. mulatta (rhesus macaque) G-GAGAGC-AC-----------CUCGG-GCCU----GUUGGUUUACAGAGAGAC
O. garnettii (bushbaby) G-GAGC-C-GC-----------CUCAG-GCCU----GUCAGUUUACAGAGAGAC
T. belangeri (treeshrew) G-GAGACCUGC-----------CUCGG-GCCU----GUCGGUUUACAGAGAGAC
R. norvegicus (rat) G-GAGACC--------------CCGGG-GCCU----GUUGGUUUACAGAGA--C
C. porcellus (guinea pig) G-GAGACC-CAC---------CCCAGG-GCCU-----UCGGUUUACAGAGAGAC
O. cuniculus (rabbit) G-GGGCAC-GGAGCCGGGC---CCUGG-GCCU----GUCGGUUUACAGAGAGAC
S. araneus (shrew) A-GACAGA-UG-------------------------GUC---------------
E. europaeus (hedgehog) A-CACACA-UGACACACACCC-CAGUG-GGCU----GUCGGUC-ACAGAGAGAC
C. l. familiaris (dog) G-GGGACC-CG------------CCGG-GCCU----GUCGGUUUACAGAGAGAC
F. catus (cat) G-GACACC-CA------------CUGG-GCCU----GUCGGUUUACAGAGAGAC
E. f. caballus (horse) G-GCAACC-CG------------CCGG-GCCU----GUCGGUUUACAGAGAGAC
B. taurus (cow) G-GAGGCC-G--------------CUG-GGCU----GUCGGUUUACAGAGAGAC
D. rerio (zebrafish) G-GAGACU-UG-----------C-GGGUGCCA----GUCGGUUUACAGAGAGAC
L. africana (elephant) G-GAGACC-CA-----------C-GUG-GCCU----GUCGGUUUACAGAAAGAC
E. telfairi (tenrec) GAGAGACC-CG-----------G-GUG-GCCU----GUCGGUUUACAGAGAGAC
M. domestica (opossum) A-GAGACG-GA-----------CAGGU-CUCU----UUCAGUU-------GGAC
O. anatinus (platypus) A-GAGACG-AG-----------AUCCG-GUCUCUCUCUCGGUUUACAAAAGGAU
A. carolinensis (lizard) -----------------------------CUU----UUUGGUUUACAAAAGGAC
G. gallus (chicken) -----------------------------UCU----UUUGGUUUACAAA-GGAC
X. tropicalis (frog) -------------------------------------UUGGUUUACAGAGGAAU
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miR-33ab/33-5p 
M. musculus (mouse) ACCAC-AGAAGCUCCUCGAUGCAAUGCAUCUGU
H. sapiens (human) ACCAG-AGAAGCUACUCGAUGCAAUGCAUCUGU
P. troglodytes (chimpanzee) ACCAG-AGAAGCUACUCGAUGCAAUGCAUCUGU
M. mulatta (rhesus macaque) ACUAG-AGAAGCUACUCGAUGCAAUGCAUCUGU
O. garnettii (bushbaby) ACCAG-AGAAGCUACUCGAUGCAAUGCAUCUGU
T. belangeri (treeshrew) ACCAG-AGAAGCUACUCGAUGCAAUGCAUCUGU
R. norvegicus (rat) ACCAG-AGAAGCUACUCGAUGCAAUGCAUCUGU
C. porcellus (guinea pig) ACCAG-AGAAGCUACUCGAUGCAAUGCAUCUAU
O. cuniculus (rabbit) ACCAG-AGAAGCUAAUCGAUGCAAUGCAUCUGU
S. araneus (shrew) ACCAG-AGAAGCUACUCGAUGCAAUGCAUCUGU
E. europaeus (hedgehog) ACCAG-GAAGGAUACUCGAUGCAGUGCAUCUGU
C. l. familiaris (dog) ACCAG-AGAAGCUACUCGAUGCAAUGCAUCUGU
F. catus (cat) ACCAG-AGAAGCUACUCGAUGCAAUGCAUCUGU
E. f. caballus (horse) ACCAG-AGAAGCUACUCGAUGCAAUGCAUCUGU
B. taurus (cow) ACCAG-AGAAGCUACUCGAUGCAAUGCAUCUGU
D. rerio (zebrafish) ACCAG-AGAAGCUACUCGAUGCAAUGCAUCUGU
L. africana (elephant) ACCAG-AGAAGCUACUCGAUGCAAUGCAUCUGU
E. telfairi (tenrec) ACCAG-AGAAGCUACUCGAUGCAAUGCAUCUGU
M. domestica (opossum) GCCAG-AUAGACUACUUGAUGCAAUGCAUCCAU
O. anatinus (platypus) GCCCA-ACAGACUACUUGAUGCGACGCAUCC-C
A. carolinensis (lizard) GUGAGGAGAGACUACUUGAUGCAAUGCAUCC-A
G. gallus (chicken) GUGAGCAGAGACUACUUGAUGCAAUGCAUCC-G
X. tropicalis (frog) ACCAA-GCAGACUACUCGAUGCCAUGCAUCC-A
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miR-216a 
M. musculus (mouse) GAUAUAGAGAAGA-UAUUUAUUGAGAUUUUAAG
H. sapiens (human) AAUAUAGAGAAGA-UAUUUAUUGAAAUUU-AAG
P. troglodytes (chimpanzee) AAUAUAGAGAAGA-UAUUUAUUGAAAUUU-AAG
M. mulatta (rhesus macaque) AAUAUAGAGAAGA-UAUUUAUUGAGAUUU-AAG
O. garnettii (bushbaby) AAUAUAGAGAAGAAUAUUUAUUGAGAUUU-AAG
T. belangeri (treeshrew) AAUAUAGAGAAGA-UAUUUAUUGAGAUUU-AAG
R. norvegicus (rat) GAUAUAGAGAAGA-UAUUUAUUGAGAUUU-AAG
C. porcellus (guinea pig) AAUAUAGAGAAGA-UAUUUAUUGAGAUUU-AAG
O. cuniculus (rabbit) AAUAUAGAGAAGA-UAUUUAUUGAGAUUU-AAG
S. araneus (shrew) AUUAUAGAGAAGA-UAUUUAUUGAGAUUU-AAG
E. europaeus (hedgehog) AAUAUAGAGAAGA-UAUUUAAUGAGAUCU-AAG
C. l. familiaris (dog) AAUAUAGAGAAGA-UAUUUAUUGAGAUUU-AAG
F. catus (cat) AAUAUAGAGAAGA-UAUUUAUUGAGAUUU-AAG
E. f. caballus (horse) AAUAUAGAGAAGC-UAUUUAUUGAGAUUU-AAG
B. taurus (cow) AAUAUAGAGAAGA-UAUUUAUUGAGAUUU-AAG
D. rerio (zebrafish) AAUAUAGCGAAGA-UAUUUAUUGAGAUUU-AAG
L. africana (elephant) AAUCUAGAGAAGC-UAUUUAUUGAGAUUU-AAG
E. telfairi (tenrec) AAUAUAGAGAAGC-UAUUUAUUGAAAUUU-AAG
M. domestica (opossum) AAUAUAUAGAAGA-UAUUUAUUGAGAUUU-AAG
O. anatinus (platypus) AAUCUAUAGAAGA-UAUUUAUUGAGAUUUUAAG
A. carolinensis (lizard) AAUCUAGAGAAAA-UAUUUAUUGAGAUUU-AAG
G. gallus (chicken) AAUAUACAGAAGA-UAUUUAUUAAGAUU--AAG
X. tropicalis (frog) AUUAUAUAAAGGA-UAUUUAUUGAGAAUU-AAG
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miR-96/507/1271 
M. musculus (mouse) AUU-AAA-GUCUCUUUUC-----AAAGGUGCCAAAGUAUA
H. sapiens (human) AUU-AAA-GUUUCUUUUC-----AAAGGUGCCAAAGUAUA
P. troglodytes (chimpanzee) AUU-AAA-GUUUCUUUUC-----AAAGGUGCCAAAGUAUA
M. mulatta (rhesus macaque) AUU-AAA-GUUUCUUUUC-----AAAGGUGCCAAAGUAUA
O. garnettii (bushbaby) AUU-AAA-GUU-CUUUUC-----AAAGGUGCCAAAGUACA
T. belangeri (treeshrew) AUU-AAA-GUUUCUUUAC-----AAAGGUGCCAAAGUAUA
R. norvegicus (rat) AUU-AAA-GUCUCUUUUC-----AAAGGUGCCAAAGUAUA
C. porcellus (guinea pig) AUU-AAA-GUUUCUUUUC-----AAAGGUGCCAAAGUAUA
O. cuniculus (rabbit) AUU-AAA-GUUUCUUUUC-----AAAGGUGCCAAAGUAUA
S. araneus (shrew) AUU-GAA-GUUUCUUUUC-----AAAGGUGCCAAAGUAUA
E. europaeus (hedgehog) AUA-AAA-GUUUCUUCUC-----CAAGGUGCCAAAGUAUA
C. l. familiaris (dog) AUU-AAA-GUUUCUUUUC-----AAAGGUGCCAAAGUACA
F. catus (cat) AUU-AAA-GUUUCUUUUC-----GAAGGUGCCAAAGUAUA
E. f. caballus (horse) AUU-AAA-GUUUCUUUUC-----AAAGGUGCCAAAGUAUA
B. taurus (cow) AUU-AAA-GUUUCUUUUC-----AAAGGUGCCAAAGUAUA
D. rerio (zebrafish) AUU-AAA-GUAUCUUUUC-----AAAGGUGCCAAA---CA
L. africana (elephant) AUU-AAAAGUUUCUUUUC-----AAAGGUGCCAAAGUAUA
E. telfairi (tenrec) AUU-AAA-GUUUCUUUUC-----AAAGGUGCCAAAGUAUA
M. domestica (opossum) AUU-AAA-AUUUCUUUUC-----AAAGGUGCCAAAGUGUA
O. anatinus (platypus) AUUUGAA-GUUUCUCUUC-----AAAGGUGCCAAAGUGGA
A. carolinensis (lizard) AUU-AAA-GCUUCUUUCUUCAAAACAGGUGCCAAAGU---
G. gallus (chicken) AUU-AAA-GUUUUUUUC------AAAGGUGCCAAAGUAGG
X. tropicalis (frog) AUU-AAA-CUUUCUCUUC-----CAUGGUGCCAAAGCAGA
18 
 
miR-182 
M. musculus (mouse) UU-AAA-GUCUCUUUUC-----AAAGGUGCCAAAGUAUA
H. sapiens (human) UU-AAA-GUUUCUUUUC-----AAAGGUGCCAAAGUAUA
P. troglodytes (chimpanzee) UU-AAA-GUUUCUUUUC-----AAAGGUGCCAAAGUAUA
M. mulatta (rhesus macaque) UU-AAA-GUUUCUUUUC-----AAAGGUGCCAAAGUAUA
O. garnettii (bushbaby) UU-AAA-GUU-CUUUUC-----AAAGGUGCCAAAGUACA
T. belangeri (treeshrew) UU-AAA-GUUUCUUUAC-----AAAGGUGCCAAAGUAUA
R. norvegicus (rat) UU-AAA-GUCUCUUUUC-----AAAGGUGCCAAAGUAUA
C. porcellus (guinea pig) UU-AAA-GUUUCUUUUC-----AAAGGUGCCAAAGUAUA
O. cuniculus (rabbit) UU-AAA-GUUUCUUUUC-----AAAGGUGCCAAAGUAUA
S. araneus (shrew) UU-GAA-GUUUCUUUUC-----AAAGGUGCCAAAGUAUA
E. europaeus (hedgehog) UA-AAA-GUUUCUUCUC-----CAAGGUGCCAAAGUAUA
C. l. familiaris (dog) UU-AAA-GUUUCUUUUC-----AAAGGUGCCAAAGUACA
F. catus (cat) UU-AAA-GUUUCUUUUC-----GAAGGUGCCAAAGUAUA
E. f. caballus (horse) UU-AAA-GUUUCUUUUC-----AAAGGUGCCAAAGUAUA
B. taurus (cow) UU-AAA-GUUUCUUUUC-----AAAGGUGCCAAAGUAUA
D. rerio (zebrafish) UU-AAA-GUAUCUUUUC-----AAAGGUGCCAAA---CA
L. africana (elephant) UU-AAAAGUUUCUUUUC-----AAAGGUGCCAAAGUAUA
E. telfairi (tenrec) UU-AAA-GUUUCUUUUC-----AAAGGUGCCAAAGUAUA
M. domestica (opossum) UU-AAA-AUUUCUUUUC-----AAAGGUGCCAAAGUGUA
O. anatinus (platypus) UUUGAA-GUUUCUCUUC-----AAAGGUGCCAAAGUGGA
A. carolinensis (lizard) UU-AAA-GCUUCUUUCUUCAAAACAGGUGCCAAAGU---
G. gallus (chicken) UU-AAA-GUUUUUUUC------AAAGGUGCCAAAGUAGG
X. tropicalis (frog) UU-AAA-CUUUCUCUUC-----CAUGGUGCCAAAGCAGA
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miR-129-5p/129ab-5p 
M. musculus (mouse) AA---------GAGGGUUUUUGCUAGGC------AAAA------------------AA-----UCACU
H. sapiens (human) AA---------AAAGUUUUUUGCCAGGC------AAAA------------------A------UCACU
P. troglodytes (chimpanzee) AA---------AAAGUUUUUUGCUAGGC------AAAA------------------A------UCACU
M. mulatta (rhesus macaque) AA---------AAAGUUUUUUGCUAGGC------AAAA------------------A------UCACU
O. garnettii (bushbaby) AA---------AAAGUUUUUUGCUAGGC------AAAA------------------A------UCACU
T. belangeri (treeshrew) AA---------AAAGUUUUUCACUAGGC------AAAA------------------A------UCACU
R. norvegicus (rat) AA---------GAGGGUUUUUGCUAGGC------AAAA------------------A------UCACU
C. porcellus (guinea pig) AA---------AAAGGUUUUCUCUAGGC------AAAA------------------A------UCACU
O. cuniculus (rabbit) AA---------CAAGUUUCUCGCUAGGC------AAAA------------------A------UCACU
S. araneus (shrew) AA---------AAAGUUUUUCAUGAGGU------AAAA------------------A------UCACU
E. europaeus (hedgehog) --------------------------------------------------------------------
C. l. familiaris (dog) AA---------AAAGUUUCUCGCUAGGC------AAAA------------------A------UCACU
F. catus (cat) AA---------AAAGUUUUUCGCUAGGC------AAAA------------------A------UCACU
E. f. caballus (horse) AA---------AAAGUUUUUCACCAGGC------AAAA------------------A------UCACU
B. taurus (cow) AA---------AAAGACUUUCGCUAGGC------AAAA------------------A------UCACU
D. rerio (zebrafish) AAGUUGUGUUUCAUUUUGUUUGCUAGCC------AAAA------------------A------UCACU
L. africana (elephant) AAA--------AGGUCUUUUUGCUAGCC------AAAA------------------A------UCACU
E. telfairi (tenrec) AA-----------GUCUUUUUACUAGCC------AAAA------------------A------UCACU
M. domestica (opossum) AA---------CA-GUUUUUGGGUAGCC------AAAA------------------AAAAAAAUCACU
O. anatinus (platypus) GA---------CA-GUGAUCUGCUAGCC------AAAA------------------A------UCACU
A. carolinensis (lizard) AA---------CAAGAAUGCA-------------AACACUUUUUUUAAAAAAAAAUA------UCACU
G. gallus (chicken) AA---------CUUGAAUGCA-------------AAAA------------------A------UCACU
X. tropicalis (frog) AA---------AUAGAUGCUGG--AGGCCAACUGAAAA------------------A------UCACA
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miR-9/9ab 
M. musculus (mouse) UC---GGUCGUUUGUGUUAUACAACCAAAGUUCUC
H. sapiens (human) UU---GGUCGUUUGUGUUAUAAAACCAAAGUUCUC
P. troglodytes (chimpanzee) UU---GGUCGUUUGUGUUAUACAACCAAAGUUCUC
M. mulatta (rhesus macaque) UC---GGUCGUUUGUGUUAUACAACCAAAGUUCUC
O. garnettii (bushbaby) UU---GGUCGUUUGUGUUAUACAACCAAAGUUCUC
T. belangeri (treeshrew) UC---GGUCGUUUGUGUUAUACAACCAAAGUUCUC
R. norvegicus (rat) UC---GGUCGUUUGUGUUAUACAACCAAAGUUCUC
C. porcellus (guinea pig) UC---GGUCAUUUGUGUUAUACAACCAAAGUUCUC
O. cuniculus (rabbit) UU---GGUCGUUUGUGUUAUACAACCAAAGUUCUC
S. araneus (shrew) UU---GGUCGUUUGUGUUAUACAACCAAAGUUCUC
E. europaeus (hedgehog) -----------------------------------
C. l. familiaris (dog) UC---AGUCGUUUGUGUUAUACAACCAAAGUUCUC
F. catus (cat) -----------------------------------
E. f. caballus (horse) UU---GGUCGUUUGUGUUAUACAACCAAAGUUCUC
B. taurus (cow) UC---AGUCGUUUGUGUUAUACAACCAAAGUUCUC
D. rerio (zebrafish) UC---GGUCGUUUGUGUUAUGCAACCAAAGUUCUC
L. africana (elephant) UU---GGUCGUUUGUGUUAUACAACCAAAGUUCUC
E. telfairi (tenrec) UC---CGUCAUUUGUGUUAUACAACCAAAGUUCUC
M. domestica (opossum) UC---AGUCAUUUGUGUUAUACAACCAAAGUUCUC
O. anatinus (platypus) UC---AAUCAUUUGUGUUCUACAACCAAAGUUCUC
A. carolinensis (lizard) UC---AGACAUUUGUGUUAACCAACCAAAGUUCUC
G. gallus (chicken) UC---AGUCAUUUGUGUUAAUCAACCAAAGUUCUC
X. tropicalis (frog) UCUCAAGUCAUUUGUGUUAUUCAACCAAAGUUCCU
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miR-146ac/146b-5p 
M. musculus (mouse) CGUUUGUGUUAUACAACCAAAGUUCUCUACAA
H. sapiens (human) CGUUUGUGUUAUAAAACCAAAGUUCUCUACAG
P. troglodytes (chimpanzee) CGUUUGUGUUAUACAACCAAAGUUCUCUACAG
M. mulatta (rhesus macaque) CGUUUGUGUUAUACAACCAAAGUUCUCUACAG
O. garnettii (bushbaby) CGUUUGUGUUAUACAACCAAAGUUCUCUACAG
T. belangeri (treeshrew) CGUUUGUGUUAUACAACCAAAGUUCUCUACAG
R. norvegicus (rat) CGUUUGUGUUAUACAACCAAAGUUCUCUACAG
C. porcellus (guinea pig) CAUUUGUGUUAUACAACCAAAGUUCUCUACAG
O. cuniculus (rabbit) CGUUUGUGUUAUACAACCAAAGUUCUCUACAG
S. araneus (shrew) CGUUUGUGUUAUACAACCAAAGUUCUCUACAG
E. europaeus (hedgehog) --------------------------------
C. l. familiaris (dog) CGUUUGUGUUAUACAACCAAAGUUCUCUACAG
F. catus (cat) --------------------------------
E. f. caballus (horse) CGUUUGUGUUAUACAACCAAAGUUCUCUACAG
B. taurus (cow) CGUUUGUGUUAUACAACCAAAGUUCUCUACAG
D. rerio (zebrafish) CGUUUGUGUUAUGCAACCAAAGUUCUCUACAG
L. africana (elephant) CGUUUGUGUUAUACAACCAAAGUUCUCUACAG
E. telfairi (tenrec) CAUUUGUGUUAUACAACCAAAGUUCUCUACAG
M. domestica (opossum) CAUUUGUGUUAUACAACCAAAGUUCUCUACAA
O. anatinus (platypus) CAUUUGUGUUCUACAACCAAAGUUCUCUACAG
A. carolinensis (lizard) CAUUUGUGUUAACCAACCAAAGUUCUCUACAG
G. gallus (chicken) CAUUUGUGUUAAUCAACCAAAGUUCUCUACAG
X. tropicalis (frog) CAUUUGUGUUAUUCAACCAAAGUUCCUUACAA
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Supplementary Table 2A, related to Figure 4. GDNF levels regulate kidney size and number.  
genotype, P7.5 nr of 
animals 
analysed 
two kidneys one kidney no kidneys  kidney size 
+/+ 141 141 - - normal 
Gdnf  3’UTR-crR +/-  60 60 - - normal or mildly reduced 
Gdnf  3’UTR-crR -/- 14 14 - - severely reduced 
Gdnf KO +/- 34 26 8 - normal  
Gdnf KO -/- (E18.5) 7 - - 7 na 
 
Gdnf KO animals were obtained by crossing Gdnf 3’UTR-crR animals to Deleter-Cre mice, which results in deletion of 
GDNF protein-coding exon 3 (Fig. 1D).  
 
 
Supplementary Table 2B, related to Figure 4. Gdnf 3’UTR-crR -/-mice die before weaning, Gdnf 3’UTR-crR +/- mice 
are produced in Mendelian ratios. 
 
developmental 
stage 
nr of animals 
analysed 
Gdnf  3’UTR-
crR +/- 
expected 
Gdnf  3’UTR-
crR +/-found 
Gdnf  3’UTR-
crR -/-
expected 
Gdnf  3’UTR-
crR -/- found 
E10-E18 116 58 62 29 26 
P7.5 105 53 60 26 14 
P18 22 11 14 6 0 
2-4 months 101 50 53 25 0 
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Supplementary Table 3, related to Figure 4. Lack of correlation between serum urea and rostral brain dopamine 
levels in individual Gdnf3’UTR-crR +/- mice. 
dopamine levels in rostral 
brain, ng/g wet tissue 
genotype serum urea, mg/dL 
273.2 +/+ 78.3 
265.9 +/+ 68.8 
291.4 +/+ 92.4 
275.3 +/+ 72.9 
329.6 +/+ 69 
254.5 +/+ 103.4 
203.3 +/+ 107.6 
239.5 +/+ 107.6 
284.9 +/+ 73.9 
correlation function=-0.73  
282.1 Gdnf 3’UTR-crR +/- 197.7 
167.8 Gdnf3’UTR-crR +/- 88.4 
291.4 Gdnf3’UTR-crR +/- 90.2 
318.9 Gdnf3’UTR-crR +/- 96.8 
269.1 Gdnf3’UTR-crR +/- 104.2 
299.7 Gdnf3’UTR-crR +/- 234.2 
194.5 Gdnf3’UTR-crR +/- 266.9 
244.4 Gdnf3’UTR-crR +/- 259.5 
297.8 Gdnf3’UTR-crR +/- 208.9 
278.1 Gdnf3’UTR-crR +/- 114.2 
395.8 Gdnf3’UTR-crR +/- 110.4 
420.9 Gdnf3’UTR-crR +/- 224.6 
correlation function=-0.037 
 
Correlational analyses of rostral brain dopamine and serum urea levels in individual animals in 10 WT and 12 Gdnf 
3’UTR-crR +/- animals at P7.5 using the Correlation function in Microsoft Excel was -0.037 for Gdnf 3’UTR-crR +/-
animals for those parameters  and -0.73 in wt mice.  
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Supplementary Materials and Methods 
Cell culture Human Embryonic Kidney 293 (HEK293) cells and human glioblastoma-astrocytoma 
epithelial-like cell line U87 MG were from ATCC and were cultured at 5% CO2 , 370 C in Dulbecco’s 
Modified  Eagle Medium (DMEM, Invitrogen/Gibco) supplemented with 10% Fetal Bovine Serum 
(FBS, HyClone) and 100μg/ml NormocinTM (InvivoGen), if not indicated otherwise. Cells were not 
allowed to reach confluency beyond 70% at any point during culturing and were split one day 
before plating for an experiment.   
 
Luciferase reporter assay 
 PAC RP21-583-K20 containing mouse Gdnf gene was identified from RPCI 129S6/SvEvTac mouse 
genomic library using routine radioactive DNA hybridization screening with a probe 
complementary to Gdnf exon 3 and obtained from CHORI.  2.8 kb mouse Gdnf 3’UTR and Gdnf 
3’UTR-crR were cloned into XbaI site as indicated on Fig. S1A in Dual-Luciferase® Reporter Assay 
System vectors (Promega). Constructs were verified by sequencing. Actinomycin D (Sigma) was 
used at 2μg/ml. cDNAs encoding for indicated human RBPs were obtained from ORFeome 
Collaboration in pDEST 40 vector (Invitrogen) generated by Genome Biology Unit cloning service 
(Biocenter Finland, University of Helsinki) and sequenced. To reduce putative nonspecific effects 
stemming from DNA isolation related impurities, DNA constructs compared in this study were 
isolated twice from parallel maxi-preparations.  Mutations in Gdnf 3’UTR in miR-146 and miR-96 
seed sequences were introduced with PCR (see Primers) and verified by sequencing. HEK-293 cells 
(15.000 cell per well) were seeded per well to 96- well plate, pre-coated with 0.1% gelatin one day 
before transfection. Reporter plasmids were transfected along with pre-miRs (Ambion) as 
indicated according to standard protocol recommended for lipofectamine 2000 (Invitrogen),  Cy3- 
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or FAM-labeled negative controls alongside with non-labeled negative controls were used to verify 
transfection. Transfection efficiency of pre-miRs and anti-miRs was estimated to be about 95%. 
The medium was replaced 3-4 hours after transfection, cells were lysed 24 hours later using 
passive lysis buffer as recommended by the manufactuer (E1960, Promega). Luciferase activity 
was measured with Dual-Luciferase® Reporter Assay System (E1960, Promega) with GlomaX 20/20 
luminometer (Promega). 
 
GDNF mRNA measurements in U87 MG cells 
 Cells were plated on 12-well plates (Cellstar) at 105 cells/well, indicated pre-miRs (Ambion) were 
transfected 24h later with lipofectamine 2000 (Invitogen) as recommended by the manufacturer. 
The medium was replaced with fresh cell culture medium after 3-4 hours. Cells were washed with 
PBS and harvested in TRI Reagent® (Molecular Research Center) after 48 hours for total RNA 
isolation. See QPCR section for gene/miR levels measurements. 
 
GDNF protein measurements in U87 MG cells 
24h before transfection 105 cells were plated on 12 well plates (Cellstar). Pre-miRs (Ambion) were 
transfected as indicated, medium was replaced after 3-4 hours after the transfection, after 3 hours 
medium was replaced with 600μl of serum free OptiMEM (Invitrogen/Gibco) supplemented with 
0.5 % BSA (Sigma, A-9576). The plate was incubated at 8% CO2 and 370  for 48h as described in4, 
the medium was collected and centrifuged at +40C   at 2000rpm for 3 min. GDNF levels were 
measured using GDNF Emax® ImmunoAssay System (Promega,USA) according to the 
manufacturer’s protocol. 
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Northern blotting 
 Total RNA from cells or mouse tissues was isolated using TRI Reagent® (Molecular Research 
Center), Northern blotting was performed using standard procedures. Briefly, RNA was 
electrophoresed in 1% denaturing agarose gel, transfered to the nylon membrane, specific RNAs 
were detected using indicated probes with DIG-based nucleotide detection system (Roche).  
Cell survival assay 
Survival of U87 cells was assayed using CellTiter-Glo® Luminescent Cell Viability Assay (Promega) 
according to manufacturer’s protocol.  
 
Public databases 
Evolutionary conservation of miR seed sequences in Gdnf 3’UTR was evaluated using the most 
stringent conditions of Targetscan (http://www.targetscan.org/). Blast was used to assess the 
overall sequence conservation of Gdnf 3’UTR. miR-96 and miR-9 were identified to interact with 
Gdnf 3’UTR in two genome wide screens, i) miR CLIP-seq dataset using Argonate cross-linked 
immunopercipitation followed by RNA sequencing analysis indicating direct interaction, and ii) 
microarray analyses following miR transfection indicating functional 
interaction5 http://servers.binf.ku.dk/antar/. Prediction of AU-rich elements as potential RNA 
binding protein binding sites in Gdnf 3’UTR were performed using AREsite  
(http://rna.tbi.univie.ac.at/cgi-bin/AREsite.cgi). Number of potential miR binding sites in Gdnf 
3’UTR, Puro/TK cassette (GenBank: CR847878.1.), bovine growth hormone polyadenylation signal 
(bGHpA) and SV40 late pA was performed using PITA6. 
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Animals  
Gdnf 3’UTR-cR mice were generated using routine methods. Briefly, 5668bp  5’ and 6055bp 3’ 
homologous arms and Gdnf exon 3 until, and including the stop codon were amplified with PCR 
from Gdnf containing RP21-583-K20 (CHORI, see above) and cloned into PmeI, NotI and HindIII 
sites in pFlexible respectively (GenBank: CR847878.1.) to generate Gdnf allele as depicted on Fig. 
1D. ES (IB10) clones that had undergone homologous recombination (17%) were identified using 
standard Southern blotting with 5’ and 3’ probes located outside the homologous arms. Standard 
karyotyping was performed prior morula aggregations. Mice were maintained in 
129Ola/ICR/C57bl6 mixed genetic background, housed in 12/12 light/dark cycle with “lights-on” at 
06.00h, at ambient temperature 20-22°C, 2-5 animals per cage with ad libitum access to standard 
chow and water. All animal experiments were authorized by the national Animal Experiment 
Board of Finland. 
 
Tissue dissection 
Mice were killed by decapitation, brains were removed in about 60 seconds, cooled in ice cold 
saline and placed on an ice-cold brain matrix (Stoelting, Wood Dale, IL). Indicated brain areas were 
isolated on ice. The brains of the P7.5 animals were cut in half with a razor blade at -0.2 mm from 
bregma and the dorsal part of the brain was collected. Samples were stored at -80°C until assayed. 
Tissues were either snap frozen on dry ice immediately after separation for qPCR or Western 
blotting analysis or fixed with 4 % paraformaldehyde for GDNF in situ hybridization or 
immunohistochemistry (see below). 
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Estimation of monoamines and their metabolites 
Dopamine and its metabolites were analyzed as previously described in7 using HPLC with 
electrochemical detection.  
 
Immunohistochemistry (IHC) for light microscopy 
The mice were anesthetized with sodium pentobarbital (100 mg/kg, i.p.) and intracardially 
perfused with PBS followed by 4 % paraformaldehyde (PFA) in 0.1 M phosphate buffer, pH 7.4. 
The brains were postfixed in PFA for 4 h, and stored in phosphate buffer containing 20 % sucrose 
at 4°C. In an alternative “light” perfusion method   brains were cooled after PBS perfusion and 
dSTR was dissected from the rostral part, while the posterior part containing the midbrain was 
fixed overnight in 4% PFA for IHC. The latter method was used to reduce the number of 
experimental animals in experiments with PD model. Coronal striatal and nigral sections were cut 
and saved in serial order at -20°C until immunostained. 
TH and VMAT2 immunohistochemistry. The striatal (30 μm) and nigral (40 μm) freefloating 
sections were stained using standard immunohistochemical procedures. Briefly, after quenching 
with 3 % hydrogen peroxide (H2O2) and 10 % methanol for 5 min sections were preincubated in 2 
% normal goat serum (NGS; Vector Laboratories, Burlingame, CA) and 0.3 % Triton X-100 for 60 
min followed by incubation with rabbit anti-TH polyclonal antibody (AB 152, 1:2000, Millipore, 
Bedford, MA) overnight, followed by incubation for 2h with the biotinylated goat anti-rabbit 
antibody (BA1000, 1:200, Vector Laboratories) the next day. Vectastain Elite ABC peroxidase kit 
(Vector Laboratories) was used for visualization using 0.06 % diaminobenzidine (or 0.025 % for 
P7.5 sections) and H2O2. The sections were mounted on gelatin/chrome alume-coated slides, air-
dried, dehydrated, cleared and mounted using Pertex mounting medium (Cellpath, Hemel 
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Hempstead, UK). VMAT2 staining was done similarly except for the following differences: 
quenching period was 15 min, normal horse serum was used for pre-incubation, primary antibody 
was goat anti-VMAT2 polyclonal antibody (ab87594, 1:4000, Abcam) and secondary antibody was 
biotinylated horse anti-goat antibody (PI-9500, 1:200, Vector Laboratories). See 8 for further 
details. 
 
Stereological analysis of TH- and VMAT2-positive cells 
The number of TH- and VMAT2-positive neurons in the SNpc was assessed by a person blinded to 
the identity of the samples. Briefly, TH- and VMAT2-positive cell counts were assessed at medial 
levels of the SNpc, around the medial terminal nucleus (MTN). From each adult animal, every third 
"#$&>?[&>\[]^#""tions per animal). 
From each P7.5 animal, every second section between lev &\>_\  &>`{  ] ^
bregma was selected (3 sections per animal). StereoInvestigator (MBF Bioscience, Williston, VT) 
was used to outline the SNpc, and positively stained cells were counted within the defined 
outlines according to optical dissector rules9.  Cells were counted at regular predetermined 
$|}`??}[?#^^"
]{?{?
^

{?"$e [Olympus BX51 (Olympus Optical, Tokyo, Japan) equipped with an 
Optronics camera]. The counting frame positions within the SNpc were randomized by the 
software, which created a systematic random sample of the area. The coefficient of error was 
calculated as an estimate of precision and values <0.1 were accepted. Failure in staining or 
perfusion resulting in spoiled sections was an exclusion criterion. Please see 8 for further details. 
Striatal densitometry measurements 
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The OD analysis was performed under blinded condition on coded slides. Striatal TH-positive fiber 
immunostaining optical density (OD) measurements were performed using an Optronics (Goleta, 
CA) digital camera and Image-Pro Plus software (Version 3.0.1; Media Cybernetics, Silver Spring, 
MD) from three striatal sections from each animal and the final reading was calculated as an 
average. The nonspecific background correction in each section was done by subtracting the OD 
value of the corpus callosum from the striatal OD value of the same section. Failure in staining or 
perfusion resulting in spoiled sections was an exclusion criterion. Please see 8 for further details. 
 
Amphetamine induced locomotor activity 
Mice were individually placed in an open-field activity monitor (MED Associates, St. Albans, GA), 
and habituated for about 15 min ] " ] -amphetamine-sulphate (1 mg/kg, i.p; 
University Pharmacy, Helsinki, Finland). Locomotor activity was monitored for 60 min. Animals 
that gave no locomotor response (<2000 cm in 60 min) to amphetamine were excluded from the 
experiment. 
 
Lactacystin model of PD 
Lactacystin (A.G. Scientific/Nordic Biosite) ]
#"
$
substantia nigra (AP -3.3; ML -1.2 and DV -4.6) of 3 months old male mice. The animals were 

""11 test prior sacrificing at #">#]
experimenters blinded to the genotype. Exclusion criteria were:  histological analysis revealing a 
needle puncture or other physical damage in the SNpc; or the lesion in terms of reduction in TH 
positive "
^#""]
"> 
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Whole-mount in situ hybridization was performed with InSituPro Automate (Intavis, Cologne, 
Germany) as described previously12. The in situ hybridization protocol for the P12.5 brain tissue 
was modified from the routine as follows. The brains were fixed in 4% PFA/PBS at 4°C for 3-7 days 
and cryoprotected overnight with 20% sucrose in 4% PFA/PBS (4C), frozen at -80°C. Freely 
floating cryosections (40m) were washed for 20 min in ice cold PBS/0.25% TritonX-100, followed 
by 5 min incubation with 5x SSC (pH5; RT). The prehybridization was carried out for 2 h and 
hybridization overnight (with 1 g/ml Dig-labelled RNA probe) at 65C in 50% formamide, 5x SSC 
(pH5), 2% blocking reagent (BR), (Roche). Posthybridization washes were as follows: i) 50% 
formamide, 5x SSC (pH5), 1% SDS for 30 min at 65C; ii) 50% formamide, 2x SSC (pH5) for 30 min 
at 60C; followed by triple washes with TBST. Immunohistochemistry was carried out according to 
Wilkinson, 199313; BM Purple AP Substrate (Roche) was used as substrate. All the steps were 
performed under shaking. The stained sections were transferred onto slides in 0.5% gelatine, air 
dried and mounted with Pertex (Histolab, Malmö, Sweden).  
 
In vivo chronoamperometry 
In vivo chronoamperometry with second-by-second quantitative detection of dopamine levels was 
performed with the Fast Analytical Sensing Technology (FAST-16) system (Quanteon, Nicholasville, 
KY, USA)12 using single carbon fiber electrodes (Quanteon, Nicholasville, KY, USA) coated with 
Nafion (Sigma, Stockholm, Sweden). Electrodes were calibrated in phosphate buffered saline (0.05 
M PBS, pH=7.4), 20 mM ascorbic acid and dopamine (2 mM) were added during the calibration 
procedure. Only electrodes with selectivity of more than 200:1 for DA over ascorbic acid, a limit of 
detection below 0.05 μM, and linear response to DA (R2 >0.995) were used. Following calibration, 
the electrode was mounted parallel with a micropipette used for application of dopamine with a 
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distance of 130-`{?#^>"#^#^"
of urethane (1.7-1.9 g/kg body weight, Sigma) and fixed in a stereotaxic frame on a heating pad. 
An incision was made in the scalp and the bone overlying the striatum was removed, and an 
additional single hole was made caudally for implantation of an Ag/AgCl reference electrode. The 
electrode/micropipette-assembly was lowered into the striatum, using a microdrive, at stereotaxic 
coordinates anterior-posterior +0.3 and +1 mm and medio-lateral ±1.8 mm, calculated from 
bregma level. Recordings were performed at two distinct rostrocaudal striatal tracks in each 
hemisphere. At each recording site, data was collected from three depths below the dura: at -2.0, 
-2.5, and -3.0, mm. ^"$
(25-75nl) was monitored using a scale fitted in the ocular 
of an operation microscope. Dopamine (200 μM, in saline containing 20 μM ascorbic acid) was 
locally applied to evaluate dopamine clearance. 
During recordings, a square wave potential of 0.55 and 0 V (against an Ag/AgCl reference 
electrode) was applied over the electrode at a frequency of 5 Hz. Current produced from the 
oxidation and reduction reactions were integrated, giving an average signal per second for each 
reaction. Intras "\??
"]
"^|"
co-ordinate (AP +0,3mm; +1,0mm; ML ±1,8mm, DV-2,0; -2,5; -3,0; -3,5); data points were pooled 
for analysis and DA peaks (M) were separated into amplitude bins and plotted against uptake 
rate, M/s; calculated using Michaelis-Menten first-order rate constant, k1. 
 
GDNF protein levels measurements in tissues 
GDNF protein levels in E18.5 kidney lysate were analyzed using GDNF Emax® ImmunoAssay System 
(Promega, USA) according to the manufacturer’s protocol. GDNF protein levels in brain lysate was 
assessed as follows. Animals were decapitated; brain was isolated and cooled for 3 minutes in ice-
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cold PBS. Striata were isolated on ice, snap frozen on dry ice and stored at -70oC. GDNF protein 
level was analyzed using GDNF ELISA from (R&D Systems, USA) with acidification step included as 
suggested by the manufacturer. After preparation of the striatal lysate as suggested by the 
manufacturer the brain lysate was aliquoted and stored at -70oC. Aliquots were thawed only once. 
Total protein concentration was established using Lowry method (Bio-Rad) prior loading on ELISA. 
100μg of total protein was loaded per well. Brain lysate from Gdnf full knockout mice was used for 
defining the background signal. Tissue lysates for each mouse were analyzed with at least three 
total protein concentrations in duplicates.  
 
Serum urea and creatinine were measured with standard kits (BioAssay Sytems). 
 
 Quantitative PCR (qPCR) 
DNAse (Promega) treated RNA was used for reverse transcription (RT) with RevertAid reverse 
transcriptase (Fermentas) as recommended by the manufacturer. The LightCycler® 480 Real-Time 
PCR System (Roche) was used for routine quantitative PCR, beta-actin served as a reference gene. 
Each cDNA was analyzed in at least three qPCR runs with 3-4 technical repeats per run using the 
LightCycler® 480 Real-Time PCR System (Roche). For statistical analysis, average beta-actin Cp 
value (obtained from the Absolute Derivative Max function with the Lightcycler® 480 Software 
Release 1.5.0 SP1 software) was subtracted from Gdnf Cp value and the resulting dCt value was 
used to calculate fold difference relative to the reference gene (2-dCt).  Primer pairs used for qPCR 
are indicated below. For miR expression analysis, cDNA from 0.35-1 g RNA was synthesized with 
TaqMan® MicroRNA Reverse Transcription Kit (Applied Biosystems) using MegaplexTM RT Primers, 
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Rodent Pool A or B (Applied Biosystems) without preamplification in a final volume of 7.5 l. The 
cDNA product was diluted 1:30 and 2.5 l of the diluted cDNA was used for each real-time PCR 
reaction in a final volume of 10 l in 384-well plates. Each sample was run in duplicate. microRNA 
expression from mouse-derived cells was normalized to sno202. 
 
Western blotting  
Dorsal striatum and substantia nigra were isolated at indicated ages as described above, 
homogenized on ice and total protein levels were measured using Lowry method (Bio-Rad, USA).  
Following blotting and incubation with antibodies, nylon membranes were washed in TBS-T 
(TBS+0.1% Tween20) for 3x 15 minutes. Blocking was performed in 5 % non-fat milk in TBS-T 1 h 
RT.  1:3000 mouse anti-TH (Chemicon MAB318) for o/n at +4 °C in blocking solution followed by 
anti-mouse-HRP (DAKO P0449) for 2h at RT was used to detect TH. Rat anti-DAT (Chemicon 
MAB369) 1:2500 for o/n at +4°C in blocking solution followed by 1:1000 biotinylated anti-rat for 
2h at RT followed by 2h RT incubation with 1:2500 streptavidin-HRP (Molecular Probes S-911) 
(Vector BA-4000), were used to detect DAT. 1:1000 mouse anti p-ERK (sc 7383 Santa Cruz) for o/n 
at +4°C followed by 2h at RT incubation with donkey anti-mouse-HRP 1:3000 (Dako, P0449) was 
used to detect phospho-Erk (Pi-Erk), rabbit anti-Erk 1:1000 for o/n at +4°C (sc94 Santa Cruz) 
followed by 2h at RT incubation with "
-rabbit 1:3000 (NA9340 GE Healthcare) 
was used to detect Erk.  
Blots were stripped 15 min at +70 °C (50 mM DTT, 50 mM Tris-HCl, 2 % SDS) followed by washing 
and blocking as described above.  Gapdh 1:10 000 mouse anti-GAPDH (Millipore MAB374) o/n +4 
°C followed by 2 h RT 1:3000 anti-mouse-HRP (DAKO P0449); alpha-tubulin 1:30 000 mouse anti-
alpha-tubulin (Sigma T9026) o/n +4 °C, followed by 2 h RT 1:3000 anti-mouse-HRP (DAKO P0449). 
Signal on WB-s was visualized with Pierce ECL western blotting kit #32106 followed by film 
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exposure, gapdh or alpha-tubulin and  gene of interest and Pi-Erk/Erk signal ratio was calculated 
using ImageJ software.   
 
Behavioral and CLAMS analysis 
For open field test, non-lesioned mice were tested in three independent cohorts of comparable 
size (N=10-12 male animals per genotype in each experiment). Male wt animals from the same 
litter served as controls.  Experiment was performed by three different experimenters blind to the 
genotypes. Randomized animals were tested during the light period of the day between 9.00am 
and 4pm. Metabolic monitoring (food intake), was perfromed as described in detail in 16-18 using 
Comprehensive Lab Animal Monitoring System (CLAMS).  
Primers  
Mutation primers: 
miR-146mut agttctc -> agtctct 
F: agtctcttacaaactttatttttgtacaatatc 
R: ttggttgtataacacaaacgac 
 
miR-96mut gtgccaaa -> cgaaagtc 
F: cgaaagtcgtatatgtgctcacaaaatacaaag 
R: ctttgaaaagagactttaataaataag 
 
qPCR primers: 
Gdnf  
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F: cgctgaccagtgactccaatatgc 
R: tgccgcttgtttatctggtgacc 
beta-actin 
F: ccagttcgccatggatgac 
R: gagccgttgtcgacgacc 
 
Statistical analysis 
Data from biological repeats, i.e. cDNA or tissue/cell lysates derived from different animals or cell 
"

 ^ # 
" ] " >  " ] "^"   , 
luciferase assays) mean values were used in calculations. Statistical analysis for pairwise 
comparisons was performed using Student’s t-test with two tailed distribution using the unequal 
variance option. When not noted otherwise, the indicated p value reflects the above Student’s t-
test. 
Data from amperometry was analysed by one way ANOVA followed by Bonferroni test. 
The behavioural data were analysed using a factorial ANOVA design with genotype and cohort as 
between-
"]"#^>-hoc analysis after significant ANOVA was carried 
out by means of Student-Newman-Keuls test. All numerical results are reported as mean + 
standard error of mean. SPSS for Windows 20 software (IBM Corp., Armonk NY, USA) or 
STATISTICA 11 software (StatSoft Inc., Tulsa) were used for analysis. 
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